<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE sequence-cwu SYSTEM "us-sequence-listing-v1_3-2020-10-08.dtd" [ ]><sequence-cwu id="SEQLST-1"><publication-reference><document-id><country>US</country><doc-number>20230001014</doc-number><kind>A1</kind><date>20230105</date></document-id></publication-reference><number>1</number><sequence-list-new-rules><s100><s160>71</s160></s100><s200><s210>1</s210><s211>16</s211><s212>PRT</s212><s213>Human adenovirus serotype 5</s213><s220><s221>misc_feature</s221><s223>Adeno 5 WT fragment of HVR7</s223></s220></s200><s400> 1Leu Gly Gly Val Ile Asn Thr Glu Thr Leu Thr Lys Val Lys Pro Lys1               5                   10                  15</s400><s200><s210>2</s210><s211>16</s211><s212>PRT</s212><s213>Human adenovirus serotype 5</s213><s220><s221>misc_feature</s221><s223>Adeno 5-TEA mutant fragment of HVR7</s223></s220></s200><s400> 2Leu Gly Gly Val Ile Asn Thr Glu Ala Leu Thr Lys Val Lys Pro Lys1               5                   10                  15</s400><s200><s210>3</s210><s211>61</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Adeno 5 penton-human laminin 1 chimera</s223></s220></s200><s400> 3Asn Ala Ala Ala Ser Gly Thr Lys Leu Leu Ile Ser Gln Ala Arg Lys1               5                   10                  15Gln Ala Ala Ser Ile Lys Val Ala Val Ser Ala Asp Arg Asp Cys Ile            20                  25                  30Arg Ala Tyr Gln Pro Gln Ile Ser Ser Thr Asn Tyr Asn Thr Leu Thr        35                  40                  45Gly Ser Thr Gly Gly Ala Lys Pro Gln Lys Lys Pro Val    50                  55                  60</s400><s200><s210>4</s210><s211>68</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Adeno 5 penton-human laminin 3 chimera</s223></s220></s200><s400> 4Asn Ala Ala Ala Ser Gly Thr Arg Glu Leu Ile Gln Ala Arg Asp Ala1               5                   10                  15Ala Ser Lys Val Ala Val Pro Met Arg Phe Asn Gly Lys Ser Gly Val            20                  25                  30Glu Val Arg Leu Pro Asn Asp Leu Glu Asp Leu Lys Gly Tyr Thr Ser        35                  40                  45Leu Ser Leu Gly Ser Thr Gly Gly Ala Pro Glu Val Glu Lys Pro Gln    50                  55                  60Lys Lys Pro Val65</s400><s200><s210>5</s210><s211>14</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Adeno 5 hexon HVR1 mutation - 1</s223></s220></s200><s400> 5Glu Trp Asp Ser Ala Ala Thr Ser Thr Ala Gly Gly Thr His1               5                   10</s400><s200><s210>6</s210><s211>12</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Adeno 5 hexon HVR1 mutation - 2</s223></s220></s200><s400> 6Asp Glu Ala Ala Thr Gly Gly Ser Gly Gln Gln Lys1               5                   10</s400><s200><s210>7</s210><s211>6</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Adeno 5/41 hexon HVR1 chimera</s223></s220></s200><s400> 7Trp Lys Asp Asn Asn Lys1               5</s400><s200><s210>8</s210><s211>15</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Adeno 5/51 hexon HVR1 chimera</s223></s220></s200><s400> 8Trp Glu Gln Lys Lys Thr Thr Gly Gly Asn Asp Met Glu Thr His1               5                   10                  15</s400><s200><s210>9</s210><s211>15</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Adeno 5 penton chimera - 1</s223></s220></s200><s400> 9Met Gly Ser Gly Cys Asn Gly Gln Gly Glu Gln Cys Ala Ala Ala1               5                   10                  15</s400><s200><s210>10</s210><s211>15</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Adeno 5 penton chimera - 2</s223></s220></s200><s400> 10Met Gly Ser Gly Arg Lys Lys Arg Arg Gln Arg Arg Ala Ala Ala1               5                   10                  15</s400><s200><s210>11</s210><s211>609</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Ad5</s223></s220></s200><s400> 11Met Ala Thr Pro Ser Met Met Pro Gln Trp Ser Tyr Met His Ile Ser1               5                   10                  15Gly Gln Asp Ala Ser Glu Tyr Leu Ser Pro Gly Leu Val Gln Phe Ala            20                  25                  30Arg Ala Thr Glu Thr Tyr Phe Ser Leu Asn Asn Lys Phe Arg Asn Pro        35                  40                  45Thr Val Ala Pro Thr His Asp Val Thr Thr Asp Arg Ser Gln Arg Leu    50                  55                  60Thr Leu Arg Phe Ile Pro Val Asp Arg Glu Asp Thr Ala Tyr Ser Tyr65                  70                  75                  80Lys Ala Arg Phe Thr Leu Ala Val Gly Asp Asn Arg Val Leu Asp Met                85                  90                  95Ala Ser Thr Tyr Phe Asp Ile Arg Gly Val Leu Asp Arg Gly Pro Thr            100                 105                 110Phe Lys Pro Tyr Ser Gly Thr Ala Tyr Asn Ala Leu Ala Pro Lys Gly        115                 120                 125Ala Pro Asn Pro Cys Glu Trp Asp Glu Ala Ala Thr Ala Leu Glu Ile    130                 135                 140Asn Leu Glu Glu Glu Asp Asp Asp Asn Glu Asp Glu Val Asp Glu Gln145                 150                 155                 160Ala Glu Gln Gln Lys Thr His Val Phe Gly Gln Ala Pro Tyr Ser Gly                165                 170                 175Ile Asn Ile Thr Lys Glu Gly Ile Gln Ile Gly Val Glu Gly Gln Thr            180                 185                 190Pro Lys Tyr Ala Asp Lys Thr Phe Gln Pro Glu Pro Gln Ile Gly Glu        195                 200                 205Ser Gln Trp Tyr Glu Thr Glu Ile Asn His Ala Ala Gly Arg Val Leu    210                 215                 220Lys Lys Thr Thr Pro Met Lys Pro Cys Tyr Gly Ser Tyr Ala Lys Pro225                 230                 235                 240Thr Asn Glu Asn Gly Gly Gln Gly Ile Leu Val Lys Gln Gln Asn Gly                245                 250                 255Lys Leu Glu Ser Gln Val Glu Met Gln Phe Phe Ser Thr Thr Glu Ala            260                 265                 270Ala Ala Gly Asn Gly Asp Asn Leu Thr Pro Lys Val Val Leu Tyr Ser        275                 280                 285Glu Asp Val Asp Ile Glu Thr Pro Asp Thr His Ile Ser Tyr Met Pro    290                 295                 300Thr Ile Lys Glu Gly Asn Ser Arg Glu Leu Met Gly Gln Gln Ser Met305                 310                 315                 320Pro Asn Arg Pro Asn Tyr Ile Ala Phe Arg Asp Asn Phe Ile Gly Leu                325                 330                 335Met Tyr Tyr Asn Ser Thr Gly Asn Met Gly Val Leu Ala Gly Gln Ala            340                 345                 350Ser Gln Leu Asn Ala Val Val Asp Leu Gln Asp Arg Asn Thr Glu Leu        355                 360                 365Ser Tyr Gln Leu Leu Leu Asp Ser Ile Gly Asp Arg Thr Arg Tyr Phe    370                 375                 380Ser Met Trp Asn Gln Ala Val Asp Ser Tyr Asp Pro Asp Val Arg Ile385                 390                 395                 400Ile Glu Asn His Gly Thr Glu Asp Glu Leu Pro Asn Tyr Cys Phe Pro                405                 410                 415Leu Gly Gly Val Ile Asn Thr Glu Thr Leu Thr Lys Val Lys Pro Lys            420                 425                 430Thr Gly Gln Glu Asn Gly Trp Glu Lys Asp Ala Thr Glu Phe Ser Asp        435                 440                 445Lys Asn Glu Ile Arg Val Gly Asn Asn Phe Ala Met Glu Ile Asn Leu    450                 455                 460Asn Ala Asn Leu Trp Arg Asn Phe Leu Tyr Ser Asn Ile Ala Leu Tyr465                 470                 475                 480Leu Pro Asp Lys Leu Lys Tyr Ser Pro Ser Asn Val Lys Ile Ser Asp                485                 490                 495Asn Pro Asn Thr Tyr Asp Tyr Met Asn Lys Arg Val Val Ala Pro Gly            500                 505                 510Leu Val Asp Cys Tyr Ile Asn Leu Gly Ala Arg Trp Ser Leu Asp Tyr        515                 520                 525Met Asp Asn Val Asn Pro Phe Asn His His Arg Asn Ala Gly Leu Arg    530                 535                 540Tyr Arg Ser Met Leu Leu Gly Asn Gly Arg Tyr Val Pro Phe His Ile545                 550                 555                 560Gln Val Pro Gln Lys Phe Phe Ala Ile Lys Asn Leu Leu Leu Leu Pro                565                 570                 575Gly Ser Tyr Thr Tyr Glu Trp Asn Phe Arg Lys Asp Val Asn Met Val            580                 585                 590Leu Gln Ser Ser Leu Gly Asn Asp Leu Arg Val Asp Gly Ala Ser Ile        595                 600                 605Lys</s400><s200><s210>12</s210><s211>601</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Ad3</s223></s220></s200><s400> 12Met Ala Thr Pro Ser Met Met Pro Gln Trp Ala Tyr Met His Ile Ala1               5                   10                  15Gly Gln Asp Ala Ser Glu Tyr Leu Ser Pro Gly Leu Val Gln Phe Ala            20                  25                  30Arg Ala Thr Asp Thr Tyr Phe Ser Met Gly Asn Lys Phe Arg Asn Pro        35                  40                  45Thr Val Ala Pro Thr His Asp Val Thr Thr Asp Arg Ser Gln Arg Leu    50                  55                  60Met Leu Arg Phe Val Pro Val Asp Arg Glu Asp Asn Thr Tyr Ser Tyr65                  70                  75                  80Lys Val Arg Tyr Thr Leu Ala Val Gly Asp Asn Arg Val Leu Asp Met                85                  90                  95Ala Ser Thr Phe Phe Asp Ile Arg Gly Val Leu Asp Arg Gly Pro Ser            100                 105                 110Phe Lys Pro Tyr Ser Gly Thr Ala Tyr Asn Ser Leu Ala Pro Lys Gly        115                 120                 125Ala Pro Asn Thr Ser Gln Trp Ile Val Thr Thr Asn Gly Asp Asn Ala    130                 135                 140Val Thr Thr Thr Thr Asn Thr Phe Gly Ile Ala Ser Met Lys Gly Asp145                 150                 155                 160Asn Ile Thr Lys Glu Gly Leu Gln Ile Gly Lys Asp Ile Thr Thr Thr                165                 170                 175Glu Gly Glu Glu Lys Pro Ile Tyr Ala Asp Lys Thr Tyr Gln Pro Glu            180                 185                 190Pro Gln Val Gly Glu Glu Ser Trp Thr Asp Thr Asp Gly Thr Asn Glu        195                 200                 205Lys Phe Gly Gly Arg Ala Leu Lys Pro Ala Thr Asn Met Lys Pro Cys    210                 215                 220Tyr Gly Ser Phe Ala Arg Pro Thr Asn Ile Lys Gly Gly Gln Ala Lys225                 230                 235                 240Asn Arg Lys Val Lys Pro Thr Thr Glu Gly Gly Val Glu Thr Glu Glu                245                 250                 255Pro Asp Ile Asp Met Glu Phe Phe Asp Gly Arg Asp Ala Val Ala Gly            260                 265                 270Ala Leu Ala Pro Glu Ile Val Leu Tyr Thr Glu Asn Val Asn Leu Glu        275                 280                 285Thr Pro Asp Ser His Val Val Tyr Lys Pro Glu Thr Ser Asn Asn Ser    290                 295                 300His Ala Asn Leu Gly Gln Gln Ala Met Pro Asn Arg Pro Asn Tyr Ile305                 310                 315                 320Gly Phe Arg Asp Asn Phe Val Gly Leu Met Tyr Tyr Asn Ser Thr Gly                325                 330                 335Asn Met Gly Val Leu Ala Gly Gln Ala Ser Gln Leu Asn Ala Val Val            340                 345                 350Asp Leu Gln Asp Arg Asn Thr Glu Leu Ser Tyr Gln Leu Leu Leu Asp        355                 360                 365Ser Leu Gly Asp Arg Thr Arg Tyr Phe Ser Met Trp Asn Gln Ala Val    370                 375                 380Asp Ser Tyr Asp Pro Asp Val Arg Ile Ile Glu Asn His Gly Ile Glu385                 390                 395                 400Asp Glu Leu Pro Asn Tyr Cys Phe Pro Leu Asn Gly Ile Gly Pro Gly                405                 410                 415His Thr Tyr Gln Gly Ile Lys Val Lys Thr Asp Asp Thr Asn Gly Trp            420                 425                 430Glu Lys Asp Ala Asn Val Ala Pro Ala Asn Glu Ile Thr Ile Gly Asn        435                 440                 445Asn Leu Ala Met Glu Ile Asn Ile Gln Ala Asn Leu Trp Arg Ser Phe    450                 455                 460Leu Tyr Ser Asn Val Ala Leu Tyr Leu Pro Asp Val Tyr Lys Tyr Thr465                 470                 475                 480Pro Pro Asn Ile Thr Leu Pro Thr Asn Thr Asn Thr Tyr Glu Tyr Met                485                 490                 495Asn Gly Arg Val Val Ser Pro Ser Leu Val Asp Ser Tyr Ile Asn Ile            500                 505                 510Gly Ala Arg Trp Ser Leu Asp Pro Met Asp Asn Val Asn Pro Phe Asn        515                 520                 525His His Arg Asn Ala Gly Leu Arg Tyr Arg Ser Met Leu Leu Gly Asn    530                 535                 540Gly Arg Tyr Val Pro Phe His Ile Gln Val Pro Gln Lys Phe Phe Ala545                 550                 555                 560Val Lys Asn Leu Leu Leu Leu Pro Gly Ser Tyr Thr Tyr Glu Trp Asn                565                 570                 575Phe Arg Lys Asp Val Asn Met Val Leu Gln Ser Ser Leu Gly Asn Asp            580                 585                 590Leu Arg Thr Asp Gly Ala Thr Ile Ser        595                 600</s400><s200><s210>13</s210><s211>597</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Ad16</s223></s220></s200><s400> 13Met Ala Thr Pro Ser Met Met Pro Gln Trp Ala Tyr Met His Ile Ala1               5                   10                  15Gly Gln Asp Ala Ser Glu Tyr Leu Ser Pro Gly Leu Val Gln Phe Ala            20                  25                  30Arg Ala Thr Asp Thr Tyr Phe Ser Met Gly Asn Lys Phe Arg Asn Pro        35                  40                  45Thr Val Ala Pro Thr His Asp Val Thr Thr Asp Arg Ser Gln Arg Leu    50                  55                  60Met Leu Arg Phe Val Pro Val Asp Arg Glu Asp Asn Thr Tyr Ser Tyr65                  70                  75                  80Lys Val Arg Tyr Thr Leu Ala Val Gly Asp Asn Arg Val Leu Asp Met                85                  90                  95Ala Ser Thr Phe Phe Asp Ile Arg Gly Val Leu Asp Arg Gly Pro Ser            100                 105                 110Phe Lys Pro Tyr Ser Gly Thr Ala Tyr Asn Ser Leu Ala Pro Lys Gly        115                 120                 125Ala Pro Asn Thr Cys Gln Trp Lys Asp Ser Asp Ser Lys Met His Thr    130                 135                 140Phe Gly Val Ala Ala Met Pro Gly Val Thr Gly Lys Lys Ile Glu Ala145                 150                 155                 160Asp Gly Leu Pro Ile Gly Ile Asp Ser Thr Ser Gly Thr Asp Thr Val                165                 170                 175Ile Tyr Ala Asp Lys Thr Phe Gln Pro Glu Pro Gln Val Gly Asn Ala            180                 185                 190Ser Trp Val Asp Ala Asn Gly Thr Glu Glu Lys Tyr Gly Gly Arg Ala        195                 200                 205Leu Lys Asp Thr Thr Lys Met Lys Pro Cys Tyr Gly Ser Phe Ala Lys    210                 215                 220Pro Thr Asn Lys Glu Gly Gly Gln Ala Asn Leu Lys Asp Ser Glu Thr225                 230                 235                 240Ala Ala Thr Thr Pro Asn Tyr Asp Ile Asp Leu Ala Phe Phe Asp Asn                245                 250                 255Lys Asn Ile Ala Ala Asn Tyr Asp Pro Asp Ile Val Met Tyr Thr Glu            260                 265                 270Asn Val Asp Leu Gln Thr Pro Asp Thr His Ile Val Tyr Lys Pro Gly        275                 280                 285Thr Glu Asp Thr Ser Ser Glu Ser Asn Leu Gly Gln Gln Ala Met Pro    290                 295                 300Asn Arg Pro Asn Tyr Ile Gly Phe Arg Asp Asn Phe Ile Gly Leu Met305                 310                 315                 320Tyr Tyr Asn Ser Thr Gly Asn Met Gly Val Leu Ala Gly Gln Ala Ser                325                 330                 335Gln Leu Asn Ala Val Val Asp Leu Gln Asp Arg Asn Thr Glu Leu Ser            340                 345                 350Tyr Gln Leu Leu Leu Asp Ser Leu Gly Asp Arg Thr Arg Tyr Phe Ser        355                 360                 365Met Trp Asn Gln Ala Val Asp Ser Tyr Asp Pro Asp Val Arg Ile Ile    370                 375                 380Glu Asn His Gly Val Glu Asp Glu Leu Pro Asn Tyr Cys Phe Pro Leu385                 390                 395                 400Asn Gly Val Gly Phe Thr Asp Thr Tyr Gln Gly Val Lys Val Lys Thr                405                 410                 415Asp Ala Val Ala Gly Thr Ser Gly Thr Gln Trp Asp Lys Asp Asp Thr            420                 425                 430Thr Val Ser Thr Ala Asn Glu Ile His Gly Gly Asn Pro Phe Ala Met        435                 440                 445Glu Ile Asn Ile Gln Ala Asn Leu Trp Arg Ser Phe Leu Tyr Ser Asn    450                 455                 460Val Ala Leu Tyr Leu Pro Asp Ser Tyr Lys Tyr Thr Pro Ser Asn Val465                 470                 475                 480Thr Leu Pro Glu Asn Lys Asn Thr Tyr Asp Tyr Met Asn Gly Arg Val                485                 490                 495Val Pro Pro Ser Leu Val Asp Thr Tyr Val Asn Ile Gly Ala Arg Trp            500                 505                 510Ser Leu Asp Ala Met Asp Asn Val Asn Pro Phe Asn His His Arg Asn        515                 520                 525Ala Gly Leu Arg Tyr Arg Ser Met Leu Leu Gly Asn Gly Arg Tyr Val    530                 535                 540Pro Phe His Ile Gln Val Pro Gln Lys Phe Phe Ala Val Lys Asn Leu545                 550                 555                 560Leu Leu Leu Pro Gly Ser Tyr Thr Tyr Glu Trp Asn Phe Arg Lys Asp                565                 570                 575Val Asn Met Val Leu Gln Ser Ser Leu Gly Asn Asp Leu Arg Val Asp            580                 585                 590Gly Ala Ser Ile Ser        595</s400><s200><s210>14</s210><s211>601</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Ad14</s223></s220></s200><s400> 14Met Ala Thr Pro Ser Met Leu Pro Gln Trp Ala Tyr Met His Ile Ala1               5                   10                  15Gly Gln Asp Ala Ser Glu Tyr Leu Ser Pro Gly Leu Val Gln Phe Ala            20                  25                  30Arg Ala Thr Asp Thr Tyr Phe Asn Leu Gly Asn Lys Phe Arg Asn Pro        35                  40                  45Thr Val Ala Pro Thr His Asp Val Thr Thr Asp Arg Ser Gln Arg Leu    50                  55                  60Met Leu Arg Phe Val Pro Val Asp Arg Glu Asp Asn Thr Tyr Ser Tyr65                  70                  75                  80Lys Val Arg Tyr Thr Leu Ala Val Gly Asp Asn Arg Val Leu Asp Met                85                  90                  95Ala Ser Thr Phe Phe Asp Ile Arg Gly Val Leu Asp Arg Gly Pro Ser            100                 105                 110Phe Lys Pro Tyr Ser Gly Thr Ala Tyr Asn Ser Leu Ala Pro Lys Gly        115                 120                 125Ala Pro Asn Ala Ser Gln Trp Leu Asp Lys Gly Val Glu Thr Thr Glu    130                 135                 140Glu Arg Gln Asn Glu Asp Gly Glu Asn Asp Glu Lys Ala Thr Tyr Thr145                 150                 155                 160Phe Gly Asn Ala Pro Val Lys Ala Asp Ala Asp Ile Thr Lys Asp Gly                165                 170                 175Leu Pro Ile Gly Leu Glu Val Pro Ala Glu Gly Asp Pro Lys Pro Ile            180                 185                 190Tyr Ala Asn Lys Leu Tyr Gln Pro Glu Pro Gln Val Gly Gln Glu Ser        195                 200                 205Trp Thr Asp Thr Asp Gly Thr Glu Glu Lys Tyr Gly Gly Arg Val Leu    210                 215                 220Lys Pro Asp Thr Lys Met Lys Pro Cys Tyr Gly Ser Phe Ala Lys Pro225                 230                 235                 240Thr Asn Val Lys Gly Gly Gln Ala Lys Val Lys Thr Glu Glu Gly Asn                245                 250                 255Asn Ile Glu Tyr Asp Ile Asp Met Asn Phe Phe Asp Leu Arg Ser Gln            260                 265                 270Lys Gln Gly Leu Lys Pro Lys Ile Val Met Tyr Ala Glu Asn Val Asp        275                 280                 285Leu Glu Ser Pro Asp Thr His Val Val Tyr Lys Pro Glu Val Ser Asp    290                 295                 300Ala Ser Ser Asn Ala Asn Leu Gly Gln Gln Ser Met Pro Asn Arg Pro305                 310                 315                 320Asn Tyr Ile Gly Phe Arg Asp Ile Tyr Gly Leu Met Tyr Tyr Asn Ser                325                 330                 335Thr Gly Asn Met Gly Val Leu Ala Gly Gln Ala Ser Gln Leu Asn Ala            340                 345                 350Val Val Asp Leu Gln Asp Arg Asn Thr Glu Leu Ser Tyr Gln Leu Leu        355                 360                 365Leu Asp Ser Leu Gly Asp Arg Thr Arg Tyr Phe Ser Met Trp Asn Gln    370                 375                 380Ala Val Asp Ser Tyr Asp Pro Asp Val Arg Val Ile Glu Asn His Gly385                 390                 395                 400Val Glu Asp Glu Leu Pro Asn Tyr Cys Phe Pro Leu Asp Gly Ile Gly                405                 410                 415Pro Arg Thr Asp Ser Tyr Lys Glu Ile Gln Leu Asn Gly Asp Gln Ala            420                 425                 430Trp Lys Asp Val Asn Pro Asn Gly Ile Ser Glu Leu Val Lys Gly Asn        435                 440                 445Pro Phe Ala Met Glu Ile Asn Leu Gln Ala Asn Leu Trp Arg Ser Phe    450                 455                 460Leu Tyr Ser Asn Val Ala Leu Tyr Leu Pro Asp Ser Tyr Lys Tyr Thr465                 470                 475                 480Pro Ser Asn Val Thr Leu Pro Glu Asn Lys Asn Thr Tyr Asp Tyr Met                485                 490                 495Asn Gly Arg Val Val Pro Pro Ser Leu Val Asp Thr Tyr Val Asn Ile            500                 505                 510Gly Ala Arg Trp Ser Leu Asp Ala Met Asp Asn Val Asn Pro Phe Asn        515                 520                 525His His Arg Asn Ala Gly Leu Arg Tyr Arg Ser Met Leu Leu Gly Asn    530                 535                 540Gly Arg Tyr Val Pro Phe His Ile Gln Val Pro Gln Lys Phe Phe Ala545                 550                 555                 560Val Lys Asn Leu Leu Leu Leu Pro Gly Ser Tyr Thr Tyr Glu Trp Asn                565                 570                 575Phe Arg Lys Asp Val Asn Met Val Leu Gln Ser Ser Leu Gly Asn Asp            580                 585                 590Leu Arg Val Asp Gly Ala Ser Ile Ser        595                 600</s400><s200><s210>15</s210><s211>609</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Ad35</s223></s220></s200><s400> 15Met Ala Thr Pro Ser Met Leu Pro Gln Trp Ala Tyr Met His Ile Ala1               5                   10                  15Gly Gln Asp Ala Ser Glu Tyr Leu Ser Pro Gly Leu Val Gln Phe Ala            20                  25                  30Arg Ala Thr Asp Thr Tyr Phe Asn Leu Gly Asn Lys Phe Arg Asn Pro        35                  40                  45Thr Val Ala Pro Thr His Asp Val Thr Thr Asp Arg Ser Gln Arg Leu    50                  55                  60Met Leu Arg Phe Val Pro Val Asp Arg Glu Asp Asn Thr Tyr Ser Tyr65                  70                  75                  80Lys Val Arg Tyr Thr Leu Ala Val Gly Asp Asn Arg Val Leu Asp Met                85                  90                  95Ala Ser Thr Phe Phe Asp Ile Arg Gly Val Leu Asp Arg Gly Pro Ser            100                 105                 110Phe Lys Pro Tyr Ser Gly Thr Ala Tyr Asn Ser Leu Ala Pro Lys Gly        115                 120                 125Ala Pro Asn Ala Ser Gln Trp Ile Ala Lys Gly Val Pro Thr Ala Ala    130                 135                 140Ala Ala Gly Asn Gly Glu Glu Glu His Glu Thr Glu Glu Lys Thr Ala145                 150                 155                 160Thr Tyr Thr Phe Ala Asn Ala Pro Val Lys Ala Glu Ala Gln Ile Thr                165                 170                 175Lys Glu Gly Leu Pro Ile Gly Leu Glu Ile Ser Ala Glu Asn Glu Ser            180                 185                 190Lys Pro Ile Tyr Ala Asp Lys Leu Tyr Gln Pro Glu Pro Gln Val Gly        195                 200                 205Asp Glu Thr Trp Thr Asp Leu Asp Gly Lys Thr Glu Glu Tyr Gly Gly    210                 215                 220Arg Ala Leu Lys Pro Thr Thr Asn Met Lys Pro Cys Tyr Gly Ser Tyr225                 230                 235                 240Ala Lys Pro Thr Asn Leu Lys Gly Gly Gln Ala Lys Pro Lys Asn Ser                245                 250                 255Glu Pro Ser Ser Glu Lys Ile Glu Tyr Asp Ile Asp Met Glu Phe Phe            260                 265                 270Asp Asn Ser Ser Gln Arg Thr Asn Phe Ser Pro Lys Ile Val Met Tyr        275                 280                 285Ala Glu Asn Val Gly Leu Glu Thr Pro Asp Thr His Val Val Tyr Lys    290                 295                 300Pro Gly Thr Glu Asp Thr Ser Ser Glu Ala Asn Leu Gly Gln Gln Ser305                 310                 315                 320Met Pro Asn Arg Pro Asn Tyr Ile Gly Phe Arg Asp Asn Phe Ile Gly                325                 330                 335Leu Met Tyr Tyr Asn Ser Thr Gly Asn Met Gly Val Leu Ala Gly Gln            340                 345                 350Ala Ser Gln Leu Asn Ala Val Val Asp Leu Gln Asp Arg Asn Thr Glu        355                 360                 365Leu Ser Tyr Gln Leu Leu Leu Asp Ser Leu Gly Asp Arg Thr Arg Tyr    370                 375                 380Phe Ser Met Trp Asn Gln Ala Val Asp Ser Tyr Asp Pro Asp Val Arg385                 390                 395                 400Val Ile Glu Asn His Gly Val Glu Asp Glu Leu Pro Asn Tyr Cys Phe                405                 410                 415Pro Leu Asp Gly Ile Gly Val Pro Thr Thr Ser Tyr Lys Ser Ile Val            420                 425                 430Pro Asn Gly Glu Asp Asn Asn Asn Trp Lys Glu Pro Glu Val Asn Gly        435                 440                 445Thr Ser Glu Ile Gly Gln Gly Asn Leu Phe Ala Met Glu Ile Asn Leu    450                 455                 460Gln Ala Asn Leu Trp Arg Ser Phe Leu Tyr Ser Asn Val Ala Leu Tyr465                 470                 475                 480Leu Pro Asp Ser Tyr Lys Tyr Thr Pro Ser Asn Val Thr Leu Pro Glu                485                 490                 495Asn Lys Asn Thr Tyr Asp Tyr Met Asn Gly Arg Val Val Pro Pro Ser            500                 505                 510Leu Val Asp Thr Tyr Val Asn Ile Gly Ala Arg Trp Ser Leu Asp Ala        515                 520                 525Met Asp Asn Val Asn Pro Phe Asn His His Arg Asn Ala Gly Leu Arg    530                 535                 540Tyr Arg Ser Met Leu Leu Gly Asn Gly Arg Tyr Val Pro Phe His Ile545                 550                 555                 560Gln Val Pro Gln Lys Phe Phe Ala Val Lys Asn Leu Leu Leu Leu Pro                565                 570                 575Gly Ser Tyr Thr Tyr Glu Trp Asn Phe Arg Lys Asp Val Asn Met Val            580                 585                 590Leu Gln Ser Ser Leu Gly Asn Asp Leu Arg Val Asp Gly Ala Ser Ile        595                 600                 605Ser</s400><s200><s210>16</s210><s211>343</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Ad5</s223></s220></s200><s400> 16Phe Asp Ser Ile Cys Leu Tyr Ala Thr Phe Phe Pro Met Ala His Asn1               5                   10                  15Thr Ala Ser Thr Leu Glu Ala Met Leu Arg Asn Asp Thr Asn Asp Gln            20                  25                  30Ser Phe Asn Asp Tyr Leu Ser Ala Ala Asn Met Leu Tyr Pro Ile Pro        35                  40                  45Ala Asn Ala Thr Asn Val Pro Ile Ser Ile Pro Ser Arg Asn Trp Ala    50                  55                  60Ala Phe Arg Gly Trp Ala Phe Thr Arg Leu Lys Thr Lys Glu Thr Pro65                  70                  75                  80Ser Leu Gly Ser Gly Tyr Asp Pro Tyr Tyr Thr Tyr Ser Gly Ser Ile                85                  90                  95Pro Tyr Leu Asp Gly Thr Phe Tyr Leu Asn His Thr Phe Lys Lys Val            100                 105                 110Ala Ile Thr Phe Asp Ser Ser Val Ser Trp Pro Gly Asn Asp Arg Leu        115                 120                 125Leu Thr Pro Asn Glu Phe Glu Ile Lys Arg Ser Val Asp Gly Glu Gly    130                 135                 140Tyr Asn Val Ala Gln Cys Asn Met Thr Lys Asp Trp Phe Leu Val Gln145                 150                 155                 160Met Leu Ala Asn Tyr Asn Ile Gly Tyr Gln Gly Phe Tyr Ile Pro Glu                165                 170                 175Ser Tyr Lys Asp Arg Met Tyr Ser Phe Phe Arg Asn Phe Gln Pro Met            180                 185                 190Ser Arg Gln Val Val Asp Asp Thr Lys Tyr Lys Asp Tyr Gln Gln Val        195                 200                 205Gly Ile Leu His Gln His Asn Asn Ser Gly Phe Val Gly Tyr Leu Ala    210                 215                 220Pro Thr Met Arg Glu Gly Gln Ala Tyr Pro Ala Asn Phe Pro Tyr Pro225                 230                 235                 240Leu Ile Gly Lys Thr Ala Val Asp Ser Ile Thr Gln Lys Lys Phe Leu                245                 250                 255Cys Asp Arg Thr Leu Trp Arg Ile Pro Phe Ser Ser Asn Phe Met Ser            260                 265                 270Met Gly Ala Leu Thr Asp Leu Gly Gln Asn Leu Leu Tyr Ala Asn Ser        275                 280                 285Ala His Ala Leu Asp Met Thr Phe Glu Val Asp Pro Met Asp Glu Pro    290                 295                 300Thr Leu Leu Tyr Val Leu Phe Glu Val Phe Asp Val Val Arg Val His305                 310                 315                 320Gln Pro His Arg Gly Val Ile Glu Thr Val Tyr Leu Arg Thr Pro Phe                325                 330                 335Ser Ala Gly Asn Ala Thr Thr            340</s400><s200><s210>17</s210><s211>343</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Ad3</s223></s220></s200><s400> 17Phe Thr Ser Ile Asn Leu Tyr Ala Thr Phe Phe Pro Met Ala His Asn1               5                   10                  15Thr Ala Ser Thr Leu Glu Ala Met Leu Arg Asn Asp Thr Asn Asp Gln            20                  25                  30Ser Phe Asn Asp Tyr Leu Ser Ala Ala Asn Met Leu Tyr Pro Ile Pro        35                  40                  45Ala Asn Ala Thr Asn Ile Pro Ile Ser Ile Pro Ser Arg Asn Trp Ala    50                  55                  60Ala Phe Arg Gly Trp Ser Phe Thr Arg Leu Lys Thr Lys Glu Thr Pro65                  70                  75                  80Ser Leu Gly Ser Gly Phe Asp Pro Tyr Phe Val Tyr Ser Gly Ser Ile                85                  90                  95Pro Tyr Leu Asp Gly Thr Phe Tyr Leu Asn His Thr Phe Lys Lys Val            100                 105                 110Ser Ile Met Phe Asp Ser Ser Val Ser Trp Pro Gly Asn Asp Arg Leu        115                 120                 125Leu Ser Pro Asn Glu Phe Glu Ile Lys Arg Thr Val Asp Gly Glu Gly    130                 135                 140Tyr Asn Val Ala Gln Cys Asn Met Thr Lys Asp Trp Phe Leu Val Gln145                 150                 155                 160Met Leu Ala Asn Tyr Asn Ile Gly Tyr Gln Gly Phe Tyr Ile Pro Glu                165                 170                 175Gly Tyr Lys Asp Arg Met Tyr Ser Phe Phe Arg Asn Phe Gln Pro Met            180                 185                 190Ser Arg Gln Val Val Asp Glu Val Asn Tyr Thr Asp Tyr Lys Ala Val        195                 200                 205Thr Leu Pro Tyr Gln His Asn Asn Ser Gly Phe Val Gly Tyr Leu Ala    210                 215                 220Pro Thr Met Arg Gln Gly Glu Pro Tyr Pro Ala Asn Tyr Pro Tyr Pro225                 230                 235                 240Leu Ile Gly Thr Thr Ala Val Lys Ser Val Thr Gln Lys Lys Phe Leu                245                 250                 255Cys Asp Arg Thr Met Trp Arg Ile Pro Phe Ser Ser Asn Phe Met Ser            260                 265                 270Met Gly Ala Leu Thr Asp Leu Gly Gln Asn Met Leu Tyr Ala Asn Ser        275                 280                 285Ala His Ala Leu Asp Met Thr Phe Glu Val Asp Pro Met Asp Glu Pro    290                 295                 300Thr Leu Leu Tyr Leu Leu Phe Glu Val Phe Asp Val Val Arg Val His305                 310                 315                 320Gln Pro His Arg Gly Val Ile Glu Ala Val Tyr Leu Arg Thr Pro Phe                325                 330                 335Ser Ala Gly Asn Ala Thr Thr            340</s400><s200><s210>18</s210><s211>343</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Ad16</s223></s220></s200><s400> 18Phe Thr Ser Ile Asn Leu Tyr Ala Thr Phe Phe Pro Met Ala His Asn1               5                   10                  15Thr Ala Ser Thr Leu Glu Ala Met Leu Arg Asn Asp Thr Asn Asp Gln            20                  25                  30Ser Phe Asn Asp Tyr Leu Ser Ala Ala Asn Met Leu Tyr Pro Ile Pro        35                  40                  45Ala Asn Ala Thr Asn Ile Pro Ile Ser Ile Pro Ser Arg Asn Trp Ala    50                  55                  60Ala Phe Arg Gly Trp Ser Phe Thr Arg Leu Lys Thr Lys Glu Thr Pro65                  70                  75                  80Ser Leu Gly Ser Gly Phe Asp Pro Tyr Phe Val Tyr Ser Gly Ser Ile                85                  90                  95Pro Tyr Leu Asp Gly Thr Phe Tyr Leu Asn His Thr Phe Lys Lys Val            100                 105                 110Ser Ile Met Phe Asp Ser Ser Val Ser Trp Pro Gly Asn Asp Arg Leu        115                 120                 125Leu Ser Pro Asn Glu Phe Glu Ile Lys Arg Thr Val Asp Gly Glu Gly    130                 135                 140Tyr Asn Val Ala Gln Cys Asn Met Thr Lys Asp Trp Phe Leu Val Gln145                 150                 155                 160Met Leu Ala Asn Tyr Asn Ile Gly Tyr Gln Gly Phe Tyr Ile Pro Glu                165                 170                 175Gly Tyr Lys Asp Arg Met Tyr Ser Phe Phe Arg Asn Phe Gln Pro Met            180                 185                 190Ser Arg Gln Val Val Asp Glu Val Asn Tyr Thr Asp Tyr Lys Ala Val        195                 200                 205Thr Leu Pro Tyr Gln His Asn Asn Ser Gly Phe Val Gly Tyr Leu Ala    210                 215                 220Pro Thr Met Arg Gln Gly Glu Pro Tyr Pro Ala Asn Tyr Pro Tyr Pro225                 230                 235                 240Leu Ile Gly Thr Thr Ala Val Lys Ser Val Thr Gln Lys Lys Phe Leu                245                 250                 255Cys Asp Arg Thr Met Trp Arg Ile Pro Phe Ser Ser Asn Phe Met Ser            260                 265                 270Met Gly Ala Leu Thr Asp Leu Gly Gln Asn Leu Leu Tyr Ala Asn Ser        275                 280                 285Ala His Ala Leu Asp Met Thr Phe Glu Val Asp Pro Met Asp Glu Pro    290                 295                 300Thr Leu Leu Tyr Leu Leu Phe Glu Val Phe Asp Val Val Arg Val His305                 310                 315                 320Gln Pro His Arg Gly Val Ile Glu Ala Val Tyr Leu Arg Thr Pro Phe                325                 330                 335Ser Ala Gly Asn Ala Thr Thr            340</s400><s200><s210>19</s210><s211>343</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Ad14</s223></s220></s200><s400> 19Phe Thr Ser Ile Asn Leu Tyr Ala Thr Phe Phe Pro Met Ala His Asn1               5                   10                  15Thr Ala Ser Thr Leu Glu Ala Met Leu Arg Asn Asp Thr Asn Asp Gln            20                  25                  30Ser Phe Asn Asp Tyr Leu Ser Ala Ala Asn Met Leu Tyr Pro Ile Pro        35                  40                  45Ala Asn Ala Thr Asn Ile Pro Ile Ser Ile Pro Ser Arg Asn Trp Ala    50                  55                  60Ala Phe Arg Gly Trp Ser Phe Thr Arg Leu Lys Thr Lys Glu Thr Pro65                  70                  75                  80Ser Leu Gly Ser Gly Phe Asp Pro Tyr Phe Val Tyr Ser Gly Ser Ile                85                  90                  95Pro Tyr Leu Asp Gly Thr Phe Tyr Leu Asn His Thr Phe Lys Lys Val            100                 105                 110Ser Ile Met Phe Asp Ser Ser Val Ser Trp Pro Gly Asn Asp Arg Leu        115                 120                 125Leu Ser Pro Asn Glu Phe Glu Ile Lys Arg Thr Val Asp Gly Glu Gly    130                 135                 140Tyr Asn Val Ala Gln Cys Asn Met Thr Lys Asp Trp Phe Leu Val Gln145                 150                 155                 160Met Leu Ala Asn Tyr Asn Ile Gly Tyr Gln Gly Phe Tyr Ile Pro Glu                165                 170                 175Gly Tyr Lys Asp Arg Met Tyr Ser Phe Phe Arg Asn Phe Gln Pro Met            180                 185                 190Ser Arg Gln Val Val Asp Glu Val Asn Tyr Lys Asp Phe Lys Ala Val        195                 200                 205Ala Ile Pro Tyr Gln His Asn Asn Ser Gly Phe Val Gly Tyr Met Ala    210                 215                 220Pro Thr Met Arg Gln Gly Gln Pro Tyr Pro Ala Asn Tyr Pro Tyr Pro225                 230                 235                 240Leu Ile Gly Thr Thr Ala Val Asn Ser Val Thr Gln Lys Lys Phe Leu                245                 250                 255Cys Asp Arg Thr Met Trp Arg Ile Pro Phe Ser Ser Asn Phe Met Ser            260                 265                 270Met Gly Ala Leu Thr Asp Leu Gly Gln Asn Met Leu Tyr Ala Asn Ser        275                 280                 285Ala His Ala Leu Asp Met Thr Phe Glu Val Asp Pro Met Asp Glu Pro    290                 295                 300Thr Leu Leu Tyr Leu Leu Phe Glu Val Phe Asp Val Val Arg Val His305                 310                 315                 320Gln Pro His Arg Gly Ile Ile Glu Thr Val Tyr Leu Arg Thr Pro Phe                325                 330                 335Ser Ala Gly Asn Ala Thr Thr            340</s400><s200><s210>20</s210><s211>343</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Ad35</s223></s220></s200><s400> 20Phe Thr Ser Ile Asn Leu Tyr Ala Thr Phe Phe Pro Met Ala His Asn1               5                   10                  15Thr Ala Ser Thr Leu Glu Ala Met Leu Arg Asn Asp Thr Asn Asp Gln            20                  25                  30Ser Phe Asn Asp Tyr Leu Ser Ala Ala Asn Met Leu Tyr Pro Ile Pro        35                  40                  45Ala Asn Ala Thr Asn Ile Pro Ile Ser Ile Pro Ser Arg Asn Trp Ala    50                  55                  60Ala Phe Arg Gly Trp Ser Phe Thr Arg Leu Lys Thr Lys Glu Thr Pro65                  70                  75                  80Ser Leu Gly Ser Gly Phe Asp Pro Tyr Phe Val Tyr Ser Gly Ser Ile                85                  90                  95Pro Tyr Leu Asp Gly Thr Phe Tyr Leu Asn His Thr Phe Lys Lys Val            100                 105                 110Ser Ile Met Phe Asp Ser Ser Val Ser Trp Pro Gly Asn Asp Arg Leu        115                 120                 125Leu Ser Pro Asn Glu Phe Glu Ile Lys Arg Thr Val Asp Gly Glu Gly    130                 135                 140Tyr Asn Val Ala Gln Cys Asn Met Thr Lys Asp Trp Phe Leu Val Gln145                 150                 155                 160Met Leu Ala Asn Tyr Asn Ile Gly Tyr Gln Gly Phe Tyr Ile Pro Glu                165                 170                 175Gly Tyr Lys Asp Arg Met Tyr Ser Phe Phe Arg Asn Phe Gln Pro Met            180                 185                 190Ser Arg Gln Val Val Asp Glu Val Asn Tyr Lys Asp Phe Lys Ala Val        195                 200                 205Ala Ile Pro Tyr Gln His Asn Asn Ser Gly Phe Val Gly Tyr Met Ala    210                 215                 220Pro Thr Met Arg Gln Gly Gln Pro Tyr Pro Ala Asn Tyr Pro Tyr Pro225                 230                 235                 240Leu Ile Gly Thr Thr Ala Val Asn Ser Val Thr Gln Lys Lys Phe Leu                245                 250                 255Cys Asp Arg Thr Met Trp Arg Ile Pro Phe Ser Ser Asn Phe Met Ser            260                 265                 270Met Gly Ala Leu Thr Asp Leu Gly Gln Asn Met Leu Tyr Ala Asn Ser        275                 280                 285Ala His Ala Leu Asp Met Thr Phe Glu Val Asp Pro Met Asp Glu Pro    290                 295                 300Thr Leu Leu Tyr Leu Leu Phe Glu Val Phe Asp Val Val Arg Val His305                 310                 315                 320Gln Pro His Arg Gly Ile Ile Glu Ala Val Tyr Leu Arg Thr Pro Phe                325                 330                 335Ser Ala Gly Asn Ala Thr Thr            340</s400><s200><s210>21</s210><s211>15</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Ad5</s223></s220></s200><s400> 21Gln Ile Gly Glu Ser Gln Trp Tyr Glu Thr Glu Ile Asn His Ala1               5                   10                  15</s400><s200><s210>22</s210><s211>17</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Ad16</s223></s220></s200><s400> 22Gln Val Gly Asn Ala Ser Trp Val Asp Ala Asn Gly Thr Glu Glu Lys1               5                   10                  15Tyr</s400><s200><s210>23</s210><s211>15</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Ad2</s223></s220></s200><s400> 23Gln Ile Gly Glu Ser Gln Trp Asn Glu Ala Asp Ala Asn Ala Ala1               5                   10                  15</s400><s200><s210>24</s210><s211>17</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Ad21</s223></s220></s200><s400> 24Gln Val Gly Asp Glu Thr Trp Thr Asp Thr Asp Gly Thr Thr Glu Lys1               5                   10                  15Tyr</s400><s200><s210>25</s210><s211>17</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Ad41</s223></s220></s200><s400> 25Gln Val Gly Gln Thr Gln Trp Asn Ser Glu Val Gly Ala Ala Gln Lys1               5                   10                  15Val</s400><s200><s210>26</s210><s211>17</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Ad4</s223></s220></s200><s400> 26Gln Val Gly Asn Asp Ser Trp Val Asp Thr Asn Gly Ala Glu Glu Lys1               5                   10                  15Tyr</s400><s200><s210>27</s210><s211>17</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Ad3</s223></s220></s200><s400> 27Gln Val Gly Glu Glu Ser Trp Thr Asp Thr Asp Val Thr Asn Glu Lys1               5                   10                  15Phe</s400><s200><s210>28</s210><s211>17</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Ad35</s223></s220></s200><s400> 28Gln Val Gly Asp Glu Thr Trp Thr Asp Leu Asp Gly Lys Thr Glu Glu1               5                   10                  15Tyr</s400><s200><s210>29</s210><s211>14</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Ad51</s223></s220></s200><s400> 29Gln Val Gly Glu Glu Asn Trp Gln Glu Thr Phe Asn Phe Tyr1               5                   10</s400><s200><s210>30</s210><s211>14</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Ad9</s223></s220></s200><s400> 30Gln Val Gly Glu Glu Asn Leu Gln Asp Val Glu Asn Tyr Tyr1               5                   10</s400><s200><s210>31</s210><s211>17</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Ad50</s223></s220></s200><s400> 31Gln Val Gly Glu Glu Ser Trp Thr Asp Thr Asp Gly Thr Gly Glu Lys1               5                   10                  15Tyr</s400><s200><s210>32</s210><s211>16</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Ad5</s223></s220></s200><s400> 32Leu Gly Gly Val Ile Asn Thr Glu Thr Leu Thr Lys Val Lys Pro Lys1               5                   10                  15</s400><s200><s210>33</s210><s211>16</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Ad16</s223></s220></s200><s400> 33Leu Asn Gly Val Gly Phe Thr Asp Thr Tyr Gln Gly Val Lys Val Lys1               5                   10                  15</s400><s200><s210>34</s210><s211>16</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Ad2</s223></s220></s200><s400> 34Leu Gly Gly Ile Gly Val Thr Asp Thr Tyr Gln Ala Ile Lys Ala Asn1               5                   10                  15</s400><s200><s210>35</s210><s211>17</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Ad21</s223></s220></s200><s400> 35Leu Asp Gly Val Gly Val Pro Ile Ser Ser Tyr Lys Ile Ile Glu Pro1               5                   10                  15Asn</s400><s200><s210>36</s210><s211>16</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Ad41</s223></s220></s200><s400> 36Leu Gly Gly Ser Ala Ala Thr Asp Thr Tyr Ser Gly Ile Lys Ala Asn1               5                   10                  15</s400><s200><s210>37</s210><s211>16</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Ad4</s223></s220></s200><s400> 37Leu Asn Gly Val Gly Leu Thr Asp Thr Tyr Gln Gly Val Lys Val Lys1               5                   10                  15</s400><s200><s210>38</s210><s211>16</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Ad3</s223></s220></s200><s400> 38Leu Asp Gly Ile Gly Pro Gly Asn Arg Tyr Gln Gly Ile Lys Val Lys1               5                   10                  15</s400><s200><s210>39</s210><s211>17</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Ad35</s223></s220></s200><s400> 39Leu Asp Gly Ile Gly Val Pro Thr Thr Ser Tyr Lys Ser Ile Val Pro1               5                   10                  15Asn</s400><s200><s210>40</s210><s211>16</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Ad51</s223></s220></s200><s400> 40Leu Asp Gly Ser Gly Thr Asn Ala Ala Tyr Gln Gly Val Lys Val Thr1               5                   10                  15</s400><s200><s210>41</s210><s211>16</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Ad9</s223></s220></s200><s400> 41Leu Asp Gly Ala Gly Thr Asn Ala Thr Tyr Gln Gly Val Lys Val Lys1               5                   10                  15</s400><s200><s210>42</s210><s211>17</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Ad50</s223></s220></s200><s400> 42Leu Asp Gly Val Gly Pro Arg Ile Asp Ser Tyr Lys Gly Ile Glu Thr1               5                   10                  15Asn</s400><s200><s210>43</s210><s211>16</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic T423G;E424A</s223></s220></s200><s400> 43Leu Gly Gly Val Ile Asn Gly Ala Thr Leu Thr Lys Val Lys Pro Lys1               5                   10                  15</s400><s200><s210>44</s210><s211>16</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic E424A</s223></s220></s200><s400> 44Leu Gly Gly Val Ile Asn Thr Ala Thr Leu Thr Lys Val Lys Pro Lys1               5                   10                  15</s400><s200><s210>45</s210><s211>571</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Ad2 penton base</s223></s220></s200><s400> 45Met Gln Arg Ala Ala Met Tyr Glu Glu Gly Pro Pro Pro Ser Tyr Glu1               5                   10                  15Ser Val Val Ser Ala Ala Pro Val Ala Ala Ala Leu Gly Ser Pro Phe            20                  25                  30Asp Ala Pro Leu Asp Pro Pro Phe Val Pro Pro Arg Tyr Leu Arg Pro        35                  40                  45Thr Gly Gly Arg Asn Ser Ile Arg Tyr Ser Glu Leu Ala Pro Leu Phe    50                  55                  60Asp Thr Thr Arg Val Tyr Leu Val Asp Asn Lys Ser Thr Asp Val Ala65                  70                  75                  80Ser Leu Asn Tyr Gln Asn Asp His Ser Asn Phe Leu Thr Thr Val Ile                85                  90                  95Gln Asn Asn Asp Tyr Ser Pro Gly Glu Ala Ser Thr Gln Thr Ile Asn            100                 105                 110Leu Asp Asp Arg Ser His Trp Gly Gly Asp Leu Lys Thr Ile Leu His        115                 120                 125Thr Asn Met Pro Asn Val Asn Glu Phe Met Phe Thr Asn Lys Phe Lys    130                 135                 140Ala Arg Val Met Val Ser Arg Ser Leu Thr Lys Asp Lys Gln Val Glu145                 150                 155                 160Leu Lys Tyr Glu Trp Val Glu Phe Thr Leu Pro Glu Gly Asn Tyr Ser                165                 170                 175Glu Thr Met Thr Ile Asp Leu Met Asn Asn Ala Ile Val Glu His Tyr            180                 185                 190Leu Lys Val Gly Arg Gln Asn Gly Val Leu Glu Ser Asp Ile Gly Val        195                 200                 205Lys Phe Asp Thr Arg Asn Phe Arg Leu Gly Phe Asp Pro Val Thr Gly    210                 215                 220Leu Val Met Pro Gly Val Tyr Thr Asn Glu Ala Phe His Pro Asp Ile225                 230                 235                 240Ile Leu Leu Pro Gly Cys Gly Val Asp Phe Thr His Ser Arg Leu Ser                245                 250                 255Asn Leu Leu Gly Ile Arg Lys Arg Gln Pro Phe Gln Glu Gly Phe Arg            260                 265                 270Ile Thr Tyr Asp Asp Leu Glu Gly Gly Asn Ile Pro Ala Leu Leu Asp        275                 280                 285Val Asp Ala Tyr Gln Ala Ser Leu Lys Asp Asp Thr Glu Gln Gly Gly    290                 295                 300Gly Gly Ala Gly Gly Gly Asn Asn Ser Gly Ser Gly Ala Glu Glu Asn305                 310                 315                 320Ser Asn Ala Ala Ala Ala Ala Met Gln Pro Val Glu Asp Met Asn Asp                325                 330                 335His Ala Ile Arg Gly Asp Thr Phe Ala Thr Arg Ala Glu Glu Lys Arg            340                 345                 350Ala Glu Ala Glu Ala Ala Ala Glu Ala Ala Ala Pro Ala Ala Gln Pro        355                 360                 365Glu Val Glu Lys Pro Gln Lys Lys Pro Val Ile Lys Pro Leu Thr Glu    370                 375                 380Asp Ser Lys Lys Arg Ser Tyr Asn Leu Ile Ser Asn Asp Ser Thr Phe385                 390                 395                 400Thr Gln Tyr Arg Ser Trp Tyr Leu Ala Tyr Asn Tyr Gly Asp Pro Gln                405                 410                 415Thr Gly Ile Arg Ser Trp Thr Leu Leu Cys Thr Pro Asp Val Thr Cys            420                 425                 430Gly Ser Glu Gln Val Tyr Trp Ser Leu Pro Asp Met Met Gln Asp Pro        435                 440                 445Val Thr Phe Arg Ser Thr Ser Gln Ile Ser Asn Phe Pro Val Val Gly    450                 455                 460Ala Glu Leu Leu Pro Val His Ser Lys Ser Phe Tyr Asn Asp Gln Ala465                 470                 475                 480Val Tyr Ser Gln Leu Ile Arg Gln Phe Thr Ser Leu Thr His Val Phe                485                 490                 495Asn Arg Phe Pro Glu Asn Gln Ile Leu Ala Arg Pro Pro Ala Pro Thr            500                 505                 510Ile Thr Thr Val Ser Glu Asn Val Pro Ala Leu Thr Asp His Gly Thr        515                 520                 525Leu Pro Leu Arg Asn Ser Ile Gly Gly Val Gln Arg Val Thr Ile Thr    530                 535                 540Asp Ala Arg Arg Arg Thr Cys Pro Tyr Val Tyr Lys Ala Leu Gly Ile545                 550                 555                 560Val Ser Pro Arg Val Leu Ser Ser Arg Thr Phe                565                 570</s400><s200><s210>46</s210><s211>544</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Ad3 penton base</s223></s220></s200><s400> 46Met Arg Arg Arg Ala Val Leu Gly Gly Ala Val Val Tyr Pro Glu Gly1               5                   10                  15Pro Pro Pro Ser Tyr Glu Ser Val Met Gln Gln Gln Ala Ala Met Leu            20                  25                  30Gln Pro Pro Leu Glu Ala Pro Phe Val Pro Pro Arg Tyr Leu Ala Pro        35                  40                  45Thr Glu Gly Arg Asn Ser Ile Arg Tyr Ser Glu Leu Ser Pro Leu Tyr    50                  55                  60Asp Thr Thr Lys Leu Tyr Leu Val Asp Asn Lys Ser Ala Asp Ile Ala65                  70                  75                  80Ser Leu Asn Tyr Gln Asn Asp His Ser Asn Phe Leu Thr Thr Val Val                85                  90                  95Gln Asn Asn Asp Phe Thr Pro Thr Glu Ala Ser Thr Gln Thr Ile Asn            100                 105                 110Phe Asp Glu Arg Ser Arg Trp Gly Gly Gln Leu Lys Thr Ile Met His        115                 120                 125Thr Asn Met Pro Asn Val Asn Glu Tyr Met Phe Ser Asn Lys Phe Lys    130                 135                 140Ala Arg Val Met Val Ser Arg Lys Ala Pro Glu Gly Val Ile Val Asn145                 150                 155                 160Asp Thr Tyr Asp His Lys Glu Asp Ile Leu Lys Tyr Glu Trp Phe Glu                165                 170                 175Phe Thr Leu Pro Glu Gly Asn Phe Ser Ala Thr Met Thr Ile Asp Leu            180                 185                 190Met Asn Asn Ala Ile Ile Asp Asn Tyr Leu Glu Ile Gly Arg Gln Asn        195                 200                 205Gly Val Leu Glu Ser Asp Ile Gly Val Lys Phe Asp Thr Arg Asn Phe    210                 215                 220Arg Leu Gly Trp Asp Pro Glu Thr Lys Leu Ile Met Pro Gly Val Tyr225                 230                 235                 240Thr Tyr Glu Ala Phe His Pro Asp Ile Val Leu Leu Pro Gly Cys Gly                245                 250                 255Val Asp Phe Thr Glu Ser Arg Leu Ser Asn Leu Leu Gly Ile Arg Lys            260                 265                 270Arg His Pro Phe Gln Glu Gly Phe Lys Ile Met Tyr Glu Asp Leu Glu        275                 280                 285Gly Gly Asn Ile Pro Ala Leu Leu Asp Val Thr Ala Tyr Glu Glu Ser    290                 295                 300Lys Lys Asp Thr Thr Thr Glu Thr Thr Thr Leu Ala Val Ala Glu Glu305                 310                 315                 320Thr Ser Glu Asp Asp Asn Ile Thr Arg Gly Asp Thr Tyr Ile Thr Glu                325                 330                 335Lys Gln Lys Arg Glu Ala Ala Ala Ala Glu Val Lys Lys Glu Leu Lys            340                 345                 350Ile Gln Pro Leu Glu Lys Asp Ser Lys Ser Arg Ser Tyr Asn Val Leu        355                 360                 365Glu Asp Lys Ile Asn Thr Ala Tyr Arg Ser Trp Tyr Leu Ser Tyr Asn    370                 375                 380Tyr Gly Asn Pro Glu Lys Gly Ile Arg Ser Trp Thr Leu Leu Thr Thr385                 390                 395                 400Ser Asp Val Thr Cys Gly Ala Glu Gln Val Tyr Trp Ser Leu Pro Asp                405                 410                 415Met Met Gln Asp Pro Val Thr Phe Arg Ser Thr Arg Gln Val Asn Asn            420                 425                 430Tyr Pro Val Val Gly Ala Glu Leu Met Pro Val Phe Ser Lys Ser Phe        435                 440                 445Tyr Asn Glu Gln Ala Val Tyr Ser Gln Gln Leu Arg Gln Ala Thr Ser    450                 455                 460Leu Thr His Val Phe Asn Arg Phe Pro Glu Asn Gln Ile Leu Ile Arg465                 470                 475                 480Pro Pro Ala Pro Thr Ile Thr Thr Val Ser Glu Asn Val Pro Ala Leu                485                 490                 495Thr Asp His Gly Thr Leu Pro Leu Arg Ser Ser Ile Arg Gly Val Gln            500                 505                 510Arg Val Thr Val Thr Asp Ala Arg Arg Arg Thr Cys Pro Tyr Val Tyr        515                 520                 525Lys Ala Leu Gly Ile Val Ala Pro Arg Val Leu Ser Ser Arg Thr Phe    530                 535                 540</s400><s200><s210>47</s210><s211>544</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Ad7 penton base</s223></s220></s200><s400> 47Met Arg Arg Arg Ala Val Leu Gly Gly Ala Met Val Tyr Pro Glu Gly1               5                   10                  15Pro Pro Pro Ser Tyr Glu Ser Val Met Gln Gln Gln Ala Ala Met Ile            20                  25                  30Gln Pro Pro Leu Glu Ala Pro Phe Val Pro Pro Arg Tyr Leu Ala Pro        35                  40                  45Thr Glu Gly Arg Asn Ser Ile Arg Tyr Ser Glu Leu Ser Pro Leu Tyr    50                  55                  60Asp Thr Thr Lys Leu Tyr Leu Val Asp Asn Lys Ser Ala Asp Ile Ala65                  70                  75                  80Ser Leu Asn Tyr Gln Asn Asp His Ser Asn Phe Leu Thr Thr Val Val                85                  90                  95Gln Asn Asn Asp Phe Thr Pro Thr Glu Ala Ser Thr Gln Thr Ile Asn            100                 105                 110Phe Asp Glu Arg Ser Arg Trp Gly Gly Gln Leu Lys Thr Ile Met His        115                 120                 125Thr Asn Met Pro Asn Val Asn Glu Tyr Met Phe Ser Asn Lys Phe Lys    130                 135                 140Ala Arg Val Met Val Ser Arg Lys Ala Pro Glu Gly Val Ile Val Asn145                 150                 155                 160Asp Thr Tyr Asp His Lys Glu Asp Ile Leu Lys Tyr Glu Trp Phe Glu                165                 170                 175Phe Thr Leu Pro Glu Gly Asn Phe Ser Ala Thr Met Thr Ile Asp Leu            180                 185                 190Met Asn Asn Ala Ile Ile Asp Asn Tyr Leu Glu Ile Gly Arg Gln Asn        195                 200                 205Gly Val Leu Glu Ser Asp Ile Gly Val Lys Phe Asp Thr Arg Asn Phe    210                 215                 220Arg Leu Gly Trp Asp Pro Glu Thr Lys Leu Ile Met Pro Gly Val Tyr225                 230                 235                 240Thr Tyr Glu Ala Phe His Pro Asp Ile Val Leu Leu Pro Gly Cys Gly                245                 250                 255Val Asp Phe Thr Glu Ser Arg Leu Ser Asn Leu Leu Gly Ile Arg Lys            260                 265                 270Arg His Pro Phe Gln Glu Gly Phe Lys Ile Met Tyr Glu Asp Leu Glu        275                 280                 285Gly Gly Asn Ile Pro Ala Leu Leu Asp Val Thr Ala Tyr Glu Glu Ser    290                 295                 300Lys Lys Asp Thr Thr Thr Glu Thr Thr Thr Leu Ala Val Ala Glu Glu305                 310                 315                 320Thr Ser Glu Asp Asp Asn Ile Thr Arg Gly Asp Thr Tyr Ile Thr Glu                325                 330                 335Lys Gln Lys Arg Glu Ala Ala Ala Ala Glu Val Lys Lys Glu Leu Lys            340                 345                 350Ile Gln Pro Leu Glu Lys Asp Ser Lys Ser Arg Ser Tyr Asn Val Leu        355                 360                 365Glu Asp Lys Ile Asn Thr Ala Tyr Arg Ser Trp Tyr Leu Ser Tyr Asn    370                 375                 380Tyr Gly Asn Pro Glu Lys Gly Ile Arg Ser Trp Thr Leu Leu Thr Thr385                 390                 395                 400Ser Asp Val Thr Cys Gly Ala Glu Gln Val Tyr Trp Ser Leu Pro Asp                405                 410                 415Met Met Gln Asp Pro Val Thr Phe Arg Ser Thr Arg Gln Val Asn Asn            420                 425                 430Tyr Pro Val Val Gly Ala Glu Leu Met Pro Val Phe Ser Lys Ser Phe        435                 440                 445Tyr Asn Glu Gln Ala Val Tyr Ser Gln Gln Leu Arg Gln Ala Thr Ser    450                 455                 460Leu Thr His Val Phe Asn Arg Phe Pro Glu Asn Gln Ile Leu Ile Arg465                 470                 475                 480Pro Pro Ala Pro Thr Ile Thr Thr Val Ser Glu Asn Val Pro Ala Leu                485                 490                 495Thr Asp His Gly Thr Leu Pro Leu Arg Ser Ser Ile Arg Gly Val Gln            500                 505                 510Arg Val Thr Val Thr Asp Ala Arg Arg Arg Thr Cys Pro Tyr Val Tyr        515                 520                 525Lys Ala Leu Gly Ile Val Ala Pro Arg Val Leu Ser Ser Arg Thr Phe    530                 535                 540</s400><s200><s210>48</s210><s211>561</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Ad11 penton base</s223></s220></s200><s400> 48Met Arg Arg Val Val Leu Gly Gly Ala Val Val Tyr Pro Glu Gly Pro1               5                   10                  15Pro Pro Ser Tyr Glu Ser Val Met Gln Gln Gln Gln Ala Thr Ala Val            20                  25                  30Met Gln Ser Pro Leu Glu Ala Pro Phe Val Pro Pro Arg Tyr Leu Ala        35                  40                  45Pro Thr Glu Gly Arg Asn Ser Ile Arg Tyr Ser Glu Leu Ala Pro Gln    50                  55                  60Tyr Asp Thr Thr Arg Leu Tyr Leu Val Asp Asn Lys Ser Ala Asp Ile65                  70                  75                  80Ala Ser Leu Asn Tyr Gln Asn Asp His Ser Asn Phe Leu Thr Thr Val                85                  90                  95Val Gln Asn Asn Asp Phe Thr Pro Thr Glu Ala Ser Thr Gln Thr Ile            100                 105                 110Asn Phe Asp Glu Arg Ser Arg Trp Gly Gly Gln Leu Lys Thr Ile Met        115                 120                 125His Thr Asn Met Pro Asn Val Asn Glu Tyr Met Phe Ser Asn Lys Phe    130                 135                 140Lys Ala Arg Val Met Val Ser Arg Lys Pro Pro Asp Gly Ala Ala Val145                 150                 155                 160Gly Asp Thr Tyr Asp His Lys Gln Asp Ile Leu Lys Tyr Glu Trp Phe                165                 170                 175Glu Phe Thr Leu Pro Glu Gly Asn Phe Ser Val Thr Met Thr Ile Asp            180                 185                 190Leu Met Asn Asn Ala Ile Ile Asp Asn Tyr Leu Lys Val Gly Arg Gln        195                 200                 205Asn Gly Val Leu Glu Ser Asp Ile Gly Val Lys Phe Asp Thr Arg Asn    210                 215                 220Phe Lys Leu Gly Trp Asp Pro Glu Thr Lys Leu Ile Met Pro Gly Val225                 230                 235                 240Tyr Thr Tyr Glu Ala Phe His Pro Asp Ile Val Leu Leu Pro Gly Cys                245                 250                 255Gly Val Asp Phe Thr Glu Ser Arg Leu Ser Asn Leu Leu Gly Ile Arg            260                 265                 270Lys Lys Gln Pro Phe Gln Glu Gly Phe Lys Ile Leu Tyr Glu Asp Leu        275                 280                 285Glu Gly Gly Asn Ile Pro Ala Leu Leu Asp Val Asp Ala Tyr Glu Asn    290                 295                 300Ser Lys Lys Glu Gln Lys Ala Lys Ile Glu Ala Ala Thr Ala Ala Ala305                 310                 315                 320Glu Ala Lys Ala Asn Ile Val Ala Ser Asp Ser Thr Arg Val Ala Asn                325                 330                 335Ala Gly Glu Val Arg Gly Asp Asn Phe Ala Pro Thr Pro Val Pro Thr            340                 345                 350Ala Glu Ser Leu Leu Ala Asp Val Ser Glu Gly Thr Asp Val Lys Leu        355                 360                 365Thr Ile Gln Pro Val Glu Lys Asp Ser Lys Asn Arg Ser Tyr Asn Val    370                 375                 380Leu Glu Asp Lys Ile Asn Thr Ala Tyr Arg Ser Trp Tyr Leu Ser Tyr385                 390                 395                 400Asn Tyr Gly Asp Pro Glu Lys Gly Val Arg Ser Trp Thr Leu Leu Thr                405                 410                 415Thr Ser Asp Val Thr Cys Gly Ala Glu Gln Val Tyr Trp Ser Leu Pro            420                 425                 430Asp Met Met Lys Asp Pro Val Thr Phe Arg Ser Thr Arg Gln Val Ser        435                 440                 445Asn Tyr Pro Val Val Gly Ala Glu Leu Met Pro Val Phe Ser Lys Ser    450                 455                 460Phe Tyr Asn Glu Gln Ala Val Tyr Ser Gln Gln Leu Arg Gln Ser Thr465                 470                 475                 480Ser Leu Thr His Val Phe Asn Arg Phe Pro Glu Asn Gln Ile Leu Ile                485                 490                 495Arg Pro Pro Ala Pro Thr Ile Thr Thr Val Ser Glu Asn Val Pro Ala            500                 505                 510Leu Thr Asp His Gly Thr Leu Pro Leu Arg Ser Ser Ile Arg Gly Val        515                 520                 525Gln Arg Val Thr Val Thr Asp Ala Arg Arg Arg Thr Cys Pro Tyr Val    530                 535                 540Tyr Lys Ala Leu Gly Ile Val Ala Pro Arg Val Leu Ser Ser Arg Thr545                 550                 555                 560Phe</s400><s200><s210>49</s210><s211>508</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Ad41 penton base</s223></s220></s200><s400> 49Met Arg Arg Ala Val Gly Val Pro Pro Val Met Ala Tyr Ala Glu Gly1               5                   10                  15Pro Pro Pro Ser Tyr Glu Ser Val Met Gly Ser Ala Asp Ser Pro Ala            20                  25                  30Thr Leu Glu Ala Leu Tyr Val Pro Pro Arg Tyr Leu Gly Pro Thr Glu        35                  40                  45Gly Arg Asn Ser Ile Arg Tyr Ser Glu Leu Ala Pro Leu Tyr Asp Thr    50                  55                  60Thr Arg Val Tyr Leu Val Asp Asn Lys Ser Ala Asp Ile Ala Ser Leu65                  70                  75                  80Asn Tyr Gln Asn Asp His Ser Asn Phe Gln Thr Thr Val Val Gln Asn                85                  90                  95Asn Asp Phe Thr Pro Ala Glu Ala Gly Thr Gln Thr Ile Asn Phe Asp            100                 105                 110Glu Arg Ser Arg Trp Gly Ala Asp Leu Lys Thr Ile Leu Arg Thr Asn        115                 120                 125Met Pro Asn Ile Asn Glu Phe Met Ser Thr Asn Lys Phe Lys Ala Arg    130                 135                 140Leu Met Val Glu Lys Lys Asn Lys Glu Thr Gly Leu Pro Arg Tyr Glu145                 150                 155                 160Trp Phe Glu Phe Thr Leu Pro Glu Gly Asn Tyr Ser Glu Thr Met Thr                165                 170                 175Ile Asp Leu Met Asn Asn Ala Ile Val Asp Asn Tyr Leu Glu Val Gly            180                 185                 190Arg Gln Asn Gly Val Leu Glu Ser Asp Ile Gly Val Lys Phe Asp Thr        195                 200                 205Arg Asn Phe Arg Leu Gly Trp Asp Pro Val Thr Lys Leu Val Met Pro    210                 215                 220Gly Val Tyr Thr Asn Glu Ala Phe His Pro Asp Ile Val Leu Leu Pro225                 230                 235                 240Gly Cys Gly Val Asp Phe Thr Gln Ser Arg Leu Ser Asn Leu Leu Gly                245                 250                 255Ile Arg Lys Arg Leu Pro Phe Gln Glu Gly Phe Gln Ile Met Tyr Glu            260                 265                 270Asp Leu Glu Gly Gly Asn Ile Pro Ala Leu Leu Asp Val Ala Lys Tyr        275                 280                 285Glu Ala Ser Ile Gln Lys Ala Lys Glu Glu Gly Lys Glu Ile Gly Asp    290                 295                 300Asp Thr Phe Ala Thr Arg Pro Gln Asp Leu Val Ile Glu Pro Val Ala305                 310                 315                 320Lys Asp Ser Lys Asn Arg Ser Tyr Asn Leu Leu Pro Asn Asp Gln Asn                325                 330                 335Asn Thr Ala Tyr Arg Ser Trp Phe Leu Ala Tyr Asn Tyr Gly Asp Pro            340                 345                 350Lys Lys Gly Val Gln Ser Trp Thr Leu Leu Thr Thr Ala Asp Val Thr        355                 360                 365Cys Gly Ser Gln Gln Val Tyr Trp Ser Leu Pro Asp Met Met Gln Asp    370                 375                 380Pro Val Thr Phe Arg Pro Ser Thr Gln Val Ser Asn Tyr Pro Val Val385                 390                 395                 400Gly Val Glu Leu Leu Pro Val His Ala Lys Ser Phe Tyr Asn Glu Gln                405                 410                 415Ala Val Tyr Ser Gln Leu Ile Arg Gln Ser Thr Ala Leu Thr His Val            420                 425                 430Phe Asn Arg Phe Pro Glu Asn Gln Ile Leu Val Arg Pro Pro Ala Pro        435                 440                 445Thr Ile Thr Thr Val Ser Glu Asn Val Pro Ala Leu Thr Asp His Gly    450                 455                 460Thr Leu Pro Leu Arg Ser Ser Ile Ser Gly Val Gln Arg Val Thr Ile465                 470                 475                 480Thr Asp Ala Arg Arg Arg Thr Cys Pro Tyr Val His Lys Ala Leu Gly                485                 490                 495Ile Val Ala Pro Lys Val Leu Ser Ser Arg Thr Phe            500                 505</s400><s200><s210>50</s210><s211>497</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Ad12 penton base</s223></s220></s200><s400> 50Met Arg Arg Ala Val Glu Leu Gln Thr Val Ala Phe Pro Glu Thr Pro1               5                   10                  15Pro Pro Ser Tyr Glu Thr Val Met Ala Ala Ala Pro Pro Tyr Val Pro            20                  25                  30Pro Arg Tyr Leu Gly Pro Thr Glu Gly Arg Asn Ser Ile Arg Tyr Ser        35                  40                  45Glu Leu Ser Pro Leu Tyr Asp Thr Thr Arg Val Tyr Leu Val Asp Asn    50                  55                  60Lys Ser Ser Asp Ile Ala Ser Leu Asn Tyr Gln Asn Asp His Ser Asn65                  70                  75                  80Phe Leu Thr Thr Val Val Gln Asn Asn Asp Tyr Ser Pro Ile Glu Ala                85                  90                  95Gly Thr Gln Thr Ile Asn Phe Asp Glu Arg Ser Arg Trp Gly Gly Asp            100                 105                 110Leu Lys Thr Ile Leu His Thr Asn Met Pro Asn Val Asn Asp Phe Met        115                 120                 125Phe Thr Thr Lys Phe Lys Ala Arg Val Met Val Ala Arg Lys Thr Asn    130                 135                 140Asn Glu Gly Gln Thr Ile Leu Glu Tyr Glu Trp Ala Glu Phe Val Leu145                 150                 155                 160Pro Glu Gly Asn Tyr Ser Glu Thr Met Thr Ile Asp Leu Met Asn Asn                165                 170                 175Ala Ile Ile Glu His Tyr Leu Arg Val Gly Arg Gln His Gly Val Leu            180                 185                 190Glu Ser Asp Ile Gly Val Lys Phe Asp Thr Arg Asn Phe Arg Leu Gly        195                 200                 205Trp Asp Pro Glu Thr Gln Leu Val Thr Pro Gly Val Tyr Thr Asn Glu    210                 215                 220Ala Phe His Pro Asp Ile Val Leu Leu Pro Gly Cys Gly Val Asp Phe225                 230                 235                 240Thr Glu Ser Arg Leu Ser Asn Ile Leu Gly Ile Arg Lys Arg Gln Pro                245                 250                 255Phe Gln Glu Gly Phe Val Ile Met Tyr Glu His Leu Glu Gly Gly Asn            260                 265                 270Ile Pro Ala Leu Leu Asp Val Lys Lys Tyr Glu Asn Ser Leu Gln Asp        275                 280                 285Gln Asn Thr Val Arg Gly Asp Asn Phe Ile Ala Leu Asn Lys Ala Ala    290                 295                 300Arg Ile Glu Pro Val Glu Thr Asp Pro Lys Gly Arg Ser Tyr Asn Leu305                 310                 315                 320Leu Pro Asp Lys Lys Asn Thr Lys Tyr Arg Ser Trp Tyr Leu Ala Tyr                325                 330                 335Asn Tyr Gly Asp Pro Glu Lys Gly Val Arg Ser Trp Thr Leu Leu Thr            340                 345                 350Thr Pro Asp Val Thr Gly Gly Ser Glu Gln Val Tyr Trp Ser Leu Pro        355                 360                 365Asp Met Met Gln Asp Pro Val Thr Phe Arg Ser Ser Arg Gln Val Ser    370                 375                 380Asn Tyr Pro Val Val Ala Ala Glu Leu Leu Pro Val His Ala Lys Ser385                 390                 395                 400Phe Tyr Asn Glu Gln Ala Val Tyr Ser Gln Leu Ile Arg Gln Ser Thr                405                 410                 415Ala Leu Thr Arg Val Phe Asn Arg Phe Pro Glu Asn Gln Ile Leu Val            420                 425                 430Arg Pro Pro Ala Ala Thr Ile Thr Thr Val Ser Glu Asn Val Pro Ala        435                 440                 445Leu Thr Asp His Gly Thr Leu Pro Leu Arg Ser Ser Ile Ser Gly Val    450                 455                 460Gln Arg Val Thr Ile Thr Asp Ala Arg Arg Arg Thr Cys Pro Tyr Val465                 470                 475                 480Tyr Lys Ala Leu Gly Ile Val Ser Pro Arg Val Leu Ser Ser Arg Thr                485                 490                 495Phe</s400><s200><s210>51</s210><s211>517</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Ad17 penton base</s223></s220></s200><s400> 51Met Arg Arg Ala Val Val Ser Ser Ser Pro Pro Pro Ser Tyr Glu Ser1               5                   10                  15Val Met Ala Gln Ala Thr Leu Glu Val Pro Phe Val Pro Pro Arg Tyr            20                  25                  30Met Ala Pro Thr Glu Gly Arg Asn Ser Ile Arg Tyr Ser Glu Leu Ala        35                  40                  45Pro Leu Tyr Asp Thr Thr Arg Val Tyr Leu Val Asp Asn Lys Ser Ala    50                  55                  60Asp Ile Ala Ser Leu Asn Tyr Gln Asn Asp His Ser Asn Phe Leu Thr65                  70                  75                  80Thr Val Val Gln Asn Asn Asp Phe Thr Pro Ala Glu Ala Ser Thr Gln                85                  90                  95Thr Ile Asn Phe Asp Glu Arg Ser Arg Trp Gly Gly Asp Leu Lys Thr            100                 105                 110Ile Leu His Thr Asn Met Pro Asn Val Asn Glu Tyr Met Phe Thr Ser        115                 120                 125Lys Phe Lys Ala Arg Val Met Val Ala Arg Lys His Pro Gln Gly Val    130                 135                 140Glu Ala Thr Asp Leu Ser Lys Asp Ile Leu Glu Tyr Glu Trp Phe Glu145                 150                 155                 160Phe Thr Leu Pro Glu Gly Asn Phe Ser Glu Thr Met Thr Ile Asp Leu                165                 170                 175Met Asn Asn Ala Ile Leu Glu Asn Tyr Leu Gln Val Gly Arg Gln Asn            180                 185                 190Gly Val Leu Glu Ser Asp Ile Gly Val Lys Phe Asp Ser Arg Asn Phe        195                 200                 205Lys Leu Gly Trp Asp Pro Val Thr Lys Leu Val Met Pro Gly Val Tyr    210                 215                 220Thr Tyr Glu Ala Phe His Pro Asp Val Val Leu Leu Pro Gly Cys Gly225                 230                 235                 240Val Asp Phe Thr Glu Ser Arg Leu Ser Asn Leu Leu Gly Ile Arg Lys                245                 250                 255Lys Gln Pro Phe Gln Glu Gly Phe Arg Ile Met Tyr Glu Asp Leu Glu            260                 265                 270Gly Gly Asn Ile Pro Ala Leu Leu Asp Val Pro Lys Tyr Leu Glu Ser        275                 280                 285Lys Lys Lys Leu Glu Glu Ala Leu Glu Asn Ala Ala Lys Ala Asn Gly    290                 295                 300Pro Ala Arg Gly Asp Ser Ser Val Ser Arg Glu Val Glu Lys Ala Ala305                 310                 315                 320Glu Lys Glu Leu Val Ile Glu Pro Ile Lys Gln Asp Asp Ser Lys Arg                325                 330                 335Ser Tyr Asn Leu Ile Glu Gly Thr Met Asp Thr Leu Tyr Arg Ser Trp            340                 345                 350Tyr Leu Ser Tyr Thr Tyr Gly Asp Pro Glu Lys Gly Val Gln Ser Trp        355                 360                 365Thr Leu Leu Thr Thr Pro Asp Val Thr Cys Gly Ala Glu Gln Val Tyr    370                 375                 380Trp Ser Leu Pro Asp Leu Met Gln Asp Pro Val Thr Phe Arg Ser Thr385                 390                 395                 400Gln Gln Val Ser Asn Tyr Pro Val Val Gly Ala Glu Leu Met Pro Phe                405                 410                 415Arg Ala Lys Ser Phe Tyr Asn Asp Leu Ala Val Tyr Ser Gln Leu Ile            420                 425                 430Arg Ser Tyr Thr Ser Leu Thr His Val Phe Asn Arg Phe Pro Asp Asn        435                 440                 445Gln Ile Leu Cys Arg Pro Pro Ala Pro Thr Ile Thr Thr Val Ser Glu    450                 455                 460Asn Val Pro Ala Leu Thr Asp His Gly Thr Leu Pro Leu Arg Ser Ser465                 470                 475                 480Ile Arg Gly Val Gln Arg Val Thr Val Thr Asp Ala Arg Arg Arg Thr                485                 490                 495Cys Pro Tyr Val Tyr Lys Ala Leu Gly Ile Val Ala Pro Arg Val Leu            500                 505                 510Ser Ser Arg Thr Phe        515</s400><s200><s210>52</s210><s211>520</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Ad25 penton base</s223></s220></s200><s400> 52Met Arg Arg Ala Val Val Ser Ser Ser Pro Pro Pro Ser Tyr Glu Ser1               5                   10                  15Val Met Ala Gln Ala Thr Leu Glu Val Pro Phe Val Pro Pro Arg Tyr            20                  25                  30Met Ala Pro Thr Glu Gly Arg Asn Ser Ile Arg Tyr Ser Glu Leu Ala        35                  40                  45Pro Gln Tyr Asp Thr Thr Arg Val Tyr Leu Val Asp Asn Lys Ser Ala    50                  55                  60Asp Ile Ala Ser Leu Asn Tyr Gln Asn Asp His Ser Asn Phe Leu Thr65                  70                  75                  80Thr Val Val Gln Asn Asn Asp Phe Thr Pro Ala Glu Ala Ser Thr Gln                85                  90                  95Thr Ile Asn Phe Asp Glu Arg Ser Arg Trp Gly Gly Asp Leu Lys Thr            100                 105                 110Ile Leu His Thr Asn Met Pro Asn Val Asn Glu Tyr Met Phe Thr Ser        115                 120                 125Lys Phe Lys Ala Arg Val Met Val Ala Arg Lys His Pro Glu Asn Val    130                 135                 140Asp Lys Thr Asp Leu Ser Gln Asp Lys Leu Glu Tyr Glu Trp Phe Glu145                 150                 155                 160Phe Thr Leu Pro Glu Gly Asn Phe Ser Glu Thr Met Thr Ile Asp Leu                165                 170                 175Met Asn Asn Ala Ile Leu Glu Asn Tyr Leu Gln Val Gly Arg Gln Asn            180                 185                 190Gly Val Leu Glu Ser Asp Ile Gly Val Lys Phe Asp Ser Arg Asn Phe        195                 200                 205Lys Leu Gly Trp Asp Pro Val Thr Lys Leu Val Met Pro Gly Val Tyr    210                 215                 220Thr Tyr Glu Ala Phe His Pro Asp Val Val Leu Leu Pro Gly Cys Gly225                 230                 235                 240Val Asp Phe Thr Glu Ser Arg Leu Ser Asn Leu Leu Gly Ile Arg Lys                245                 250                 255Lys Gln Pro Phe Gln Glu Gly Phe Arg Ile Met Tyr Glu Asp Leu Glu            260                 265                 270Gly Gly Asn Ile Pro Ala Leu Leu Asp Thr Lys Lys Tyr Leu Asp Ser        275                 280                 285Lys Lys Glu Leu Glu Asp Ala Ala Lys Glu Ala Ala Lys Gln Gln Gly    290                 295                 300Asp Gly Ala Val Thr Arg Gly Asp Thr His Leu Thr Val Ala Gln Glu305                 310                 315                 320Lys Ala Ala Glu Lys Glu Leu Val Ile Val Pro Ile Glu Lys Asp Glu                325                 330                 335Ser Asn Arg Ser Tyr Asn Leu Ile Lys Asp Thr His Asp Thr Met Tyr            340                 345                 350Arg Ser Trp Tyr Leu Ser Tyr Thr Tyr Gly Asp Pro Glu Lys Gly Val        355                 360                 365Gln Ser Trp Thr Leu Leu Thr Thr Pro Asp Val Thr Cys Gly Ala Glu    370                 375                 380Gln Val Tyr Trp Ser Leu Pro Asp Leu Met Gln Asp Pro Val Thr Phe385                 390                 395                 400Arg Ser Thr Gln Gln Val Ser Asn Tyr Pro Val Val Gly Ala Glu Leu                405                 410                 415Met Pro Phe Arg Ala Lys Ser Phe Tyr Asn Asp Leu Ala Val Tyr Ser            420                 425                 430Gln Leu Ile Arg Ser Tyr Thr Ser Leu Thr His Val Phe Asn Arg Phe        435                 440                 445Pro Asp Asn Gln Ile Leu Cys Arg Pro Pro Ala Pro Thr Ile Thr Thr    450                 455                 460Val Ser Glu Asn Val Pro Ala Leu Thr Asp His Gly Thr Leu Pro Leu465                 470                 475                 480Arg Ser Ser Ile Arg Gly Val Gln Arg Val Thr Val Thr Asp Ala Arg                485                 490                 495Arg Arg Thr Cys Pro Tyr Val Tyr Lys Ala Leu Gly Ile Val Ala Pro            500                 505                 510Arg Val Leu Ser Ser Arg Thr Phe        515                 520</s400><s200><s210>53</s210><s211>519</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Ad37 penton base</s223></s220></s200><s400> 53Met Arg Arg Ala Val Val Ser Ser Ser Pro Pro Pro Ser Tyr Glu Ser1               5                   10                  15Val Met Ala Gln Ala Thr Leu Glu Val Pro Phe Val Pro Pro Arg Tyr            20                  25                  30Met Ala Pro Thr Glu Gly Arg Asn Ser Ile Arg Tyr Ser Glu Leu Ala        35                  40                  45Pro Leu Tyr Asp Thr Thr Arg Val Tyr Leu Val Asp Asn Lys Ser Ala    50                  55                  60Asp Ile Ala Ser Leu Asn Tyr Gln Asn Asp His Ser Asn Phe Leu Thr65                  70                  75                  80Thr Val Val Gln Asn Asn Asp Phe Thr Pro Ala Glu Ala Ser Thr Gln                85                  90                  95Thr Ile Asn Phe Asp Glu Arg Ser Arg Trp Gly Gly Asp Leu Lys Thr            100                 105                 110Ile Leu His Thr Asn Met Pro Asn Val Asn Glu Tyr Met Phe Thr Ser        115                 120                 125Lys Phe Lys Ala Arg Val Met Val Ala Arg Lys Lys Ala Glu Gly Ala    130                 135                 140Asp Ala Asn Asp Arg Ser Lys Asp Ile Leu Glu Tyr Gln Trp Phe Glu145                 150                 155                 160Phe Thr Leu Pro Glu Gly Asn Phe Ser Glu Thr Met Thr Ile Asp Leu                165                 170                 175Met Asn Asn Ala Ile Leu Glu Asn Tyr Leu Gln Val Gly Arg Gln Asn            180                 185                 190Gly Val Leu Glu Ser Asp Ile Gly Val Lys Phe Asp Ser Arg Asn Phe        195                 200                 205Lys Leu Gly Trp Asp Pro Val Thr Lys Leu Val Met Pro Gly Val Tyr    210                 215                 220Thr Tyr Glu Ala Phe His Pro Asp Val Val Leu Leu Pro Gly Cys Gly225                 230                 235                 240Val Asp Phe Thr Glu Ser Arg Leu Ser Asn Leu Leu Gly Ile Arg Lys                245                 250                 255Lys Gln Pro Phe Gln Glu Gly Phe Arg Ile Met Tyr Glu Asp Leu Val            260                 265                 270Gly Gly Asn Ile Pro Ala Leu Leu Asn Val Lys Glu Tyr Leu Lys Asp        275                 280                 285Lys Glu Glu Ala Gly Lys Ala Asp Ala Asn Thr Ile Lys Ala Gln Asn    290                 295                 300Asp Ala Val Pro Arg Gly Asp Asn Tyr Ala Ser Ala Ala Glu Ala Lys305                 310                 315                 320Ala Ala Gly Lys Glu Ile Glu Leu Lys Ala Ile Leu Lys Asp Asp Ser                325                 330                 335Asp Arg Ser Tyr Asn Val Ile Glu Gly Thr Thr Asp Thr Leu Tyr Arg            340                 345                 350Ser Trp Tyr Leu Ser Tyr Thr Tyr Gly Asp Pro Glu Lys Gly Val Gln        355                 360                 365Ser Trp Thr Leu Leu Thr Thr Pro Asp Val Thr Cys Gly Ala Glu Gln    370                 375                 380Val Tyr Trp Ser Leu Pro Asp Leu Met Gln Asp Pro Val Thr Phe Arg385                 390                 395                 400Ser Thr Gln Gln Val Ser Asn Tyr Pro Val Val Gly Ala Glu Leu Met                405                 410                 415Pro Phe Arg Ala Lys Ser Phe Tyr Asn Asp Leu Ala Val Tyr Ser Gln            420                 425                 430Leu Ile Arg Ser Tyr Thr Ser Leu Thr His Val Phe Asn Arg Phe Pro        435                 440                 445Asp Asn Gln Ile Leu Cys Arg Pro Pro Ala Pro Thr Ile Thr Thr Val    450                 455                 460Ser Glu Asn Val Pro Ala Leu Thr Asp His Gly Thr Leu Pro Leu Arg465                 470                 475                 480Ser Ser Ile Arg Gly Val Gln Arg Val Thr Val Thr Asp Ala Arg Arg                485                 490                 495Arg Thr Cys Pro Tyr Val Tyr Lys Ala Leu Gly Ile Val Ala Pro Arg            500                 505                 510Val Leu Ser Ser Arg Thr Phe        515</s400><s200><s210>54</s210><s211>101</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Wild type Ad5 penton base</s223></s220></s200><s400> 54Asp Ala Tyr Gln Ala Ser Leu Lys Asp Asp Thr Glu Gln Gly Gly Gly1               5                   10                  15Gly Ala Gly Gly Ser Asn Ser Ser Gly Ser Gly Ala Glu Glu Asn Ser            20                  25                  30Asn Ala Ala Ala Ala Ala Met Gln Pro Val Glu Asp Met Asn Asp His        35                  40                  45Ala Ile Arg Gly Asp Thr Phe Ala Thr Arg Ala Glu Glu Lys Arg Ala    50                  55                  60Glu Ala Glu Ala Ala Ala Glu Ala Ala Ala Pro Ala Ala Gln Pro Glu65                  70                  75                  80Val Glu Lys Pro Gln Lys Lys Pro Val Ile Lys Pro Leu Thr Glu Asp                85                  90                  95Ser Lys Lys Arg Ser            100</s400><s200><s210>55</s210><s211>98</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic RGD-motif-deleted penton base</s223></s220></s200><s400> 55Asp Ala Tyr Gln Ala Ser Leu Lys Asp Asp Thr Glu Gln Gly Gly Gly1               5                   10                  15Gly Ala Gly Gly Ser Asn Ser Ser Gly Ser Gly Ala Glu Glu Asn Ser            20                  25                  30Asn Ala Ala Ala Ala Ala Met Gln Pro Val Glu Asp Met Asn Asp His        35                  40                  45Ala Ile Thr Phe Ala Thr Arg Ala Glu Glu Lys Arg Ala Glu Ala Glu    50                  55                  60Ala Ala Ala Glu Ala Ala Ala Pro Ala Ala Gln Pro Glu Val Glu Lys65                  70                  75                  80Pro Gln Lys Lys Pro Val Ile Lys Pro Leu Thr Glu Asp Ser Lys Lys                85                  90                  95Arg Ser</s400><s200><s210>56</s210><s211>57</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Ad5-GFP</s223></s220></s200><s400> 56Asn Ala Ala Ala Ala Ala Met Gln Pro Val Glu Asp Met Asn Asp His1               5                   10                  15Ala Ile Arg Gly Asp Thr Phe Ala Thr Arg Ala Glu Glu Lys Arg Ala            20                  25                  30Glu Ala Glu Ala Ala Ala Glu Ala Ala Ala Pro Ala Ala Gln Pro Glu        35                  40                  45Val Glu Lys Pro Gln Lys Lys Pro Val    50                  55</s400><s200><s210>57</s210><s211>54</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic dRGD</s223></s220></s200><s400> 57Asn Ala Ala Ala Ala Ala Met Gln Pro Val Glu Asp Met Asn Asp His1               5                   10                  15Ala Ile Thr Phe Ala Thr Arg Ala Glu Glu Lys Arg Ala Glu Ala Glu            20                  25                  30Ala Ala Ala Glu Ala Ala Ala Pro Ala Ala Gln Pro Glu Val Glu Lys        35                  40                  45Pro Gln Lys Lys Pro Val    50</s400><s200><s210>58</s210><s211>12</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic HVR1-deletion in Ad3M</s223></s220></s200><s400> 58Glu Trp Asp Ser Ala Ala Thr Ser Thr Ala Gly Gly1               5                   10</s400><s200><s210>59</s210><s211>67</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Ad5</s223></s220></s200><s400> 59Asn Pro Cys Glu Trp Asp Glu Ala Ala Thr Ala Leu Glu Ile Asn Leu1               5                   10                  15Glu Glu Glu Asp Asp Asp Asn Glu Asp Glu Val Asp Glu Gln Ala Glu            20                  25                  30Gln Gln Lys Thr His Val Phe Gly Gln Ala Pro Tyr Ser Gly Ile Asn        35                  40                  45Ile Thr Lys Glu Gly Ile Gln Ile Gly Val Glu Gly Gln Thr Pro Lys    50                  55                  60Tyr Ala Asp65</s400><s200><s210>60</s210><s211>78</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Ad2</s223></s220></s200><s400> 60Asn Ser Cys Glu Trp Glu Gln Thr Glu Asp Ser Gly Arg Ala Val Ala1               5                   10                  15Glu Asp Glu Glu Glu Glu Asp Glu Asp Glu Glu Glu Glu Glu Glu Glu            20                  25                  30Gln Asn Ala Arg Asp Gln Ala Thr Lys Lys Thr His Val Tyr Ala Gln        35                  40                  45Ala Pro Leu Ser Gly Glu Thr Ile Thr Lys Ser Gly Leu Gln Ile Gly    50                  55                  60Ser Asp Asn Ala Glu Thr Gln Ala Lys Pro Val Tyr Ala Asp65                  70                  75</s400><s200><s210>61</s210><s211>50</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Ad16</s223></s220></s200><s400> 61Asn Thr Cys Gln Trp Lys Asp Ser Asp Ser Lys Met His Thr Phe Gly1               5                   10                  15Val Ala Ala Met Pro Gly Val Thr Gly Lys Lys Ile Glu Ala Asp Gly            20                  25                  30Leu Pro Ile Gly Ile Asp Ser Thr Ser Gly Thr Asp Thr Val Ile Tyr        35                  40                  45Ala Asp    50</s400><s200><s210>62</s210><s211>50</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Ad4</s223></s220></s200><s400> 62Asn Thr Cys Gln Trp Lys Asp Ser Asp Ser Lys Met His Thr Phe Gly1               5                   10                  15Ala Ala Ala Met Pro Gly Val Thr Gly Lys Lys Ile Glu Ala Asp Gly            20                  25                  30Leu Pro Ile Arg Ile Asp Ser Thr Ser Gly Thr Asp Thr Val Ile Tyr        35                  40                  45Ala Asp    50</s400><s200><s210>63</s210><s211>56</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Ad3</s223></s220></s200><s400> 63Asn Thr Ser Gln Trp Ile Val Thr Thr Asn Gly Asp Asn Ala Val Thr1               5                   10                  15Thr Thr Thr Asn Thr Phe Gly Ile Ala Ser Met Lys Gly Asp Asn Ile            20                  25                  30Thr Lys Glu Gly Leu Gln Ile Gly Lys Asp Ile Thr Thr Thr Glu Gly        35                  40                  45Glu Glu Lys Pro Ile Tyr Ala Asp    50                  55</s400><s200><s210>64</s210><s211>65</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Ad21</s223></s220></s200><s400> 64Asn Thr Ser Gln Trp Ile Ala Glu Gly Val Lys Lys Glu Asp Gly Gly1               5                   10                  15Ser Asp Glu Glu Glu Glu Lys Asn Leu Thr Thr Tyr Thr Phe Gly Asn            20                  25                  30Ala Pro Val Lys Ala Glu Gly Gly Asp Ile Thr Lys Asp Lys Gly Leu        35                  40                  45Pro Ile Gly Ser Glu Ile Thr Asp Gly Glu Ala Lys Pro Ile Tyr Ala    50                  55                  60Asp65</s400><s200><s210>65</s210><s211>68</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Ad35</s223></s220></s200><s400> 65Asn Ala Ser Gln Trp Ile Ala Lys Gly Val Pro Thr Ala Ala Ala Ala1               5                   10                  15Gly Asn Gly Glu Glu Glu His Glu Thr Glu Glu Lys Thr Ala Thr Tyr            20                  25                  30Thr Phe Ala Asn Ala Pro Val Lys Ala Glu Ala Gln Ile Thr Lys Glu        35                  40                  45Gly Leu Pro Ile Gly Leu Glu Ile Ser Ala Glu Asn Glu Ser Lys Pro    50                  55                  60Ile Tyr Ala Asp65</s400><s200><s210>66</s210><s211>58</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Ad50</s223></s220></s200><s400> 66Asn Thr Ser Gln Trp Leu Asn Lys Gly Asp Glu Glu Asp Gly Glu Asp1               5                   10                  15Asp Gln Gln Ala Thr Tyr Thr Phe Gly Asn Ala Pro Val Lys Ala Glu            20                  25                  30Ala Glu Ile Thr Lys Glu Gly Leu Pro Ile Gly Leu Glu Val Pro Ser        35                  40                  45Glu Gly Gly Pro Lys Pro Ile Tyr Ala Asp    50                  55</s400><s200><s210>67</s210><s211>54</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Ad51</s223></s220></s200><s400> 67Asn Ser Ser Gln Trp Glu Gln Lys Lys Thr Thr Gly Gly Gly Asn Asp1               5                   10                  15Met Glu Thr His Thr Phe Gly Val Ala Ala Met Gly Gly Glu Asn Ile            20                  25                  30Thr Lys Asp Gly Leu Gln Ile Gly Thr Asp Thr Thr Ala Asp Ala Asp        35                  40                  45Lys Pro Ile Tyr Ala Asp    50</s400><s200><s210>68</s210><s211>54</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Ad9</s223></s220></s200><s400> 68Asn Ser Ser Gln Trp Leu Ala Lys Asp Thr Asn Ala Gly Asp Gln Ala1               5                   10                  15Leu Lys Thr His Thr His Gly Val Ala Ala Met Gly Gly Thr Asp Ile            20                  25                  30Thr Ala Lys Gly Leu Gln Ile Gly Val Asp Thr Thr Glu Asn Lys Asn        35                  40                  45Glu Pro Ile Tyr Ala Asn    50</s400><s200><s210>69</s210><s211>44</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Ad41</s223></s220></s200><s400> 69Asn Pro Cys Glu Trp Lys Asp Asn Asn Lys Ile Lys Val Arg Gly Gln1               5                   10                  15Ala Pro Phe Ile Gly Thr Asn Ile Asn Lys Asp Asn Gly Ile Gln Ile            20                  25                  30Gly Thr Asp Thr Thr Asn Gln Pro Ile Tyr Ala Asp        35                  40</s400><s200><s210>70</s210><s211>69</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic RGD-loop-mutated penton base -      a3b1-integrin-binding peptide</s223></s220></s200><s400> 70Asp Ala Tyr Gln Ala Ser Leu Lys Asp Asp Thr Glu Gln Gly Gly Gly1               5                   10                  15Gly Ala Gly Gly Ser Asn Ser Ser Gly Ser Gly Cys Asn Gly Gln Gly            20                  25                  30Glu Gln Cys Ala Ala Ala Glu Ala Ala Ala Pro Ala Ala Gln Pro Glu        35                  40                  45Val Glu Lys Pro Gln Lys Lys Pro Val Ile Lys Pro Leu Thr Glu Asp    50                  55                  60Ser Lys Lys Arg Ser65</s400><s200><s210>71</s210><s211>70</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic RGD-loop-mutated penton base -      a5b1-integrin-binding peptide</s223></s220></s200><s400> 71Asp Ala Tyr Gln Ala Ser Leu Lys Asp Asp Thr Glu Gln Gly Gly Gly1               5                   10                  15Gly Ala Gly Gly Ser Asn Ser Ser Gly Ser Gly Arg Lys Lys Arg Arg            20                  25                  30Gln Arg Arg Arg Ala Ala Ala Glu Ala Ala Ala Pro Ala Ala Gln Pro        35                  40                  45Glu Val Glu Lys Pro Gln Lys Lys Pro Val Ile Lys Pro Leu Thr Glu    50                  55                  60Asp Ser Lys Lys Arg Ser65                  70</s400></sequence-list-new-rules></sequence-cwu><?xml version="1.0" encoding="UTF-8"?><!DOCTYPE us-patent-application SYSTEM "us-patent-application-v46-2022-02-17.dtd" [ ]><us-patent-application lang="EN" dtd-version="v4.6 2022-02-17" file="US20230001015A1-20230105.XML" status="PRODUCTION" id="us-patent-application" country="US" date-produced="20221221" date-publ="20230105"><us-bibliographic-data-application lang="EN" country="US"><publication-reference><document-id><country>US</country><doc-number>20230001015</doc-number><kind>A1</kind><date>20230105</date></document-id></publication-reference><application-reference appl-type="utility"><document-id><country>US</country><doc-number>17719019</doc-number><date>20220412</date></document-id></application-reference><us-application-series-code>17</us-application-series-code><classifications-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>48</main-group><subgroup>00</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>07</class><subclass>K</subclass><main-group>14</main-group><subgroup>47</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>38</main-group><subgroup>17</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>31</main-group><subgroup>7088</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>12</class><subclass>N</subclass><main-group>15</main-group><subgroup>11</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>12</class><subclass>N</subclass><main-group>15</main-group><subgroup>113</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>12</class><subclass>N</subclass><main-group>15</main-group><subgroup>86</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>P</subclass><main-group>21</main-group><subgroup>00</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>9</main-group><subgroup>00</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>P</subclass><main-group>19</main-group><subgroup>04</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>35</main-group><subgroup>761</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>12</class><subclass>N</subclass><main-group>15</main-group><subgroup>864</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr></classifications-ipcr><classifications-cpc><main-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>48</main-group><subgroup>005</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></main-cpc><further-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>14</main-group><subgroup>4708</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>38</main-group><subgroup>1709</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>31</main-group><subgroup>7088</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>15</main-group><subgroup>111</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>15</main-group><subgroup>113</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>48</main-group><subgroup>0058</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>15</main-group><subgroup>86</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20180101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>P</subclass><main-group>21</main-group><subgroup>00</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>9</main-group><subgroup>0019</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>38</main-group><subgroup>1719</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20180101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>P</subclass><main-group>19</main-group><subgroup>04</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>35</main-group><subgroup>761</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>48</main-group><subgroup>0075</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>15</main-group><subgroup>8645</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>2750</main-group><subgroup>14143</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>2800</main-group><subgroup>22</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>2310</main-group><subgroup>141</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>2830</main-group><subgroup>008</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>2330</main-group><subgroup>51</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>2320</main-group><subgroup>31</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>2750</main-group><subgroup>14141</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></further-cpc></classifications-cpc><invention-title id="d2e43">Adeno-Associated Virus Vector Delivery of Microrna-29 to Treat Muscular Dystrophy</invention-title><us-related-documents><division><relation><parent-doc><document-id><country>US</country><doc-number>16092711</doc-number><date>20181010</date></document-id><parent-grant-document><document-id><country>US</country><doc-number>11298429</doc-number></document-id></parent-grant-document><parent-pct-document><document-id><country>WO</country><doc-number>PCT/US17/27630</doc-number><date>20170414</date></document-id></parent-pct-document></parent-doc><child-doc><document-id><country>US</country><doc-number>17719019</doc-number></document-id></child-doc></relation></division><us-provisional-application><document-id><country>US</country><doc-number>62473253</doc-number><date>20170317</date></document-id></us-provisional-application><us-provisional-application><document-id><country>US</country><doc-number>62323163</doc-number><date>20160415</date></document-id></us-provisional-application></us-related-documents><us-parties><us-applicants><us-applicant sequence="00" app-type="applicant" designation="us-only" applicant-authority-category="assignee"><addressbook><orgname>RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL</orgname><address><city>Columbus</city><state>OH</state><country>US</country></address></addressbook><residence><country>US</country></residence></us-applicant></us-applicants><inventors><inventor sequence="00" designation="us-only"><addressbook><last-name>Rodino-Klapac</last-name><first-name>Louise</first-name><address><city>Columbus</city><state>OH</state><country>US</country></address></addressbook></inventor><inventor sequence="01" designation="us-only"><addressbook><last-name>Mendell</last-name><first-name>Jerry R.</first-name><address><city>Columbus</city><state>OH</state><country>US</country></address></addressbook></inventor><inventor sequence="02" designation="us-only"><addressbook><last-name>Heller</last-name><first-name>Kristin N.</first-name><address><city>Columbus</city><state>OH</state><country>US</country></address></addressbook></inventor></inventors></us-parties></us-bibliographic-data-application><abstract id="abstract"><p id="p-0001" num="0000">The invention provides for recombinant AAV vectors comprising a polynucleotide sequence comprising the guide strand of miR-29c and methods of using the recombinant vectors to reduce or prevent fibrosis in subjects suffering from muscular dystrophy.</p></abstract><drawings id="DRAWINGS"><figure id="Fig-EMI-D00000" num="00000"><img id="EMI-D00000" he="181.61mm" wi="158.75mm" file="US20230001015A1-20230105-D00000.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00001" num="00001"><img id="EMI-D00001" he="198.63mm" wi="168.23mm" file="US20230001015A1-20230105-D00001.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00002" num="00002"><img id="EMI-D00002" he="140.89mm" wi="133.86mm" file="US20230001015A1-20230105-D00002.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00003" num="00003"><img id="EMI-D00003" he="166.45mm" wi="146.73mm" file="US20230001015A1-20230105-D00003.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00004" num="00004"><img id="EMI-D00004" he="212.68mm" wi="100.67mm" orientation="landscape" file="US20230001015A1-20230105-D00004.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00005" num="00005"><img id="EMI-D00005" he="218.61mm" wi="169.33mm" orientation="landscape" file="US20230001015A1-20230105-D00005.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00006" num="00006"><img id="EMI-D00006" he="185.93mm" wi="154.18mm" file="US20230001015A1-20230105-D00006.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00007" num="00007"><img id="EMI-D00007" he="199.22mm" wi="161.04mm" file="US20230001015A1-20230105-D00007.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00008" num="00008"><img id="EMI-D00008" he="150.37mm" wi="143.93mm" file="US20230001015A1-20230105-D00008.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00009" num="00009"><img id="EMI-D00009" he="214.04mm" wi="172.80mm" orientation="landscape" file="US20230001015A1-20230105-D00009.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00010" num="00010"><img id="EMI-D00010" he="180.26mm" wi="114.05mm" orientation="landscape" file="US20230001015A1-20230105-D00010.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00011" num="00011"><img id="EMI-D00011" he="199.47mm" wi="179.92mm" orientation="landscape" file="US20230001015A1-20230105-D00011.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00012" num="00012"><img id="EMI-D00012" he="232.41mm" wi="107.10mm" orientation="landscape" file="US20230001015A1-20230105-D00012.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00013" num="00013"><img id="EMI-D00013" he="165.35mm" wi="140.97mm" file="US20230001015A1-20230105-D00013.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00014" num="00014"><img id="EMI-D00014" he="185.59mm" wi="85.85mm" orientation="landscape" file="US20230001015A1-20230105-D00014.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00015" num="00015"><img id="EMI-D00015" he="212.17mm" wi="180.34mm" orientation="landscape" file="US20230001015A1-20230105-D00015.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00016" num="00016"><img id="EMI-D00016" he="229.70mm" wi="77.30mm" orientation="landscape" file="US20230001015A1-20230105-D00016.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00017" num="00017"><img id="EMI-D00017" he="209.89mm" wi="174.16mm" orientation="landscape" file="US20230001015A1-20230105-D00017.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00018" num="00018"><img id="EMI-D00018" he="188.13mm" wi="156.46mm" file="US20230001015A1-20230105-D00018.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00019" num="00019"><img id="EMI-D00019" he="198.29mm" wi="155.87mm" file="US20230001015A1-20230105-D00019.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00020" num="00020"><img id="EMI-D00020" he="191.18mm" wi="168.40mm" file="US20230001015A1-20230105-D00020.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00021" num="00021"><img id="EMI-D00021" he="224.45mm" wi="168.49mm" file="US20230001015A1-20230105-D00021.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00022" num="00022"><img id="EMI-D00022" he="215.98mm" wi="168.49mm" file="US20230001015A1-20230105-D00022.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00023" num="00023"><img id="EMI-D00023" he="215.65mm" wi="51.14mm" orientation="landscape" file="US20230001015A1-20230105-D00023.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00024" num="00024"><img id="EMI-D00024" he="220.73mm" wi="168.49mm" file="US20230001015A1-20230105-D00024.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00025" num="00025"><img id="EMI-D00025" he="215.14mm" wi="168.23mm" file="US20230001015A1-20230105-D00025.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00026" num="00026"><img id="EMI-D00026" he="222.08mm" wi="168.40mm" file="US20230001015A1-20230105-D00026.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00027" num="00027"><img id="EMI-D00027" he="167.30mm" wi="168.49mm" file="US20230001015A1-20230105-D00027.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00028" num="00028"><img id="EMI-D00028" he="222.67mm" wi="168.23mm" file="US20230001015A1-20230105-D00028.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00029" num="00029"><img id="EMI-D00029" he="221.15mm" wi="168.49mm" file="US20230001015A1-20230105-D00029.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00030" num="00030"><img id="EMI-D00030" he="83.57mm" wi="168.49mm" file="US20230001015A1-20230105-D00030.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00031" num="00031"><img id="EMI-D00031" he="223.44mm" wi="168.49mm" file="US20230001015A1-20230105-D00031.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00032" num="00032"><img id="EMI-D00032" he="220.81mm" wi="168.49mm" file="US20230001015A1-20230105-D00032.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00033" num="00033"><img id="EMI-D00033" he="152.23mm" wi="168.32mm" file="US20230001015A1-20230105-D00033.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure></drawings><description id="description"><?cross-reference-to-related-applications description="Cross Reference To Related Applications" end="lead"?><p id="p-0002" num="0001">This application is a divisional application of U.S. patent application Ser. No. 16/092,711, filed Oct. 10, 2018, which is a national phase application of International Application No. PCT/US17/27630, filed Apr. 14, 2017 which claims priority benefit of U.S. Provisional Application No. 62/323,163, filed Apr. 15, 2016 and U.S. Provisional Application No. 62/473,253, filed Mar. 17, 2017, both of which are incorporated by reference herein in their entirety.</p><?cross-reference-to-related-applications description="Cross Reference To Related Applications" end="tail"?><?summary-of-invention description="Summary of Invention" end="lead"?><heading id="h-0001" level="1">FIELD OF INVENTION</heading><p id="p-0003" num="0002">The invention provides gene therapy vectors, such as adeno-associated virus (AAV) vectors, expressing the microRNA miR-29 and method of using these vectors to reduce and prevent fibrosis in subjects suffering from muscular dystrophy and to protect muscle fibers from injury, increase muscle strength.</p><heading id="h-0002" level="1">BACKGROUND</heading><p id="p-0004" num="0003">The importance of muscle mass and strength for daily activities, such as locomotion and breathing, and for whole body metabolism is unequivocal. Deficits in muscle function produce muscular dystrophies (MDs) that are characterized by muscle weakness and wasting and have serious impacts on quality of life. The most well-characterized MDs result from mutations in genes encoding members of the dystrophin-associated protein complex (DAPC). These MDs result from membrane fragility associated with the loss of sarcolemmal-cytoskeleton tethering by the DAPC. Duchenne Muscular Dystrophy (DMD) is one of the most devastating muscle diseases affecting 1 in 5000 newborn males.</p><p id="p-0005" num="0004">This application includes two translational approaches to develop treatment for DMD. Fibrotic infiltration is profound in DMD and is a significant impediment to any potential therapy. It is also important to consider that gene replacement alone is hampered by the severity of fibrosis, already present in very young children with DMD. In fact, muscle biopsies at the usual age of diagnosis, between 4-5 years old, show very significant levels of fibrosis.</p><p id="p-0006" num="0005">DMD is caused by mutations in the DMD gene leading to reductions in mRNA and the absence of dystrophin, a 427 kD sarcolemmal protein associated with the dystrophin-associated protein complex (DAPC) (Hoffman et al., Cell 51(6):919-28, 1987). The DAPC is composed of multiple proteins at the muscle sarcolemma that form a structural link between the extra-cellular matrix (ECM) and the cytoskeleton via dystrophin, an actin binding protein, and alpha-dystroglycan, a laminin-binding protein. These structural links act to stabilize the muscle cell membrane during contraction and protect against contraction-induced damage. With dystrophin loss, membrane fragility results in sarcolemmal tears and an influx of calcium, triggering calcium-activated proteases and segmental fiber necrosis (Straub et al., Curr Opin. Neurol. 10(2): 168-75, 1997). This uncontrolled cycle of muscle degeneration and regeneration ultimately exhausts the muscle stem cell population (Sacco et al., Cell, 2010. 143(7): p. 1059-71; Wallace et al., Annu Rev Physiol, 2009. 71: p. 37-57), resulting in progressive muscle weakness, endomysial inflammation, and fibrotic scarring.</p><p id="p-0007" num="0006">Without membrane stabilization from dystrophin or a micro-dystrophin, DMD will manifest uncontrolled cycles of tissue injury and repair and ultimately replace lost muscle fibers with fibrotic scar tissue through connective tissue proliferation. Fibrosis is characterized by the excessive deposits of ECM matrix proteins, including collagen and elastin. ECM proteins are primarily produced from cytokines such as TGF&#x3b2; that is released by activated fibroblasts responding to stress and inflammation. Although the primary pathological feature of DMD is myofiber degeneration and necrosis, fibrosis as a pathological consequence has equal repercussions. The over-production of fibrotic tissue restricts muscle regeneration and contributes to progressive muscle weakness in the DMD patient. In one study, the presence of fibrosis on initial DMD muscle biopsies was highly correlated with poor motor outcome at a 10-year follow-up (Desguerre et al., J Neuropathol Exp Neurol, 2009. 68(7): p. 762-7). These results point to fibrosis as a major contributor to DMD muscle dysfunction and highlight the need to develop therapies that reduce fibrotic tissue. Most anti-fibrotic therapies that have been tested in mdx mice act to block fibrotic cytokine signaling through inhibition of the TGF&#x3b2; pathway. MicroRNAs (miRNAs) are single-stranded RNAs of &#x2dc;22 nucleotides that mediate gene silencing at the post-transcriptional level by pairing with bases within the 3&#x2032; UTR of mRNA, inhibiting translation or promoting mRNA degradation. A seed sequence of 7 bp at the 5&#x2032; end of the miRNA targets the miRNA; additional recognition is provided by the remainder of the targeted sequence, as well as its secondary structure. MiRNAs play an important role in muscle disease pathology and exhibit expression profiles that are uniquely dependent on the type of muscular dystrophy in question (Eisenberg et al. Proc Natl Acad Sci USA, 2007. 104(43): p. 17016-21). A growing body of evidence suggests that miRNAs are involved in the fibrotic process in many organs including heart, liver, kidney, and lung (Jiang et al., Proc Natl Acad Sci USA, 2007. 104(43): p. 17016-21). Recently, the down-regulation of miR-29 was shown to contribute to cardiac fibrosis (Cacchiarelli et al., Cell Metab, 2010. 12(4): p. 341-51) and reduced expression of miR-29 was genetically linked with human DMD patient muscles (Eisenberg et al. Proc Natl Acad Sci USA, 2007. 104(43): p. 17016-2). The miR-29 family consists of three family members expressed from two bicistronic miRNA clusters. MiR-29a is coexpressed with miR-29b (miR-29b-1); miR-29c is coexpressed with a second copy of miR-29b (miR-29b-2). The miR-29 family shares a conserved seed sequence and miR-29a and miR-29b each differ by only one base from miR-29c. Furthermore, electroporation of miR-29 plasmid (a cluster of miR-29a and miR-29b-1) into mdx mouse muscle reduced the expression levels of ECM components, collagen and elastin, and strongly decreased collagen deposition in muscle sections within 25 days post-treatment (Cacchiarelli et al., Cell Metab, 2010. 12(4): p. 341-51).</p><p id="p-0008" num="0007">Adeno-associated virus (AAV) is a replication-deficient parvovirus, the single-stranded DNA genome of which is about 4.7 kb in length including 145 nucleotide inverted terminal repeat (ITRs). There are multiple serotypes of AAV. The nucleotide sequences of the genomes of the AAV serotypes are known. For example, the nucleotide sequence of the AAV serotype 2 (AAV2) genome is presented in Srivastava et al., J Virol, 45: 555-564 (1983) as corrected by Ruffing et al., J Gen Virol, 75: 3385-3392 (1994). As other examples, the complete genome of AAV-1 is provided in GenBank Accession No. NC_002077; the complete genome of AAV-3 is provided in GenBank Accession No. NC_1829; the complete genome of AAV-4 is provided in GenBank Accession No. NC_001829; the AAV-5 genome is provided in GenBank Accession No. AF085716; the complete genome of AAV-6 is provided in GenBank Accession No. NC_00 1862; at least portions of AAV-7 and AAV-8 genomes are provided in GenBank Accession Nos. AX753246 and AX753249, respectively (see also U.S. Pat. Nos. 7,282,199 and 7,790,449 relating to AAV-8); the AAV-9 genome is provided in Gao et al., <i>J. Virol., </i>78: 6381-6388 (2004); the AAV-10 genome is provided in <i>Mol. Ther., </i>13(1): 67-76 (2006); and the AAV-11 genome is provided in Virology, 330(2): 375-383 (2004). The AAVrh74 serotype is described in Rodino-Klapac et al. <i>J. Trans. Med. </i>5: 45 (2007). Cis-acting sequences directing viral DNA replication (rep), encapsidation/packaging and host cell chromosome integration are contained within the ITRs. Three AAV promoters (named p5, p19, and p40 for their relative map locations) drive the expression of the two AAV internal open reading frames encoding rep and cap genes. The two rep promoters (p5 and p19), coupled with the differential splicing of the single AAV intron (e.g., at AAV2 nucleotides 2107 and 2227), result in the production of four rep proteins (rep 78, rep 68, rep 52, and rep 40) from the rep gene. Rep proteins possess multiple enzymatic properties that are ultimately responsible for replicating the viral genome. The cap gene is expressed from the p40 promoter and it encodes the three capsid proteins VP1, VP2, and VP3. Alternative splicing and non-consensus translational start sites are responsible for the production of the three related capsid proteins. A single consensus polyadenylation site is located at map position 95 of the AAV genome. The life cycle and genetics of AAV are reviewed in Muzyczka, <i>Current Topics in Microbiology and Immunology, </i>158: 97-129 (1992).</p><p id="p-0009" num="0008">AAV possesses unique features that make it attractive as a vector for delivering foreign DNA to cells, for example, in gene therapy. AAV infection of cells in culture is noncytopathic, and natural infection of humans and other animals is silent and asymptomatic. Moreover, AAV infects many mammalian cells allowing the possibility of targeting many different tissues in vivo. Moreover, AAV transduces slowly dividing and non-dividing cells, and can persist essentially for the lifetime of those cells as a transcriptionally active nuclear episome (extrachromosomal element). The AAV proviral genome is infectious as cloned DNA in plasmids which makes construction of recombinant genomes feasible. Furthermore, because the signals directing AAV replication, genome encapsidation and integration are contained within the ITRs of the AAV genome, some or all of the internal approximately 4.3 kb of the genome (encoding replication and structural capsid proteins, rep-cap) may be replaced with foreign DNA such as a gene cassette containing a promoter, a DNA of interest and a polyadenylation signal. The rep and cap proteins may be provided in trans. Another significant feature of AAV is that it is an extremely stable and hearty virus. It easily withstands the conditions used to inactivate adenovirus (56&#xb0; to 65&#xb0; C. for several hours), making cold preservation of AAV less critical. AAV may even be lyophilized. Finally, AAV-infected cells are not resistant to superinfection.</p><p id="p-0010" num="0009">Multiple studies have demonstrated long-term (&#x3e;1.5 years) recombinant AAV-mediated protein expression in muscle. See, Clark et al., <i>Hum Gene Ther, </i>8: 659-669 (1997); Kessler et al., <i>Proc Nat. Acad Sc. USA, </i>93: 14082-14087 (1996); and Xiao et al., <i>J Virol, </i>70: 8098-8108 (1996). See also, Chao et al., <i>Mol Ther, </i>2:619-623 (2000) and Chao et al., <i>Mol Ther, </i>4:217-222 (2001). Moreover, because muscle is highly vascularized, recombinant AAV transduction has resulted in the appearance of transgene products in the systemic circulation following intramuscular injection as described in Herzog et al., <i>Proc Natl Acad Sci USA, </i>94: 5804-5809 (1997) and Murphy et al., <i>Proc Natl Acad Sci USA, </i>94: 13921-13926 (1997). Moreover, Lewis et al., <i>J Virol, </i>76: 8769-8775 (2002) demonstrated that skeletal myofibers possess the necessary cellular factors for correct antibody glycosylation, folding, and secretion, indicating that muscle is capable of stable expression of secreted protein therapeutics.</p><p id="p-0011" num="0010">Functional improvement in patients suffering from DMD and other muscular dystrophies require both gene restoration and reduction of fibrosis. There is a need for methods of reducing fibrosis that may be paired with gene restoration methods for more effective treatments of DMD and other muscular dystrophies. miR29 is a potential gene regulator and an ideal candidate for reducing muscle fibrosis.</p><heading id="h-0003" level="1">SUMMARY OF INVENTION</heading><p id="p-0012" num="0011">The present invention is directed to gene therapy methods that directly reduce the three primary components of connective tissue (collagen 1, collagen 3 and fibronectin) by delivering the microRNA miR29. In this system, the miR29 binds to the 3&#x2032; UTR of the collagen and fibronectin gene to down regulate expression. The invention is directed to gene therapy vectors, e.g. AAV, expressing the guide strand of the microRNA miR29 and method of delivering miR29 to the muscle to reduce and/or prevent fibrosis.</p><p id="p-0013" num="0012">In addition, the invention provides for combination therapies and approaches for reducing and preventing fibrosis using gene therapy vectors deliver miR-29 to suppress fibrosis along with micro-dystrophin to address the gene defect observed in DMD. As shown in Examples 5-7, the combination treatment resulted in a greater reduction in fibrosis, increased muscle size and increased muscle force.</p><p id="p-0014" num="0013">In one embodiment, the invention provides for a rAAV vector expressing miR-29. For example, the rAAV vector comprises a polynucleotide sequence expressing miR29c such as a nucleotide sequence comprising the miR-29c target guide strand of SEQ ID NO: 3, the miR-29c guide strand of SEQ ID NO: 4 and the natural miR-30 back bone and stem loop (SEQ ID NO: 5). An exemplary polynucleotide sequence comprising the miR-29c cDNA in a miR-30 backbone is set out as SEQ ID NO: 2 (<figref idref="DRAWINGS">FIG. <b>1</b></figref>).</p><p id="p-0015" num="0014">An exemplary rAAV of the invention is the pAAV.CMV.Mir29C which comprises the nucleotide sequence of SEQ ID NO: 1; wherein the CMV promoter spans nucleotides 120-526, an EF1a intron spans nucleotides 927-1087 and nucleotides 1380-1854, the guide stand of miR-29c spans nucleotide 1257-1284 and the shRNA-miR29-c with primary seed sequence spans nucleotides 1088-1375, and the poly A sequence spans nucleotides 1896-2091. In one aspect, the rAAV vectors of the invention are AAV1, AAV2, AAV4, AAV5, AAV6, AAV7, AAVrh.74, AAV8, AAV9, AAV10, AAV11, AAV12 or AAV13.</p><p id="p-0016" num="0015">Another exemplary rAAV of the invention is the pAAV.MCK.Mir29C which comprises the nucleotide sequence of SEQ ID NO: 12; wherein the MCK enhancer spans nucleotides 190-395, the WIC promoter spans nucleotides 396-753, an EF1a intron spans nucleotides 1155-1315 and nucleotides 1609-2083, the guide stand of miR-29c spans nucleotide 1487-1512 and the shRNA-miR29-c with primary seed sequence spans nucleotides 1316-1608, and the poly A sequence spans nucleotides 2094-2146. In one aspect, the rAAV vectors of the invention are AAV1, AAV2, AAV4, AAV5, AAV6, AAV7, AAVrh.74, AAV8, AAV9, AAV10, AAV11, AAV12 or AAV13.</p><p id="p-0017" num="0016">In another aspect, the rAAV vectors of the invention may be operably linked to a muscle-specific control element or an ubiquitous promoter such as cytomegalovirus (CMV) promoter. For example the muscle-specific control element is human skeletal actin gene element, cardiac actin gene element, myocyte-specific enhancer binding factor MEF, muscle creatine kinase (MCK), tMCK (truncated MCK), myosin heavy chain (MHC), MHCK7 (a hybrid version of MHC and MCK), C5-12 (synthetic promoter), murine creatine kinase enhancer element, skeletal fast-twitch troponin C gene element, slow-twitch cardiac troponin C gene element, the slow-twitch troponin I gene element, hypozia-inducible nuclear factors, steroid-inducible element or glucocorticoid response element (GRE).</p><p id="p-0018" num="0017">For example, any of the rAAV vectors of the invention are operably linked to the muscle-specific control element comprising the MHC enhancer nucleotide sequence of SEQ ID NO: 10 and/or the MHC promoter sequence of SEQ ID NO: 11. In addition, any of the rAAV vectors of the invention are operably linked to the muscle specific control element comprising the MHCK7 enhancer nucleotide sequence of SEQ ID NO: 13.</p><p id="p-0019" num="0018">The invention also provides for pharmaceutical compositions (or sometimes referred to herein as simply &#x201c;compositions&#x201d;) comprising any of the rAAV vectors of the invention.</p><p id="p-0020" num="0019">In another embodiment, the invention provides for methods of producing a rAAV vector particle comprising culturing a cell that has been transfected with any rAAV vector of the invention and recovering rAAV particles from the supernatant of the transfected cells. The invention also provides for viral particles comprising any of the recombinant AAV vectors of the invention.</p><p id="p-0021" num="0020">The invention also provides for methods of producing a mature miR-29 nucleotide sequence comprising infecting a host cell with a recombinant AAV vector expressing miR-29 of the invention and expressing a mature miR-29 in the host cell.</p><p id="p-0022" num="0021">In another embodiment, the invention provides for methods of reducing fibrosis in a subject in need comprising administering a therapeutically effective amount of any rAAV vector of the invention expressing miR-29. For example, any of the rAAV of the invention are administered to subjects suffering from muscular dystrophy to reduce fibrosis, and in particular reduces fibrosis in skeletal muscle or in cardiac muscle of the subject. These methods may further comprise the step of administering a rAAV expressing micro-dystrophin.</p><p id="p-0023" num="0022">For any of the methods, compositions and uses of the invention the term &#x201c;muscular dystrophy&#x201d; may be Duchenne muscular dystrophy, Becker muscular dystrophy, dysferlin-associated muscular dystrophy, Limb Girdle muscular dystrophy including limb girdle muscular dystrophy type 2L or Miyoshi myopathy type 3, Bethlem myopathy, calpainopathy, desmin myopathy, dysferlinopathy, dystrophinopathy, myofibrillar myopathy, sarcoglycanopathy, congenital muscular dystrophy, anterior tibial myopathy, facioscapulohumeral muscular dystrophy, myotonic dystrophy, oculopharngeal muscular dystrophy or ZASP-related myopathy.</p><p id="p-0024" num="0023">&#x201c;Fibrosis&#x201d; refers to the excessive or unregulated deposition of extracellular matrix (ECM) components and abnormal repair processes in tissues upon injury including skeletal muscle, cardiac muscle, liver, lung, kidney, and pancreas. The ECM components that are deposited include fibronectin and collagen, e.g. collagen 1, collagen 2 or collagen 3.</p><p id="p-0025" num="0024">In another embodiment, the invention provides for methods of preventing fibrosis in a subject in need comprising administering a therapeutically effective amount of the any recombinant AAV vector of the invention expressing miR-29. For example, any of the rAAV of the invention are administered to subjects suffering from muscular dystrophy to prevent fibrosis, e.g. the rAAV of the invention expressing miR-29 are administered before fibrosis is observed in the subject. In addition, the rAAV of the invention expressing miR-29 are administered to a subject at risk of developing fibrosis, such as those suffering or diagnosed with dystrophinopathy or muscular dystrophy, e.g. DMD, Becker muscular dystrophy, Limb Girdle muscular dystrophy or any other dystrophin associated muscular dystrophy. The rAAV of the invention are administered to the subject suffering from muscular dystrophy in order to prevent new fibrosis in these subjects. These methods may further comprise the step of administering a rAAV expressing micro-dystrophin.</p><p id="p-0026" num="0025">The invention also provides for methods of increasing muscular force and/or muscle mass in a subject suffering from muscular dystrophy comprising administering a therapeutically effective amount of any of the rAAV vector of the invention expressing miR-29. These methods may further comprise the step of administering a rAAV expressing micro-dystrophin.</p><p id="p-0027" num="0026">The terms &#x201c;combination therapy&#x201d; and &#x201c;combination treatment&#x201d; refer to administration of a rAAV vector of the invention expressing miR-29 and an rAAV vector expressing micro-dystrophin.</p><p id="p-0028" num="0027">In any of the methods of the invention, the subject may be suffering from dystrophinopathy or muscular dystrophysuch as DMD, Becker muscular dystrophy, Limb Girdle muscular dystrophy or any other dystrophin-associated muscular dystrophy.</p><p id="p-0029" num="0028">Any of the foregoing methods of the invention may comprise a further step of administering a rAAV expressing micro-dystrophin. The micro-dystrophin protein comprises the amino acid sequence of SEQ ID NO: 8. The methods may comprises the step of administering a rAAV comprising the coding sequence for the micro-dystrophin gene (SEQ ID NO: 7) or comprising a nucleotide sequence that is at least 85% identical to the nucleotide sequence of SEQ ID NO: 7.</p><p id="p-0030" num="0029">An exemplary rAAV expressing micro-dystrophin of the invention is the pAAV.mck.micro-dystrophin which comprises the nucleotide sequence of SEQ ID NO: 9 and shown in <figref idref="DRAWINGS">FIGS. <b>10</b> and <b>11</b></figref>. This rAAV vector comprises the MCK promoter, a chimeric intron sequence, the coding sequence for the micro-dystrophin gene, polyA, ampicillin resistance and the pGEX plasmid backbone with pBR322 origin or replication. In one aspect, the recombinant AAV vectors of the invention are AAV1, AAV2, AAV4, AAV5, AAV6, AAV7, AAVrh.74, AAV8, AAV9, AAV10, AAV11, AAV12 or AAV13.</p><p id="p-0031" num="0030">The methods of the invention are carried out with rAAV vectors encoding the micro-dystrophin protein that is, e.g., at least at least 65%, at least 70%, at least 75%, at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, or 89%, more typically at least 90%, 91%, 92%, 93%, or 94% and even more typically at least 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 8, wherein the protein retains micro-dystrophin activity. The micro-dystrophin protein provides stability to the muscle membrane during muscle contraction, e.g. micro-dystrophin acts as a shock absorber during muscle contraction.</p><p id="p-0032" num="0031">The methods of the invention are carried out with rAAV vectors expressing the micro-dystrophin comprising a nucleotide sequence that has at least 65%, at least 70%, at least 75%, at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, or 89%, more typically at least 90%, 91%, 92%, 93%, or 94% and even more typically at least 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 7, and encodes a functional micro-dystrophin.</p><p id="p-0033" num="0032">The methods of the invention are carried out with rAAV vectors expressing the micro-dystrophin comprising a nucleotide sequence that hybridizes under stringent conditions to the nucleic acid sequence of SEQ ID NOS: 7, or compliments thereof, and encodes a functional micro-dystrophin.</p><p id="p-0034" num="0033">The term &#x201c;stringent&#x201d; is used to refer to conditions that are commonly understood in the art as stringent. Hybridization stringency is principally determined by temperature, ionic strength, and the concentration of denaturing agents such as formamide. Examples of stringent conditions for hybridization and washing are 0.015 M sodium chloride, 0.0015 M sodium citrate at 65-68&#xb0; C. or 0.015 M sodium chloride, 0.0015M sodium citrate, and 50% formamide at 42&#xb0; C. See Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory, (Cold Spring Harbor, N.Y. 1989). More stringent conditions (such as higher temperature, lower ionic strength, higher formamide, or other denaturing agent) may also be used, however, the rate of hybridization will be affected. In instances wherein hybridization of deoxyoligonucleotides is concerned, additional exemplary stringent hybridization conditions include washing in 6&#xd7;SSC 0.05% sodium pyrophosphate at 37&#xb0; C. (for 14-base oligos), 48&#xb0; C. (for 17-base oligos), 55&#xb0; C. (for 20-base oligos), and 60&#xb0; C. (for 23-base oligos).</p><p id="p-0035" num="0034">Other agents may be included in the hybridization and washing buffers for the purpose of reducing non-specific and/or background hybridization. Examples are 0.1% bovine serum albumin, 0.1% polyvinyl-pyrrolidone, 0.1% sodium pyrophosphate, 0.1% sodium dodecylsulfate, NaDodSO4, (SDS), ficoll, Denhardt's solution, sonicated salmon sperm DNA (or other non-complementary DNA), and dextran sulfate, although other suitable agents can also be used. The concentration and types of these additives can be changed without substantially affecting the stringency of the hybridization conditions. Hybridization experiments are usually carried out at pH 6.8-7.4, however, at typical ionic strength conditions, the rate of hybridization is nearly independent of pH. See Anderson et al., <i>Nucleic Acid Hybridisation: A Practical Approach</i>, Ch. 4, IRL Press Limited (Oxford, England). Hybridization conditions can be adjusted by one skilled in the art in order to accommodate these variables and allow DNAs of different sequence relatedness to form hybrids.</p><p id="p-0036" num="0035">In another aspect, the rAAV vectors expressing micro-dystrophin comprises the coding sequence of micro-dystrophin gene operably linked to a muscle-specific control element. For example, the muscle-specific control element is human skeletal actin gene element, cardiac actin gene element, myocyte-specific enhancer binding factor MEF, muscle creatine kinase (MCK), tMCK (truncated MCK), myosin heavy chain (MHC), C5-12 (synthetic promoter), murine creatine kinase enhancer element, skeletal fast-twitch troponin C gene element, slow-twitch cardiac troponin C gene element, the slow-twitch troponin I gene element, hypozia-inducible nuclear factors, steroid-inducible element or glucocorticoid response element (GRE).</p><p id="p-0037" num="0036">In the methods of administering an rAAV vector expressing miR-29 and an rAAV vector expressing micro-dystrophin, these rAAV vectors may be administered concurrently, or administered consecutively with the rAAV vector expressing miR29 administered immediately before the rAAV expressing micro-dystrophin, or administered consecutively with the rAAV vector expressing miR29 is administered immediately after the rAAV expressing micro-dystrophin. Alternatively, the methods of the invention are carried out wherein the AAV vector expressing micro-dystrophin is administered within about 1-5 hours or 5-12 hours or 12 to 15 hours or 15 to 24 hours after administering the rAAV expressing miR-29 or the methods of the invention are carried out wherein the AAV vector expressing micro-dystrophin is administered within about 1-5 hours or 5-12 hours or 12 to 15 hours or 15 to 24 hours before administering the rAAV expressing miR-29. Alternatively, the methods of the invention are carried out wherein the AAV vector expressing micro-dystrophin is administered within about 1 or 6 or 12 or 24 hours after administering the rAAV expressing miR-29 or the methods of the invention are carried out wherein the AAV vector expressing micro-dystrophin is administered within about 1 or 6 or 12 or 24 hours before administering the rAAV expressing miR-29.</p><p id="p-0038" num="0037">The invention contemplates administering any of the AAV vectors of the invention to patients diagnosed with dystrophinopathy or muscular dystrophy such as DMD, Becker muscular dystrophy, Limb Girdle muscular dystrophy or any other dystrophin associated muscular dystrophy before fibrosis is observed in the subject or before the muscle force has been reduced in the subject or before the muscle mass has been reduced in the subject.</p><p id="p-0039" num="0038">The invention also contemplates administering any of the rAAV of the invention to a subject suffering from dystrophinopathy or muscular dystrophy, such as DMD, Becker muscular dystrophy, Limb Girdle muscular dystrophy or any other dystrophin associated muscular dystrophy who already has developed fibrosis, in order to prevent new fibrosis in these subjects. The invention also provides for administering any of the rAAV of the invention to the patient suffering from muscular dystrophy who already has reduced muscle force or has reduced muscle mass in order to protect the muscle from further injury.</p><p id="p-0040" num="0039">In any of the methods of the invention, the rAAV vector are administered by intramuscular injection or intravenous injection.</p><p id="p-0041" num="0040">In addition, in any of the methods of the invention, the rAAV vector or composition is administered systemically. For examples, the rAAV vector or composition is parentally administration by injection, infusion or implantation.</p><p id="p-0042" num="0041">In another embodiment, the invention provides for composition comprising any of the rAAV vectors expressing miR29 for reducing fibrosis in a subject in need. In some embodiments, this composition also comprises a rAAV vector expressing micro-dystrophin. For example, this composition comprises a rAAV comprising the coding sequence for micro-dystrophin gene (SEQ ID NO: 7) or comprises a nucleotide sequence that is at least 85% identical to the nucleotide sequence of SEQ ID NO: 7.</p><p id="p-0043" num="0042">In addition, the invention provides for compositions comprising any of the recombinant AAV vectors expressing miR29 for preventing fibrosis in a patient suffering from dystrophinopathy or muscular dystrophy such as DMD, Becker muscular dystrophy, Limb Girdle muscular dystrophy or any other dystrophin associated muscular dystrophy. In some embodiments, this composition also comprises a rAAV vector expressing micro-dystrophin. For example, this composition comprises a rAAV comprising the coding sequence for micro-dystrophin gene (SEQ ID NO: 7) or may comprising a nucleotide sequence that is at least 85% identical to the nucleotide sequence of SEQ ID NO: 7.</p><p id="p-0044" num="0043">The invention also provides for compositions comprising any of the rAAV vectors of the invention expressing miR29 for increasing muscular force and/or muscle mass in a subject suffering from dystrophinopathy or muscular dystrophy, such as DMD, Becker muscular dystrophy, Limb Girdle muscular dystrophy or any other dystrophin associated muscular dystrophy. In some embodiments, this composition also comprises a rAAV vector expressing micro-dystrophin. For example, this composition comprises a rAAV vector comprising the coding sequence for micro-dystrophin gene (SEQ ID NO: 7) or comprises a nucleotide sequence that is at least 85% identical to the nucleotide sequence of SEQ ID NO: 7.</p><p id="p-0045" num="0044">In a further embodiment, the invention provides for compositions comprising any of the rAAV vectors of the invention expressing miR29 for treatment of dystrophinopathy muscular dystrophy, such as DMD, Becker muscular dystrophy, Limb Girdle muscular dystrophy or any other dystrophin associated muscular dystrophy. In some embodiments, this composition also comprises a rAAV vector expressing micro-dystrophin. For example, this composition comprises a rAAV vector comprising the coding sequence for micro-dystrophin gene (SEQ ID NO: 7) or comprises a nucleotide sequence that is at least 85% identical to the nucleotide sequence of SEQ ID NO: 7.</p><p id="p-0046" num="0045">The compositions of the invention are formulated for intramuscular injection or intravenous injection. The composition of the invention is also formulated for systemic administration, such as parentally administration by injection, infusion or implantation. In addition, any of the compositions are formulated for administration to a subject suffering from dystrophinopathy or muscular dystrophy such as DMD, Becker muscular dystrophy, Limb Girdle muscular dystrophy or any other dystrophin associated muscular dystrophy.</p><p id="p-0047" num="0046">In a further embodiment, the invention provides for use of any of the rAAV vectors of the invention expressing miR29 for preparation of a medicament for reducing fibrosis in a subject in need. For example, the subject is in need suffering from dystrophinopathy or muscular dystrophy, such as DMD, Becker muscular dystrophy, Limb Girdle muscular dystrophy or any other dystrophin associated muscular dystrophy. In some embodiments, the medicament further comprises a rAAV vector expressing micro-dystrophin. For example, this medicament comprises a rAAV comprising the coding sequence for micro-dystrophin gene (SEQ ID NO: 7) or comprises a nucleotide sequence that is at least 85% identical to the nucleotide sequence of SEQ ID NO: 7.</p><p id="p-0048" num="0047">In another embodiment, the invention provides for provides for use of any of the rAAV vectors of the invention expressing miR29 for the preparation of a medicament for preventing fibrosis in a subject suffering from dystrophinopathy or muscular dystrophy, such as DMD, Becker muscular dystrophy, Limb Girdle muscular dystrophy or any other dystrophin associated muscular dystrophy. In some embodiments, the medicament further comprises a rAAV vector expressing micro-dystrophin. For example, this medicament comprises a rAAV vector comprising the coding sequence for the micro-dystrophin gene (SEQ ID NO: 7) or comprising a nucleotide sequence that is at least 85% identical to the nucleotide sequence of SEQ ID NO: 7.</p><p id="p-0049" num="0048">In addition, the invention provides for use of the recombinant AAV vectors of the invention expressing miR29 for the preparation of a medicament for the increasing muscular strength and/or muscle mass in a subject suffering from dystrophinopathy or muscular dystrophy, such as DMD, Becker muscular dystrophy, Limb Girdle muscular dystrophy or any other dystrophin associated muscular dystrophy. In some embodiments, the medicament further comprises a rAAV vector expressing micro-dystrophin. For example, this medicament comprises a rAAV comprising the coding sequence for the micro-dystrophin gene (SEQ ID NO: 7) or comprises a nucleotide sequence that is at least 85% identical to the nucleotide sequence of SEQ ID NO: 7.</p><p id="p-0050" num="0049">The invention contemplates use of the any of the AAV vectors of the invention for the preparation of a medicament for administration to a patient diagnosed with dystrophinopathy or muscular dystrophy, such as DMD, Becker muscular dystrophy, Limb Girdle muscular dystrophy or any other dystrophin associated muscular dystrophy before fibrosis is observed in the subject or before the muscle force has been reduced in the subject or before the muscle mass has been reduced in the subject.</p><p id="p-0051" num="0050">The invention also contemplates use of any of the AAV vectors of the invention for the preparation of a medicament for administration to administering any of the rAAV of the invention to a subject suffering from dystrophinopathy or muscular dystrophy, such as DMD, Becker muscular dystrophy, Limb Girdle muscular dystrophy or any other dystrophin associated muscular dystrophy who already has developed fibrosis, in order to prevent new fibrosis in these subjects. The invention also provides for administering any of the rAAV of the invention to the patient suffering from muscular dystrophy who already has reduced muscle force or has reduced muscle mass in order to protect the muscle from further injury.</p><p id="p-0052" num="0051">The invention also provides for use of the rAAV vectors of the invention expressing miR296 for the preparation of a medicament for treatment of dystrophinopathy or muscular dystrophy, such as DMD, Becker muscular dystrophy, Limb Girdle muscular dystrophy or any other dystrophin associated muscular dystrophy. In some embodiments, the medicament further comprises a rAAV vector expressing micro-dystrophin. For example, this medicament comprises a rAAV comprising the coding sequence for the micro-dystrophin gene (SEQ ID NO: 7) or comprises a nucleotide sequence that is at least 85% identical to the nucleotide sequence of SEQ ID NO: 7.</p><p id="p-0053" num="0052">In any of the uses of the invention, the medicament is formulated for intramuscular injection. In addition, any of the medicaments may be prepared for administration to a subject suffering from dystrophinopathy muscular dystrophy, such as DMD, Becker muscular dystrophy, Limb Girdle muscular dystrophy or any other dystrophin associated muscular dystrophy.</p><p id="p-0054" num="0053">In addition, any of the medicaments of the invention may be a combination therapy in which the rAAV vectors expressing miR-29 and rAAV vectors expressing micro-dystrophin are administered concurrently, or administered consecutively with the rAAV vector expressing miR29 administered immediately before the rAAV expressing micro-dystrophin, or administered consecutively with the rAAV vector expressing miR29 administered immediately after the rAAV expressing micro-dystrophin. Alternatively, the medicament comprises administration of the AAV vector expressing micro-dystrophin administered within about 1-5 hours after administering the rAAV expressing miR-29 or the medicament comprises the AAV vector expressing micro-dystrophin administered within about 1-5 hours before administering the rAAV expressing miR-29.</p><?summary-of-invention description="Summary of Invention" end="tail"?><?brief-description-of-drawings description="Brief Description of Drawings" end="lead"?><description-of-drawings><heading id="h-0004" level="1">BRIEF DESCRIPTION OF DRAWING</heading><p id="p-0055" num="0054"><figref idref="DRAWINGS">FIG. <b>1</b></figref> provide a schematic of rAAV vector scAAVCrh.74.CMV.miR29c and the nucleotide sequence of the miR-29c in a natural miR-30 backbone and the nucleotide sequence of the predicted hairpin structure.</p><p id="p-0056" num="0055"><figref idref="DRAWINGS">FIG. <b>2</b>A-<b>2</b>C</figref> illustrates that injection of miR-29c into muscle reduces collagen throughout the muscle and restores miR-29c expression.</p><p id="p-0057" num="0056"><figref idref="DRAWINGS">FIG. <b>3</b>A-<b>3</b>C</figref> demonstrates that injection of miR-29c improves absolute muscle force (panel A) and specific muscle force (panel B) but does not protect against contraction-induced damage (panel C).</p><p id="p-0058" num="0057"><figref idref="DRAWINGS">FIG. <b>4</b>A-<b>4</b>C</figref> displays the number of muscle fibers expression micro-dystrophin to measure of efficacy of transgene delivery.</p><p id="p-0059" num="0058"><figref idref="DRAWINGS">FIG. <b>5</b>A-<b>5</b>C</figref> demonstrates that co-delivery of miR-29c with micro-dystrophin reduces collagen expression (panel A) and fibrosis-induced dystrophin expression.</p><p id="p-0060" num="0059"><figref idref="DRAWINGS">FIG. <b>6</b>A-<b>6</b>D</figref> illustrates that intramuscular injection of miR-29c/micro-dystrophin inhibits extracellular matrix (ECM) in mdx/utrn<sup>+/&#x2212;</sup> mice as measured by collagen 1 alpha (panel A), collagen 3 alpha (panel B), fibronectin (panel C) and TGF-&#x3b2; (panel D).</p><p id="p-0061" num="0060"><figref idref="DRAWINGS">FIG. <b>7</b>A-<b>7</b>C</figref> demonstrates the intramuscular injection of miR-29c increased absolute force (panel A), normalized specific force (panel B) and added protection from contraction-induce damage (panel C) in the muscle.</p><p id="p-0062" num="0061"><figref idref="DRAWINGS">FIG. <b>8</b></figref> illustrates that the miR-29c/&#x3bc;-dys combination increases muscle size in mice treated at 3 months of age. Sections of treated and untreated mdx/utrn<sup>+/&#x2212;</sup> gastrocnemius muscles stained with picrosirius Red to stain for collagen are shown. Fibrotic areas are pink and intact muscle is in green. On the macroscopic level, miR-29c/&#x3bc;-dys combination decreases fibrosis and increases total cross sectional area.</p><p id="p-0063" num="0062"><figref idref="DRAWINGS">FIG. <b>9</b>A-<b>9</b>F</figref> demonstrates that treatment with miR-29c co-delivered with micro-dystrophin increased muscle hypertrophy and hyperplasia as shown by an increase in the overall weight of the injected gastroc compared to either one injected alone (panel A), an increase in the an increase in average fiber size (panel B), an increase in cross-sectional area of the muscle (panel D; uninjected: 24.6 vs. miR-29c: 26.3 vs. micro-dys: 26.6 vs. micro-dys/miR-29c: 33.1) and an increase in the number of muscle fibers (panel E) but the number of muscle fibers per unit area was not affected (panel F). Panel C compares mdx/utrn<sup>+/&#x2212;</sup> controls with miR-29c/&#x3bc;-dys treated mdx/utrn<sup>+/&#x2212;</sup>, the average diameter increased from 25.96 to 30.97 &#x3bc;m</p><p id="p-0064" num="0063"><figref idref="DRAWINGS">FIG. <b>10</b>A-<b>10</b>G</figref> demonstrates that early treatment of AAV.miR-29c/micro-dystrophin combination therapy is more effective at reducing fibrosis and ECM expression. Panel A shows picrosirius red staining of wild-type, uninjected, AAV.miR-29c, AAV.micro-dystrophin, and AAV.miR-29c/AAV.micro-dystrophin of mice injected at 4-5 wks of age taken out twelve weeks post-injection. Panel B provides quantification of picrosirius red staining showing co-treated muscle had a 51.1% reduction in collagen compared to uninjected GAS muscle. Panel C demonstrates that qRT-PCR confirms an increase in miR-29c transcript levels in the treated cohorts. Semi-quantitative qRT-PCR shows a significant reduction in collagen I and III (panels d, e), fbn (panel f) and TGF-&#x3b2;1 (panel g) levels in the AAV.miR-29c/AAV.micro-dystrophin treated muscle compared to the contralateral limb and each of the single therapies Error bars, SEM for n=5 (scAAVrh.74.CMV.miR-29c), n=5 (scAAVrh.74.CMV.miR-29c/ssAAVrh.74.MCK.micro-dystrophin), n=6 (ssAAVrh.74.MCK.micro-dystrophin), n=9 (mdx/utrn<sup>+/&#x2212;</sup> mice). 1-way ANOVA (*p&#x3c;0.05, **p&#x3c;0.01, ***p&#x3c;0.001)</p><p id="p-0065" num="0064"><figref idref="DRAWINGS">FIG. <b>11</b></figref> demonstrates early combination therapy restores force and protects against contraction-induced damage. Measurement of absolute (panel A) and normalized specific force (panel b) following tetanic contraction in all three treatment injected GAS muscles were significantly increased compared to untreated mdx/utrn<sup>+/&#x2212;</sup> muscle (panel C). Muscles were then assessed for loss of force following repetitive eccentric contractions. Only mice co-treated with miR-29c/micro-dystrophin and micro-dystrophin alone showed a protection from loss of force compared with untreated mdx/utrn<sup>+\&#x2212;</sup> muscles (blue). Two-way analysis of variance demonstrates significance in decay curves Error bars, SEM for n=5 (rAAVrh.74.CMV.miR-29c), n=6 (rAAVrh.74.CMV.miR-29c/rAAVrh.74.MCK.micro-dystrophin), n=5 (rAAVrh.74.MCK.micro-dystrophin), n=15 (mdx/utrn+/&#x2212; mice). 1-way ANOVA (*p&#x3c;0.05,**p&#x3c;0.01, ***p&#x3c;0.001, ****p&#x3c;0.0001).</p><p id="p-0066" num="0065"><figref idref="DRAWINGS">FIG. <b>12</b></figref> illustrates miR-29c/micro-dystrophin combination treatment increases muscle size in mice treated at 1 month of age. Treated and untreated mdx/utrn<sup>+/&#x2212;</sup> GAS muscles were sectioned and staining with picrosirius Red to stain for collagen. Fibrotic areas are pink and intact muscle is in green. On the macroscopic level, miR-29c/micro-dystrophin combination decreases fibrosis and increases total cross sectional area.</p><p id="p-0067" num="0066"><figref idref="DRAWINGS">FIG. <b>13</b>A-<b>13</b>G</figref> demonstrates that early treatment (at 4-5 weeks) of AAV.MCK.miR-29c/micro-dystrophin combination therapy is more effective at reducing fibrosis and ECM expression. Panel A provide picrosirius red staining of uninjected and AAV.MCK.miR-29c/AAV.MCK.micro-dystrophin of mice injected at 4-5 wks of age taken out twelve weeks post-injection. Original magnification, &#xd7;20 Panel B provides quantification of picrosirius red staining demonstrating co-treated muscle had a 50.9% reduction in collagen compared to untreated GAS muscle Panel C provides qRT-PCR confirming an increase in miR-29c transcript levels in the treated cohort. Semi-quantitative qRT-PCR shows a significant reduction in Collagen 1A (CollA; panel D) and Collagen 3A (Col3A; panel E), Fibronectin (Fbn; panel F) and Tgf&#x3b2;1 (panel G) levels in the AAV.MCK.miR-29c/AAV.micro-dystrophin treated muscle compared to the contralateral limb therapies. (*p&#x3c;0.05,****p&#x3c;0.0001).</p><p id="p-0068" num="0067"><figref idref="DRAWINGS">FIG. <b>14</b>A-<b>14</b>G</figref> demonstrates that late treatment (treatment at 12 weeks) with AAV.MCK.miR-29c/micro-dystrophin combination therapy is effective at reducing fibrosis and ECM expression. Panel A provides picrosirius red staining of untreated, AAV.MCK.miR-29c and AAV.MCK.miR-29c/AAV.micro-dystrophin twelve weeks post-injection. Original magnification, &#xd7;20. Panel B provides quantification of picrosirius red staining which demonstrates that co-treated muscle had a 30.3% reduction in collagen compared to untreated GAS muscle. Panel C provides qRT-PCR confirming an increase in miR-29c transcript levels in the treated cohorts. Semi-quantitative qRT-PCR demonstrated a significant reduction in Collagen 1A (CollA; panel D), Collagen 3A (Col3A; panel E), Fibronectin (Fbn; Panel F) and Tgf131 (panel G) levels in the AAV.miR-29c/AAV.micro-dystrophin treated muscle compared to the contralateral limb. One-way ANOVA. All data represent mean&#xb1;SEM. (**p&#x3c;0.01, ****p&#x3c;0.0001).</p><p id="p-0069" num="0068"><figref idref="DRAWINGS">FIG. <b>15</b>A-<b>15</b>C</figref> demonstrates that early combination therapy (treatment at 4-5 weeks) restored force and protected against contraction-induced damage. Measurement of absolute (panel A) and normalized specific force (panel B) following tetanic contraction MCK.miR-29c/micro-dystrophin injected GAS muscles were significantly increased compared to untreated mdx/utrn<sup>+/&#x2212;</sup> muscle. (C) Muscles were then assessed for loss of force following repetitive eccentric contractions. Mice co-treated with miR-29c/micro-dystrophin and micro-dystrophin alone showed protection from loss of force compared with untreated mdx/utrn<sup>+\&#x2212;</sup> muscles (red). Two-way ANOVA. All data represent mean&#xb1;SEM (****p&#x3c;0.0001).</p><p id="p-0070" num="0069"><figref idref="DRAWINGS">FIG. <b>16</b>A-<b>16</b>C</figref> demonstrates that late combination therapy restored force and protected against contraction-induced damage. Measurement of absolute (panel A) and normalized specific force (panel B) following tetanic contraction rAAV.MCK.miR-29c and rAAV expressing micro-dystrophin injected GAS muscles were significantly increased compared to untreated mdx/utrn<sup>+/&#x2212;</sup> muscle. In Panel C, muscles were then assessed for loss of force following repetitive eccentric contractions. Mice co-treated with rAAV.MCK.miR-29c/rAAV expressing micro-dystrophin showed a protection from loss of force compared with untreated mdx/utrn<sup>+\&#x2212;</sup> muscles (red). Two-way ANOVA. All data represent mean&#xb1;SEM (**p&#x3c;0.01, ****p&#x3c;0.0001).</p><p id="p-0071" num="0070"><figref idref="DRAWINGS">FIG. <b>17</b>A-<b>17</b>D</figref> demonstrates that combination treatment increases muscle hypertrophy 3 months post injection. Panel A demonstrates that rAAV. MCK.miR-29c co-delivered with rAAV expressing micro-dystrophin failed to increase the overall weight of the injected GAS. Panel B demonstrates that rAAV.MCK.miR-29c/rAAV expressing micro-dystrophin combination treatment induced an increase in average fiber size. Comparing mdx/utrn<sup>+/&#x2212;</sup> controls with miR-29c/micro-dystrophin treated mdx/utrn<sup>+/&#x2212;</sup>, the average diameter increased from 28.96 to 36.03 &#x3bc;m. Panel C shows that co-delivery produced a shift towards wild-type fiber size distribution. Panel D provided the number of muscle fibers per mm<sup>2 </sup>in the miR-29c/micro-dystrophin combination treatment was significantly less than untreated mice and wild-type (***p&#x3c;0.01, ****p&#x3c;0.0001).</p><p id="p-0072" num="0071"><figref idref="DRAWINGS">FIG. <b>18</b>A-<b>18</b>B</figref> provides the nucleic acid sequence (SEQ ID NO: 1 pAAV.CMV.Mir29C) of an exemplary rAAV vector comprising the mature guide strand of miR-29c (nucleotides 1257-1284) and the natural mi-30 backbone (nucleotides 1088-1375). The construct also comprises the CMV promoter (nucleotides 120-526), two EF1a introns at nucleotides 927-1087 and 1380-1854 and a polA at nucleotides 1896-2091.</p><p id="p-0073" num="0072"><figref idref="DRAWINGS">FIG. <b>19</b></figref> provides a schematic of the rAAV vector pAAV.MCK.micro-dystrophin.</p><p id="p-0074" num="0073"><figref idref="DRAWINGS">FIG. <b>20</b>A-<b>20</b>D</figref> provide the nucleic acid sequence (SEQ ID NO: 9; pAAV.MCK.micro-dystrophin) of an exemplary rAAV vector expressing micro-dystrophin.</p><p id="p-0075" num="0074"><figref idref="DRAWINGS">FIG. <b>21</b>A-<b>21</b>C</figref> provide the nucleotide sequence of the human micro-dystrophin nucleotide sequence (SEQ ID NO: 7)</p><p id="p-0076" num="0075"><figref idref="DRAWINGS">FIG. <b>22</b>A-<b>22</b>C</figref> provide the nucleotide sequence (SEQ ID NO: 12 pAAV.MCK.Mir29C) of an exemplary rAAV vector comprising the mature guide strand of miR-29c (nucleotides 1487-1512) and the natural mi-30 backbone (nucleotides 1088-1375). The construct also comprises the MCK enhancer (nucleotides 190-395), MCK promoter (nucleotides 396-753), two EF1a introns at nucleotides 1155-1315 and 1609-2083 and a polA at nucleotides 2094-2148.</p></description-of-drawings><?brief-description-of-drawings description="Brief Description of Drawings" end="tail"?><?detailed-description description="Detailed Description" end="lead"?><heading id="h-0005" level="1">DETAILED DESCRIPTION</heading><p id="p-0077" num="0076">The present invention provides for gene therapy vectors, e.g. rAAV vectors, overexpressing miR-29 microRNA and methods of reducing and preventing fibrosis in muscular dystrophy patients. The present invention also provides for combination gene therapy methods which comprise administering a gene therapy vector expressing miR-29 in combination with a gene therapy vector expressing micro-dystrophin that is deleted in DMD patients.</p><p id="p-0078" num="0077">Muscle biopsies taken at the earliest age of diagnosis of DMD reveal prominent connective tissue proliferation. Muscle fibrosis is deleterious in multiple ways. It reduces normal transit of endomysial nutrients through connective tissue barriers, reduces the blood flow and deprives muscle of vascular-derived nutritional constituents, and functionally contributes to early loss of ambulation through limb contractures. Over time, treatment challenges multiply as a result of marked fibrosis in muscle. This can be observed in muscle biopsies comparing connective tissue proliferation at successive time points. The process continues to exacerbate leading to loss of ambulation and accelerating out of control, especially in wheelchair-dependent patients.</p><p id="p-0079" num="0078">Without a parallel approach to reduce fibrosis it is unlikely that the benefits of exon skipping, stop-codon read-through, or gene replacement therapies can ever be fully achieved. Even small molecules or protein replacement strategies are likely to fail without an approach to reduce muscle fibrosis. Previous work in aged mdx mice with existing fibrosis treated with AAV.micro-dystrophin demonstrated that we could not achieve full functional restoration (Rodino-Klapac et al., <i>Human molecular genetics </i>22, 4929-4937 (2013)). It is also known that progression of DMD cardiomyopathy is accompanied by scarring and fibrosis in the ventricular wall. Micro-RNA delivery is particularly innovative because of lack of immune barriers and relative ease of delivery. Micro-RNAs are small (&#x2dc;200 bp) and can therefore be packaged in AAV along with a therapeutic cassette to correct or bypass the genetic defect.</p><p id="p-0080" num="0079">As used herein, the term &#x201c;AAV&#x201d; is a standard abbreviation for adeno-associated virus. Adeno-associated virus is a single-stranded DNA parvovirus that grows only in cells in which certain functions are provided by a co-infecting helper virus. There are currently thirteen serotypes of AAV that have been characterized. General information and reviews of AAV can be found in, for example, Carter, 1989, Handbook of Parvoviruses, Vol. 1, pp. 169-228, and Berns, 1990, Virology, pp. 1743-1764, Raven Press, (New York). However, it is fully expected that these same principles will be applicable to additional AAV serotypes since it is well known that the various serotypes are quite closely related, both structurally and functionally, even at the genetic level. (See, for example, Blacklowe, 1988, pp. 165-174 of Parvoviruses and Human Disease, J. R. Pattison, ed.; and Rose, Comprehensive Virology 3:1-61 (1974)). For example, all AAV serotypes apparently exhibit very similar replication properties mediated by homologous rep genes; and all bear three related capsid proteins such as those expressed in AAV2. The degree of relatedness is further suggested by heteroduplex analysis which reveals extensive cross-hybridization between serotypes along the length of the genome; and the presence of analogous self-annealing segments at the termini that correspond to &#x201c;inverted terminal repeat sequences&#x201d; (ITRs). The similar infectivity patterns also suggest that the replication functions in each serotype are under similar regulatory control.</p><p id="p-0081" num="0080">An &#x201c;AAV vector&#x201d; as used herein refers to a vector comprising one or more polynucleotides of interest (or transgenes) that are flanked by AAV terminal repeat sequences (ITRs). Such AAV vectors can be replicated and packaged into infectious viral particles when present in a host cell that has been transfected with a vector encoding and expressing rep and cap gene products.</p><p id="p-0082" num="0081">An &#x201c;AAV virion&#x201d; or &#x201c;AAV viral particle&#x201d; or &#x201c;AAV vector particle&#x201d; refers to a viral particle composed of at least one AAV capsid protein and an encapsidated polynucleotide AAV vector. If the particle comprises a heterologous polynucleotide (i.e. a polynucleotide other than a wild-type AAV genome such as a transgene to be delivered to a mammalian cell), it is typically referred to as an &#x201c;AAV vector particle&#x201d; or simply an &#x201c;AAV vector&#x201d;. Thus, production of AAV vector particle necessarily includes production of AAV vector, as such a vector is contained within an AAV vector particle.</p><heading id="h-0006" level="2">AAV</heading><p id="p-0083" num="0082">Recombinant AAV genomes of the invention comprise nucleic acid molecule of the invention and one or more AAV ITRs flanking a nucleic acid molecule. AAV DNA in the rAAV genomes may be from any AAV serotype for which a recombinant virus can be derived including, but not limited to, AAV serotypes AAV-1, AAV-2, AAV-3, AAV-4, AAV-5, AAV-6, AAV-7, AAV-8, AAV-9, AAV-10, AAV-11, AAV-12 and AAV-13. Production of pseudotyped rAAV is disclosed in, for example, WO 01/83692. Other types of rAAV variants, for example rAAV with capsid mutations, are also contemplated. See, for example, Marsic et al., Molecular Therapy, 22(11): 1900-1909 (2014). As noted in the Background section above, the nucleotide sequences of the genomes of various AAV serotypes are known in the art. To promote skeletal muscle specific expression, AAV1, AAV6, AAV8 or AAVrh.74 may be used.</p><p id="p-0084" num="0083">DNA plasmids of the invention comprise rAAV genomes of the invention. The DNA plasmids are transferred to cells permissible for infection with a helper virus of AAV (e.g., adenovirus, E1-deleted adenovirus or herpes virus) for assembly of the rAAV genome into infectious viral particles. Techniques to produce rAAV particles, in which an AAV genome to be packaged, rep and cap genes, and helper virus functions are provided to a cell, are standard in the art. Production of rAAV requires that the following components are present within a single cell (denoted herein as a packaging cell): a rAAV genome, AAV rep and cap genes separate from (i.e., not in) the rAAV genome, and helper virus functions. The AAV rep and cap genes may be from any AAV serotype for which recombinant virus can be derived and may be from a different AAV serotype than the rAAV genome ITRs, including, but not limited to, AAV serotypes AAV-1, AAV-2, AAV-3, AAV-4, AAV-5, AAV-6, AAV-7, AAVrh.74, AAV-8, AAV-9, AAV-10, AAV-11, AAV-12 and AAV-13. Production of pseudotyped rAAV is disclosed in, for example, WO 01/83692 which is incorporated by reference herein in its entirety.</p><p id="p-0085" num="0084">A method of generating a packaging cell is to create a cell line that stably expresses all the necessary components for AAV particle production. For example, a plasmid (or multiple plasmids) comprising a rAAV genome lacking AAV rep and cap genes, AAV rep and cap genes separate from the rAAV genome, and a selectable marker, such as a neomycin resistance gene, are integrated into the genome of a cell. AAV genomes have been introduced into bacterial plasmids by procedures such as GC tailing (Samulski et al., 1982, Proc. Natl. Acad. S6. USA, 79:2077-2081), addition of synthetic linkers containing restriction endonuclease cleavage sites (Laughlin et al., 1983, Gene, 23:65-73) or by direct, blunt-end ligation (Senapathy &#x26; Carter, 1984, J. Biol. Chem., 259:4661-4666). The packaging cell line is then infected with a helper virus such as adenovirus. The advantages of this method are that the cells are selectable and are suitable for large-scale production of rAAV. Other examples of suitable methods employ adenovirus or baculovirus rather than plasmids to introduce rAAV genomes and/or rep and cap genes into packaging cells.</p><p id="p-0086" num="0085">General principles of rAAV production are reviewed in, for example, Carter, 1992, Current Opinions in Biotechnology, 1533-539; and Muzyczka, 1992, Curr. Topics in Microbial. and Immunol., 158:97-129). Various approaches are described in Ratschin et al., Mol. Cell. Biol. 4:2072 (1984); Hermonat et al., Proc. Natl. Acad. Sci. USA, 81:6466 (1984); Tratschin et al., Mol. Cell. Biol. 5:3251 (1985); McLaughlin et al., J. Virol., 62:1963 (1988); and Lebkowski et al., 1988 Mol. Cell. Biol., 7:349 (1988). Samulski et al. (1989, J. Virol., 63:3822-3828); U.S. Pat. No. 5,173,414; WO 95/13365 and corresponding U.S. Pat. No. 5,658,776; WO 95/13392; WO 96/17947; PCT/US98/18600; WO 97/09441 (PCT/US96/14423); WO 97/08298 (PCT/US96/13872); WO 97/21825 (PCT/US96/20777); WO 97/06243 (PCT/FR96/01064); WO 99/11764; Perrin et al. (1995) Vaccine 13:1244-1250; Paul et al. (1993) Human Gene Therapy 4:609-615; Clark et al. (1996) Gene Therapy 3:1124-1132; U.S. Pat. Nos. 5,786,211; 5,871,982; and 6,258,595. The foregoing documents are hereby incorporated by reference in their entirety herein, with particular emphasis on those sections of the documents relating to rAAV production.</p><p id="p-0087" num="0086">The invention thus provides packaging cells that produce infectious rAAV. In one embodiment packaging cells may be stably transformed cancer cells such as HeLa cells, 293 cells and PerC.6 cells (a cognate 293 line). In another embodiment, packaging cells are cells that are not transformed cancer cells, such as low passage 293 cells (human fetal kidney cells transformed with E1 of adenovirus), MRC-5 cells (human fetal fibroblasts), WI-38 cells (human fetal fibroblasts), Vero cells (monkey kidney cells) and FRhL-2 cells (rhesus fetal lung cells).</p><p id="p-0088" num="0087">Recombinant AAV (i.e., infectious encapsidated rAAV particles) of the invention comprise a rAAV genome. In exemplary embodiments, the genomes of both rAAV lack AAV rep and cap DNA, that is, there is no AAV rep or cap DNA between the ITRs of the genomes. Examples of rAAV that may be constructed to comprise the nucleic acid molecules of the invention are set out in International Patent Application No. PCT/US2012/047999 (WO 2013/016352) incorporated by reference herein in its entirety.</p><p id="p-0089" num="0088">The rAAV may be purified by methods standard in the art such as by column chromatography or cesium chloride gradients. Methods for purifying rAAV vectors from helper virus are known in the art and include methods disclosed in, for example, Clark et al., <i>Hum. Gene Ther., </i>10(6): 1031-1039 (1999); Schenpp and Clark, <i>Methods Mol. Med., </i>69 427-443 (2002); U.S. Pat. No. 6,566,118 and WO 98/09657.</p><p id="p-0090" num="0089">In another embodiment, the invention contemplates compositions comprising rAAV of the present invention. Compositions of the invention comprise rAAV and a pharmaceutically acceptable carrier. The compositions may also comprise other ingredients such as diluents and adjuvants. Acceptable carriers, diluents and adjuvants are nontoxic to recipients and are preferably inert at the dosages and concentrations employed, and include buffers such as phosphate, citrate, or other organic acids; antioxidants such as ascorbic acid; low molecular weight polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counter ions such as sodium; and/or nonionic surfactants such as Tween, pluronics or polyethylene glycol (PEG).</p><p id="p-0091" num="0090">Titers of rAAV to be administered in methods of the invention will vary depending, for example, on the particular rAAV, the mode of administration, the treatment goal, the individual, and the cell type(s) being targeted, and may be determined by methods standard in the art. Titers of rAAV may range from about 1&#xd7;10<sup>6</sup>, about 1&#xd7;10<sup>7</sup>, about 1&#xd7;10<sup>8</sup>, about 1&#xd7;10<sup>9</sup>, about 1&#xd7;10<sup>10</sup>, about 1&#xd7;10<sup>11</sup>, about 1&#xd7;10<sup>12</sup>, about 1&#xd7;10<sup>13 </sup>to about 1&#xd7;10<sup>14 </sup>or more DNase resistant particles (DRP) per ml. Dosages may also be expressed in units of viral genomes (vg).</p><p id="p-0092" num="0091">Methods of transducing a target cell with rAAV, in vivo or in vitro, are contemplated by the invention. The in vivo methods comprise the step of administering an effective dose, or effective multiple doses, of a composition comprising a rAAV of the invention to an animal (including a human being) in need thereof. If the dose is administered prior to development of a disorder/disease, the administration is prophylactic. If the dose is administered after the development of a disorder/disease, the administration is therapeutic. In embodiments of the invention, an effective dose is a dose that alleviates (eliminates or reduces) at least one symptom associated with the disorder/disease state being treated, that slows or prevents progression to a disorder/disease state, that slows or prevents progression of a disorder/disease state, that diminishes the extent of disease, that results in remission (partial or total) of disease, and/or that prolongs survival. An example of a disease contemplated for prevention or treatment with methods of the invention is FSHD.</p><p id="p-0093" num="0092">Combination therapies are also contemplated by the invention. Combination as used herein includes both simultaneous treatment and sequential treatments. Combinations of methods of the invention with standard medical treatments (e.g., corticosteroids) are specifically contemplated, as are combinations with novel therapies.</p><p id="p-0094" num="0093">Administration of an effective dose of the compositions may be by routes standard in the art including, but not limited to, intramuscular, parenteral, intravenous, oral, buccal, nasal, pulmonary, intracranial, intraosseous, intraocular, rectal, or vaginal. Route(s) of administration and serotype(s) of AAV components of the rAAV (in particular, the AAV ITRs and capsid protein) of the invention may be chosen and/or matched by those skilled in the art taking into account the infection and/or disease state being treated and the target cells/tissue(s) that are to express the miR-29 miRNA and/or micro-dystrophin.</p><p id="p-0095" num="0094">The invention provides for local administration and systemic administration of an effective dose of rAAV and compositions of the invention including combination therapy of the invention. For example, systemic administration is administration into the circulatory system so that the entire body is affected. Systemic administration includes enteral administration such as absorption through the gastrointestinal tract and parental administration through injection, infusion or implantation.</p><p id="p-0096" num="0095">In particular, actual administration of rAAV of the present invention may be accomplished by using any physical method that will transport the rAAV recombinant vector into the target tissue of an animal. Administration according to the invention includes, but is not limited to, injection into muscle, the bloodstream and/or directly into the liver. Simply resuspending a rAAV in phosphate buffered saline has been demonstrated to be sufficient to provide a vehicle useful for muscle tissue expression, and there are no known restrictions on the carriers or other components that can be co-administered with the rAAV (although compositions that degrade DNA should be avoided in the normal manner with rAAV). Capsid proteins of a rAAV may be modified so that the rAAV is targeted to a particular target tissue of interest such as muscle. See, for example, WO 02/053703, the disclosure of which is incorporated by reference herein. Pharmaceutical compositions can be prepared as injectable formulations or as topical formulations to be delivered to the muscles by transdermal transport. Numerous formulations for both intramuscular injection and transdermal transport have been previously developed and can be used in the practice of the invention. The rAAV can be used with any pharmaceutically acceptable carrier for ease of administration and handling.</p><p id="p-0097" num="0096">The dose of rAAV to be administered in methods disclosed herein will vary depending, for example, on the particular rAAV, the mode of administration, the treatment goal, the individual, and the cell type(s) being targeted, and may be determined by methods standard in the art. Titers of each rAAV administered may range from about 1&#xd7;10<sup>6</sup>, about 1&#xd7;10<sup>7</sup>, about 1&#xd7;10<sup>8</sup>, about 1&#xd7;10<sup>9</sup>, about 1&#xd7;10<sup>10</sup>, about 1&#xd7;10<sup>11</sup>, about 1&#xd7;10<sup>12</sup>, about 1&#xd7;10<sup>13</sup>, about 1&#xd7;10<sup>14</sup>, or to about 1&#xd7;10<sup>15 </sup>or more DNase resistant particles (DRP) per ml. Dosages may also be expressed in units of viral genomes (vg) (i.e., 1&#xd7;10<sup>7 </sup>vg, 1&#xd7;10<sup>8 </sup>vg, 1&#xd7;10<sup>9 </sup>vg, 1&#xd7;10<sup>10 </sup>vg 1&#xd7;10<sup>11 </sup>vg, 1&#xd7;10<sup>12 </sup>vg, 1&#xd7;10<sup>13 </sup>vg, 1&#xd7;10<sup>14 </sup>vg, 1&#xd7;10<sup>15 </sup>respectively). Dosages may also be expressed in units of viral genomes (vg) per kilogram (kg) of bodyweight (i.e., 1&#xd7;10<sup>10 </sup>vg/kg, 1&#xd7;10<sup>11 </sup>vg/kg, 1&#xd7;10<sup>12 </sup>vg/kg, 1&#xd7;10<sup>13 </sup>vg/kg, 1&#xd7;10<sup>14 </sup>vg/kg, 1&#xd7;10<sup>15 </sup>vg/kg respectively). Methods for titering AAV are described in Clark et al., Hum. Gene Ther., 10: 1031-1039 (1999).</p><p id="p-0098" num="0097">In particular, actual administration of rAAV of the present invention may be accomplished by using any physical method that will transport the rAAV recombinant vector into the target tissue of an animal. Administration according to the invention includes, but is not limited to, injection into muscle, the bloodstream and/or directly into the liver. Simply resuspending a rAAV in phosphate buffered saline has been demonstrated to be sufficient to provide a vehicle useful for muscle tissue expression, and there are no known restrictions on the carriers or other components that can be co-administered with the rAAV (although compositions that degrade DNA should be avoided in the normal manner with rAAV). Capsid proteins of a rAAV may be modified so that the rAAV is targeted to a particular target tissue of interest such as muscle. See, for example, WO 02/053703, the disclosure of which is incorporated by reference herein. Pharmaceutical compositions can be prepared as injectable formulations or as topical formulations to be delivered to the muscles by transdermal transport. Numerous formulations for both intramuscular injection and transdermal transport have been previously developed and can be used in the practice of the invention. The rAAV can be used with any pharmaceutically acceptable carrier for ease of administration and handling.</p><p id="p-0099" num="0098">For purposes of intramuscular injection, solutions in an adjuvant such as sesame or peanut oil or in aqueous propylene glycol can be employed, as well as sterile aqueous solutions. Such aqueous solutions can be buffered, if desired, and the liquid diluent first rendered isotonic with saline or glucose. Solutions of rAAV as a free acid (DNA contains acidic phosphate groups) or a pharmacologically acceptable salt can be prepared in water suitably mixed with a surfactant such as hydroxpropylcellulose. A dispersion of rAAV can also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms. In this connection, the sterile aqueous media employed are all readily obtainable by standard techniques well-known to those skilled in the art.</p><p id="p-0100" num="0099">The pharmaceutical carriers, diluents or excipients suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating actions of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, liquid polyethylene glycol and the like), suitable mixtures thereof, and vegetable oils. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of a dispersion and by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal and the like. In many cases it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by use of agents delaying absorption, for example, aluminum monostearate and gelatin.</p><p id="p-0101" num="0100">Sterile injectable solutions are prepared by incorporating rAAV in the required amount in the appropriate solvent with various other ingredients enumerated above, as required, followed by filter sterilization. Generally, dispersions are prepared by incorporating the sterilized active ingredient into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and the freeze drying technique that yield a powder of the active ingredient plus any additional desired ingredient from the previously sterile-filtered solution thereof.</p><p id="p-0102" num="0101">Transduction with rAAV may also be carried out in vitro. In one embodiment, desired target muscle cells are removed from the subject, transduced with rAAV and reintroduced into the subject. Alternatively, syngeneic or xenogeneic muscle cells can be used where those cells will not generate an inappropriate immune response in the subject.</p><p id="p-0103" num="0102">Suitable methods for the transduction and reintroduction of transduced cells into a subject are known in the art. In one embodiment, cells can be transduced in vitro by combining rAAV with muscle cells, e.g., in appropriate media, and screening for those cells harboring the DNA of interest using conventional techniques such as Southern blots and/or PCR, or by using selectable markers. Transduced cells can then be formulated into pharmaceutical compositions, and the composition introduced into the subject by various techniques, such as by intramuscular, intravenous, subcutaneous and intraperitoneal injection, or by injection into smooth and cardiac muscle, using e.g., a catheter.</p><p id="p-0104" num="0103">Transduction of cells with rAAV of the invention results in sustained expression of miR-29 or micro-dystrophin. The present invention thus provides methods of administering/delivering rAAV which express of miR-29 and or micro-dystrophin to an animal, preferably a human being. These methods include transducing tissues (including, but not limited to, tissues such as muscle, organs such as liver and brain, and glands such as salivary glands) with one or more rAAV of the present invention. Transduction may be carried out with gene cassettes comprising tissue specific control elements. For example, one embodiment of the invention provides methods of transducing muscle cells and muscle tissues directed by muscle specific control elements, including, but not limited to, those derived from the actin and myosin gene families, such as from the myoD gene family [See Weintraub et al., <i>Science, </i>251: 761-766 (1991)], the myocyte-specific enhancer binding factor MEF-2 [Cserjesi and Olson, <i>Mol Cell Biol </i>11: 4854-4862 (1991)], control elements derived from the human skeletal actin gene [Muscat et al., <i>Mol Cell Biol, </i>7: 4089-4099 (1987)], the cardiac actin gene, muscle creatine kinase sequence elements [See Johnson et al., <i>Mol Cell Biol, </i>9:3393-3399 (1989)] and the murine creatine kinase enhancer (mCK) element, control elements derived from the skeletal fast-twitch troponin C gene, the slow-twitch cardiac troponin C gene and the slow-twitch troponin I gene: hypoxia-inducible nuclear factors (Semenza et al., <i>Proc Natl Acad Sci USA, </i>88: 5680-5684 (1991)), steroid-inducible elements and promoters including the glucocorticoid response element (GRE) (See Mader and White, <i>Proc. Natl. Acad. Sci. USA </i>90: 5603-5607 (1993)), and other control elements.</p><p id="p-0105" num="0104">Muscle tissue is an attractive target for in vivo DNA delivery, because it is not a vital organ and is easy to access. The invention contemplates sustained expression of miRNAs from transduced myofibers.</p><p id="p-0106" num="0105">By &#x201c;muscle cell&#x201d; or &#x201c;muscle tissue&#x201d; is meant a cell or group of cells derived from muscle of any kind (for example, skeletal muscle and smooth muscle, e.g. from the digestive tract, urinary bladder, blood vessels or cardiac tissue). Such muscle cells may be differentiated or undifferentiated, such as myoblasts, myocytes, myotubes, cardiomyocytes and cardiomyoblasts.</p><p id="p-0107" num="0106">The term &#x201c;transduction&#x201d; is used to refer to the administration/delivery of the miiR29 guide strand or the coding region of micro-dystrophin to a recipient cell either in vivo or in vitro, via a replication-deficient rAAV of the invention resulting in expression of a miR29 or micro-dystrophin by the recipient cell.</p><p id="p-0108" num="0107">Thus, the invention provides methods of administering an effective dose (or doses, administered essentially simultaneously or doses given at intervals) of rAAV that encode miR29 and/or micro-dystrophin to a patient in need thereof.</p><heading id="h-0007" level="1">EXAMPLES</heading><heading id="h-0008" level="1">Example 1</heading><heading id="h-0009" level="1">Confirmation of Duchenne Muscular Dystrophy Models</heading><p id="p-0109" num="0108">The mdx mouse provides a convenient, yet incomplete, animal model to study DMD pathogenesis. This model is a cross of the mdx mouse with a heterozygous knockout of the utrophin gene (mdx:utrn+/&#x2212;), which presents with increased fibrosis and more faithfully recapitulates the pathology of human DMD. Mdx mice have a nonsense mutation in exon 23 of DMD that results in a relatively mild phenotype and a near-normal life span. By 3 weeks of age, the diaphragm and limb muscle of mdx mice develop signs of endomysial inflammation. These symptoms subside in the limb muscle after the mice reach adulthood while the inflammation in the diaphragm muscle continues to progressively worsen. In mdx mice lacking telomerase, muscular dystrophy progressively worsens with age; mdx mice lacking utrophin (DKO) have a phenotype more characteristic of human DMD with early onset muscle weakness, severe fibrosis, and premature death. Utrophin, an autosomal paralog of the dystrophin, shares a high degree of sequence homology that may compensate for the lack of dystrophin in the mdx mouse in the double KO (dystrophin plus utrophin); a severe phenotype with early death is observed. The premature death in the DKO mouse precludes progression of inflammation and fibrosis, but the mdx:utrn<sup>+/&#x2212;</sup> mouse presents a model with similarities to the human disease exhibiting a striking degree of fibrosis, and a longer survival than the DKO, providing a better model for our proposed translational studies. A recent report confirms the use of the mdx:utrn<sup>+/&#x2212;</sup> mouse as an ideal model to study fibrosis in the context of DMD. In the present study, increased fibrosis as measured by Sirius red staining was accompanied by increased collagen transcript levels and decreased mir29c levels.</p><heading id="h-0010" level="1">Example 2</heading><heading id="h-0011" level="1">Delivery of miR29 to DMD Mice Reduces Fibrosis</heading><p id="p-0110" num="0109">Preliminary studies have demonstrated that there is a significant increase in Sirius Red staining for collagen and a decrease in miR-29c levels in human DMD patients and the mdx/utrn<sup>+/&#x2212;</sup> mouse. Gene delivery of miR-29 using muscle specific AAV vectors is potentially safe and efficient. To generate the rAAV vector, referred to herein as rAAVrh.74.CMV.miR29c, the 22 nucleotide miR29c sequence (target strand SEQ ID NO: 3 and guide strand SEQ ID NO: 4) was cloned into a miR-30 scaffold driven by a CMV promoter. The expression cassette (SEQ ID NO: 2) was cloned into a self-complementary AAV plasmid and packaged using AAVrh.74, a serotype known to express well in muscle. The miR-29c cDNA was synthesized using a custom primer containing the miR-29c target (sense) strand, miR-30 stem loop and miR-29c guide (antisense) strand in the miR-30 backbone. Three bases of the miR-29c sequence were modified. This sequence was then cloned into a self-complementary AAV ITR containing plasmid driven by the CMV promoter and polyA sequence.</p><p id="p-0111" num="0110">As shown in <figref idref="DRAWINGS">FIG. <b>1</b></figref>, the pAAV.CMV.miR29C plasmid contains the mir29c cDNA in a miR-30 stem loop backbone flanked by AAV2 inverted terminal repeat sequences (ITR). It is this sequence that was encapsidated into AAVrh.74 virions. In addition, a few nucleotides with in the miR-29c target sequence were changed to mimic Watson-crick pairing at this site as in shRNA-miR(luc). According to ShRNA-luc design, the hairpin should be perfectly complementary throughout its length. Plus, the more changes to the passenger strand, the more likely the elimination of any endogenous mechanism that regulates miR-29 processing that could recognize the miRNA via the stem. The 19<sup>th </sup>base of the guide strand was modified to a cytosine to mimic the nucleotide that precedes the cleavage site in natural mi-29c sequence and the corresponding base on the other strand was changed to preserve pairing.</p><p id="p-0112" num="0111">The gene therapy vector scrAAVrh.74.CMV.miR29c (1&#xd7;10<sup>11 </sup>vgs) was injected into the quadriceps muscle of 3 month old mdx/utrn<sup>+/&#x2212;</sup> mice. Quadriceps muscle was analyzed 3 months post-injection by Sirius Red staining and analyzed by NIH ImageJ software as described in Nevo et al. (PloS One, 6: e18049 (2011). MiR29c, collagen and elastin levels were quantified by RT-PCR. Delivery of miR-29c to young mdx/utrn<sup>+/&#x2212;</sup> mice significantly increases mir-29c levels and a significant reduction in Sirius red staining in the quadriceps muscle of 6 month old mdx/utrn<sup>+/&#x2212;</sup> mice (3 months post injection). There was a reduction in collagen and elastin levels in the treated muscles when evaluated by RT-PCR.</p><p id="p-0113" num="0112">Demonstration of increased fibrosis and decreased miR29 expression in the mdx/utrn<sup>+/&#x2212;</sup> mice and dystrophin-deficient patients validates the mouse model as being representative of the human disease. Initial results using AAV-delivered miR29 as an anti-fibrotic therapy suggest that there is significant beneficial effect with reduction in Sirius Red staining and collagen and elastin levels, which are key contributors in fibrosis.</p><heading id="h-0012" level="1">Example 3</heading><heading id="h-0013" level="1">Injection of MiR-29c Reduces Collagen and Restores miR-29c</heading><p id="p-0114" num="0113">To determine whether rAAVrh.74.CMV.MiR-29c could reduce fibrosis, 12-week-old mdx/utrn<sup>+\&#x2212;</sup> mice received an intramuscular injection of rAAVrh.74.CMV.MiR-29c at 5&#xd7;10<sup>11 </sup>vgs to the left gastrocnemius (GAS) muscle. The mice were analyzed at 12 weeks post injection. Picrosirius red staining revealed a significant decrease in collagen staining throughout the GAS muscles (<figref idref="DRAWINGS">FIG. <b>2</b><i>a</i></figref>) compared to the untreated contralateral mdx/utrn+/&#x2212; GAS muscle. Quantification of the picrosirius red staining shows that treated muscle had a 18.3% reduction in collagen compared to the untreated muscle (treated&#x2014;23.3%&#xb1;1.3 vs. untreated&#x2014;29.5%&#xb1;0.7)(<figref idref="DRAWINGS">FIG. <b>2</b><i>b</i></figref>). To confirm overexpression of miR-29c in treated muscle, total RNA was extracted from the GAS muscle from 24 week old WT, miR-29c treated and mdx/utrn<sup>+/&#x2212;</sup> mice and subjected to quantitative reverse-transcription&#x2014;PCR (qRT-PCR) analysis for miR-29c expression. The results showed that miR-29c was significantly increased in the GAS muscle of the treated mice compared to untreated mice (<figref idref="DRAWINGS">FIG. <b>2</b><i>d</i></figref>).</p><heading id="h-0014" level="1">Example 4</heading><heading id="h-0015" level="1">MiR-29c Improves Absolute and Specific Muscle Force but does not Protect Against Contraction-Induced Damage</heading><p id="p-0115" num="0114">Knowing that fibrosis can impact muscle function, we wanted to test whether reducing fibrosis by increasing expression of MiR-29c could protect mdx/utrn<sup>+/&#x2212;</sup> muscle from contraction-induced injury and increase overall force. The functional properties of the gastrocnemius muscle from mdx/utrn<sup>+/&#x2212;</sup> mice treated with rAAVrh.74.CMV.MiR-29c were assessed. Twelve weeks post injection, the GAS was isolated to perform in vivo force measurements.</p><p id="p-0116" num="0115">The GAS procedure follows the protocol listed in Hakim et al., (Methods Mol Biol. 709: 75-89, 2011) for analyzing transverse abdominal muscle physiology but adapted for the GAS. Briefly, mice were anesthetized using ketamine/xylazine mixture. The hind limb skin was removed to expose the GAS muscle and the Achilles tendon. The distal tendon was dissected out and a double square knot was tied around the tendon with 4-0 suture as close to the muscle as possible, another second double square knot is tied right next to the first knot and then tendon is cut. The exposed muscle was constantly dampened with saline. Mice were then transferred to a thermal controlled platform and maintained at 37&#xb0;. The knee was secured to the platform with a needle through the patella tendon, the tendon suture to the level arm of the force transducer (Aurora Scientific, Aurora, ON, Canada), and the foot was secured with tape. The GAS muscle contractions were elicited by stimulating the sciatic nerve via bipolar platinum electrodes. Once the muscle was stabilized, the optimal length was determined by incremental stretching the muscle until the maximum twitch force was achieved. After a 3-minute rest period, the GAS was stimulated at 50,100,150, and 200 Hz, allowing a 1-minute rest period between each stimulus to determine maximum tetanic force. Muscle length was measured. Following a 5-minute rest, the susceptibility of the GAS muscle to contraction-induced damage was assessed. After 500 ms of stimulation, the muscle was lengthened by 10% of the optimal length. This consisted of stimulating the muscle at 150 Hz for 700 ms. After the stimulation, the muscle was returned to the optimal length. The cycle was repeated every minute for a total of 5 cycles. Specific force was calculated by dividing the maximum tetanic force by the GAS muscle cross sectional area. After the eccentric contractions, the mice were then euthanized and the GAS muscle was dissected out, weighed and frozen for analysis.</p><p id="p-0117" num="0116">Each GAS was subjected to a series of repeated eccentric contraction. By comparing the force ratio of each contraction versus the first contraction revealed that after the fifth contraction untreated muscle decayed to 0.56&#xb1;0.05 versus treated 0.50&#xb1;0.04 (p&#x3c;0.0001). The injected group showed a slight decrease in the degree of protection compared to WT controls, that decayed to 0.92&#xb1;0.02 (<figref idref="DRAWINGS">FIG. <b>3</b><i>c</i></figref>). This data shows that reducing fibrosis by increasing expression of miR-29c leads to increase in both absolute and specific force but does not significantly protect muscle from contraction-induced injury.</p><p id="p-0118" num="0117">rAAVrh.74.MiR-29c treated GAS muscle showed significant improvement in absolute force when compared to untreated mdx/utrn<sup>+/&#x2212;</sup> GAS muscle (rAAV.miR-29c&#x2014;2277&#xb1;161.7 vs. mdx/utrn<sup>+/&#x2212;</sup> untreated&#x2014;1722&#xb1;145.7; <figref idref="DRAWINGS">FIG. <b>3</b><i>a</i></figref>), and also normalized specific force in rAAVrh.74.miR-29c treated GAS muscle specific improvement when compared to untreated GAS muscle (rAAV.miR-29c&#x2014;204.7&#xb1;11.7 vs. mdx/utrn<sup>+/&#x2212;</sup> untreated&#x2014;151.6&#xb1;14.5; <figref idref="DRAWINGS">FIG. <b>3</b><i>b</i></figref>). Force was still significantly reduced when compared to wild-type controls (rAAV.miR-29c&#x2014;204.7&#xb1;11.7 vs. wild-type&#x2014;312.0&#xb1;34.1).</p><heading id="h-0016" level="1">Example 5</heading><heading id="h-0017" level="1">Co-Delivery with Micro-Dystrophin Further Reduces Fibrosis</heading><p id="p-0119" num="0118">To determine whether miR-29c/micro-dystrophin combined gene therapy approach would be more beneficial at reducing fibrosis, 12-week-old mdx/utrn<sup>+\&#x2212;</sup> mice received an intramuscular injection of rAAVrh.74.CMV.MiR-29c at 5&#xd7;10<sup>11 </sup>vgs to the left gastrocnemius muscle. The following gene therapy vectors were administered by intramuscular injection (IM) into the left gastrocnemius (GAS) muscle of 3 month old mdx/utrn<sup>+/&#x2212;</sup> mice, a DMD mouse model: scAAVrh.74.CMV.miR-29c alone, co-delivered with rAAVrh.74.MCK.micro-dystrophin, and rAAVrh.74.MCK.micro-dystrophin alone.</p><p id="p-0120" num="0119">The pAAV.MCK.micro-dystrophin plasmid contains the human micro-dystrophin cDNA expression cassette flanked by AAV2 inverted terminal repeat sequences (ITR) as shown in <figref idref="DRAWINGS">FIG. <b>10</b></figref>. It is this sequence that was encapsidated into AAV rh.74 virions. The pAAV.MCK.micro-dystrophin plasmid was constructed by inserting the MCK expression cassette driving a codon optimized human micro-dystrophin cDNA sequence into the AAV cloning vector as described in Rodino-Klapac et al. (Mol Ther. 2010 January;18(1):109-17). A MCK promoter/enhancer sequence was used to drive muscle-specific gene expression and is composed of the mouse MCK core enhancer (206 bp) fused to the 351 bp MCK core promoter (proximal). After the core promoter, the 53 bp endogenous mouse MCK Exon1 (untranslated) is present for efficient transcription initiation, followed by the SV40 late 16S/19S splice signals (97 bp) and a small 5&#x2032;UTR (61 bp). The intron and 5&#x2032; UTR are derived from plasmid pCMV&#x3b2; (Clontech). The micro-dystrophin cassette has a consensus Kozak immediately in front of the ATG start and a small 53 bp synthetic polyA signal for mRNA termination. The human micro-dystrophin cassette contains the (R4-R23/&#x394;71-78) domains. The complementary DNA was codon optimized for human usage and synthesized by GenScript (Piscataway, N.J.).</p><p id="p-0121" num="0120">The mice were analyzed at 12 and 24 weeks post injection. First, the number of muscle fibers expressing micro-dystrophin was used to assess the efficacy of transgene delivery and to make sure we had similar levels of micro-dystrophin expressed in each group. We found that micro-dystrophin was not different between cohorts treated with micro-dystrophin alone (71.85&#xb1;2.25%) compared with miR-29c/micro-dystrophin combination therapy (75.03&#xb1;1.91%) (<figref idref="DRAWINGS">FIG. <b>4</b></figref>).</p><p id="p-0122" num="0121">GAS muscle was analyzed 12 months post-injection to assess collagen accumulation by Sirius Red staining and subsequent quantification with ImageJ. Additional outcomes included miR-29c and collagen transcript levels, force measurements in the GAS muscle, fiber diameter measurements and western blot analysis for proteins involved in muscle regeneration (MyoD, Myogenin). The amount of fibrosis was analyzed by picrosirius red staining, which revealed a significant decrease in collagen staining throughout the GAS muscles in all treated groups (<figref idref="DRAWINGS">FIG. <b>5</b><i>a</i></figref>) compared to the untreated contralateral mdx/utrn+/&#x2212; GAS muscle or micro-dystrophin alone. Quantification of the picrosirius red staining shows that co-treated muscle had a 40.8% reduction in collagen compared to the untreated muscle (treated&#x2014;17.47%&#xb1;0.75 vs. untreated&#x2014;29.5%&#xb1;0.7) (<figref idref="DRAWINGS">FIG. <b>5</b><i>b</i></figref>). To confirm expression of miR-29c, qRT-PCR was performed on the GAS muscle and all treatment groups had an increase in miR-29c compared to untreated muscle (<figref idref="DRAWINGS">FIG. <b>5</b><i>c</i></figref>).</p><p id="p-0123" num="0122">Analogous to DMD tissue, a significant reduction in miR-29c levels in mdx/utrn<sup>+/&#x2212;</sup> muscle was observed which correlated with increased fibrosis measured by picrosirius red staining. Following 3 months of treatment with scAAV.miR-29c alone, there was a significant reduction in fibrosis (treated&#x2014;23.5%&#xb1;1.3 vs. untreated&#x2014;27.8%&#xb1;0.6) in the GAS muscle. When co-delivered with micro-dystrophin, further reduction in collagen (41%) was observed by picrosirius red staining (combination treatment: 17.47%&#xb1;0.75 vs. untreated: 29.5%&#xb1;0.7) (p&#x3c;0.0001) (<figref idref="DRAWINGS">FIG. <b>5</b><i>b</i></figref>). To confirm expression of miR-29c, qRT-PCR was performed on the GAS muscle and all treatment groups had an increase in miR-29c compared to untreated muscle (<figref idref="DRAWINGS">FIG. <b>5</b><i>b</i></figref>).</p><p id="p-0124" num="0123">At 24 weeks post-injection, the results were similar to those observed 12 weeks post injection. There was a 47% reduction in collagen by picrosirius red staining compared to the untreated muscle (combination treatment: 16.5&#xb1;1.23 vs. untreated: 31.07&#xb1;0.93; p&#x3c;0.0001) and a coincident increase in miR-29c transcript level.</p><p id="p-0125" num="0124">To further validate reduction of collagen observed by picrosirius red staining, qRT-PCR was performed on the muscle to quantify transcript levels of Col1A, Col3A and also another ECM component, fibronectin (Fbn). qRT-PCR analysis detected a decrease in Col1A and Col3A following each treatment, however only the cohort treated with both micro-dystrophin and miR-29c showed significant reduction (<figref idref="DRAWINGS">FIGS. <b>6</b><i>a </i>and <b>6</b><i>b</i></figref>). The analysis revealed that Fbn was significantly reduced only in the co-treated cohort (<figref idref="DRAWINGS">FIG. <b>6</b><i>c</i></figref>).</p><p id="p-0126" num="0125">TGF-&#x3b2;1 has been previously shown to be up regulated in dystrophic muscle, likely playing a role in the initiation of the fibrotic cascade. TGF-&#x3b2;1 is a known pro-fibrotic cytokine that down regulates miR-29c and is responsible for conversion of myoblasts to myofibroblasts with an increase in collagen and muscle fibrogenesis. qRT-PCR analysis shows that co-treated muscle had significantly lower levels of TGF-&#x3b2;1 compared to uninjected muscle and either treatment alone (<figref idref="DRAWINGS">FIG. <b>6</b><i>d</i></figref>). At 6 months post injection, co-treated muscle continued to show reduced Col1A, Col3A, Fbn and TGF-&#x3b2;1 levels, whereas only slight reductions in Col1A mRNA levels in the miR-29 and micro-dystrophin only groups were observed</p><p id="p-0127" num="0126">An increase in specific and absolute force was observed in the muscle treated with miR-29c alone compared to the untreated limb, which when combined with micro-dystrophin led to absolute and specific force that were not significantly different than wild-type. We also observed a significant increase in gastroc weight in those muscles that were co-treated.</p><p id="p-0128" num="0127">Initial results using rAAV.miR-29c as an anti-fibrotic therapy suggest that there is beneficial effect with reduction in collagen levels, a key contributor in fibrosis. Moreover, when combined with micro-dystrophin to improve membrane stability, miR29 up regulation normalized muscle force.</p><heading id="h-0018" level="1">Example 6</heading><heading id="h-0019" level="1">Further Increase in Absolute Force and Added Protection from Contraction-Induced Damage</heading><p id="p-0129" num="0128">Knowing that miR-29-treated muscle had a modest but significant increase in absolute and specific force, the combination therapy of miR-29c overexpression and micro-dystrophin gene replacement impact on muscle function was investigated. Twelve weeks post injection, we isolated the GAS for which we performed in vivo force measurements. The rAAVrh.74.MiR-29c vector described above in Example 2 and a rAAV</p><p id="p-0130" num="0129">Co-treated rAAVrh.74.MiR-29c and rAAV expressing Micro-Dys treated GAS muscle showed significant improvement in absolute force when compared to untreated mdx/utrn<sup>+/&#x2212;</sup> GAS muscle (co-treated&#x2014;3582.4&#xb1;79.4 nM vs. mdx/utrn<sup>+/&#x2212;</sup> untreated&#x2014;1722&#xb1;145.7 nM vs. wild-type&#x2014;3005&#xb1;167.3 nM) (<figref idref="DRAWINGS">FIG. <b>7</b></figref>), and also normalized specific force in rAAVrh.74.miR-29c/micro-dys treated GAS muscle specific improvement when compared to untreated GAS muscle (co-treated mice-244.2&#xb1;6.6 nM/mm<sup>2 </sup>vs. mdx/utrn<sup>+/&#x2212;</sup> untreated&#x2014;151.6&#xb1;14.5 nM/mm<sup>2 </sup>vs. 312.0&#xb1;34.1 nM/mm<sup>2</sup>) (<figref idref="DRAWINGS">FIG. <b>7</b></figref>). Both absolute and specific force was not significantly different from wild-type controls.</p><p id="p-0131" num="0130">Each GAS was subjected to a series of repeated eccentric contraction. By comparing the force ratio of each contraction versus the first contraction revealed that after the fifth contraction untreated muscle decayed to 0.54&#xb1;0.06 versus co-treated 0.66&#xb1;0.04 (p&#x2264;0.0001), which can be contributed to micro-dystrophin since micro-dystrophin alone also decayed to 0.66&#xb1;0.04. The treated group was still significantly lower than wild-type that decayed to 0.92&#xb1;0.02 (<figref idref="DRAWINGS">FIG. <b>7</b><i>c</i></figref>). Similar findings were seen at 24 weeks post injection This data shows that reducing fibrosis and gene replacement leads to increase in both absolute and specific 5 force and significantly protects muscle from contraction-induced injury.</p><heading id="h-0020" level="1">Example 7</heading><heading id="h-0021" level="1">Combination Treatment Increases Muscle Hypertrophy and Hyperplasia</heading><p id="p-0132" num="0131">MiR-29c co-delivered with micro-dystrophin increased the overall weight of the injected gastroc compared to either one injected alone at three months of age (<figref idref="DRAWINGS">FIG. <b>8</b></figref>, <figref idref="DRAWINGS">FIG. <b>9</b><i>a</i></figref>). To investigate the source of increased muscle mass, myofiber diameters are measured. miR-29c/&#x3bc;-dys combination treatment demonstrated an increase in average fiber size. Comparing mdx/utrn<sup>+/&#x2212;</sup> controls with miR-29c/&#x3bc;-dys treated mdx/utrn<sup>+/&#x2212;</sup>, the average diameter increased from 25.96 to 30.97 &#x3bc;m (<figref idref="DRAWINGS">FIG. <b>9</b><i>b</i></figref>). The co-delivery produced a shift towards wild-type fiber size distribution (<figref idref="DRAWINGS">FIG. <b>9</b><i>c</i></figref>). Although the average fiber size was increased does not explain the &#x2dc;30% increase in gross muscle weight. Total cross-sectional area of the muscle was also measured. Gastroc muscles from all groups were full slide scanned and the total area was measured. Muscles co-treated with micro-dys/miR-29c had a significant increase in cross sectional area compared to untreated and either treatment alone (uninjected: 24.6 vs. miR-29c: 26.3 vs. micro-dys: 26.6 vs. micro-dys/miR-29c: 33.1) (<figref idref="DRAWINGS">FIG. <b>8</b></figref>, <figref idref="DRAWINGS">FIG. <b>9</b><i>d</i></figref>).</p><p id="p-0133" num="0132">miR-29c has been reported it to play a role in the myoD/Pax7/myogenin pathway and it was hypothesized that miR-29c may be impacting regeneration and activation of satellite cells (muscle stem cells) to differentiate in myogenic lineage. To test this, the total number of muscle fibers from the full slide scanned images was counted. An increased number of muscle fibers following miR-29c/&#x3bc;-dys combination treatment (<figref idref="DRAWINGS">FIG. <b>9</b><i>e</i></figref>). Finally, given that muscle fiber diameters in mdx/utrn+/&#x2212; mice are heterogeneous with many small fibers and some hypertrophic fibers, it was determined whether the number of fibers per unit area (cells/mm2) was affected with treatment. miR-29c/&#x3bc;-dys combination treatment was not different than wild-type (<figref idref="DRAWINGS">FIG. <b>9</b><i>f</i></figref>).</p><heading id="h-0022" level="1">Example 8</heading><heading id="h-0023" level="1">Early Treatment with Combination Prevents Fibrosis</heading><p id="p-0134" num="0133">In view of the potential importance of combinatorial miR-29c and micro-dystrophin as a prophylactic therapy for DMD, a cohort of younger mdx/utrn<sup>+/&#x2212;</sup> mice were treated at 4 weeks of age. Using the same paradigm as for other groups as described herein, the following treatments were compared for efficacy for prevention of fibrosis by intramuscular injection of GAS: scAAVrh.74.CMV.miR-29c alone, ssAAVrh74.MCK.micro-dystrophin+scAAVrh.74.CMV.miR-29c combination therapy, or ssAAVrh74.MCK.micro-dystrophin alone at the same dose. The mice were necropsied 12 weeks post injection. A significant decrease in collagen staining throughout the GAS muscles in all treated groups compared to the untreated contralateral mdx/utrn<sup>+/&#x2212;</sup> GAS muscle was observed (<figref idref="DRAWINGS">FIG. <b>10</b>A</figref>). Quantification of the picrosirius red staining showed that muscle co-treated with micro-dystrophin/miR-29c had a 51% reduction in collagen compared to the untreated muscle (treated&#x2014;11.32%&#xb1;1.18 vs. untreated&#x2014;23.15%&#xb1;0.90) (p&#x3c;0.0001) (<figref idref="DRAWINGS">FIG. <b>10</b></figref>) and qRT-PCR confirmed Col1A, Col3A, Fbn and TGF-&#x3b2;1 reduction following combinatorial therapy (<figref idref="DRAWINGS">FIGS. <b>10</b>D</figref> and E).</p><heading id="h-0024" level="1">Example 9</heading><heading id="h-0025" level="1">Early Combination Therapy Restores Force and Protects from Contraction-Induced Damage Better than Late Treatment</heading><p id="p-0135" num="0134">In vivo force measurement was carried out on the GAS of the mice treated early with the combination therapy as described in Example 8. In 4-week-old mdx/utrn<sup>+/&#x2212;</sup> mice, co-treatment using miR-29c/micro-dystrophin showed significant improvement in absolute force when compared to untreated mdx/utrn<sup>+/&#x2212;</sup> mice and there was no difference from wild type (co-treated: 2908&#xb1;129.5 mN vs. untreated: 1639.4&#xb1;116.9 mN vs. wild-type: 3369.73&#xb1;154.1 mN). Specific force was also normalized to wild type levels following combinatorial therapy (co-treated 338.9&#xb1;22.34 mN/mm2 vs. untreated 184.3&#xb1;13.42 mN/mm<sup>2 </sup>vs. WT 364.3&#xb1;7.79 mN/mm<sup>2</sup>) (<figref idref="DRAWINGS">FIGS. <b>11</b>A</figref> and B and <b>12</b>).</p><p id="p-0136" num="0135">Next, each GAS was subjected to a series of repeat eccentric contractions. By comparing the force ratio of each contraction by the fifth contraction, untreated muscle decayed to 0.53&#xb1;0.04 versus co-treated 0.82&#xb1;0.04 (p&#x3c;0.0001). The combinatorial treatment group was slightly lower than wild type but not significantly different, which decayed to 0.93&#xb1;0.01 (<figref idref="DRAWINGS">FIG. <b>11</b>C</figref>). These data show that reducing fibrosis and gene replacement lead to increase in both absolute and specific force and significantly protects muscle from contraction-induced injury.</p><p id="p-0137" num="0136">These experiments suggest that gene replacement should be started in the newborn period. Efforts are clearly moving in the direction of identifying DMD and other muscular dystrophies in the newborn period. The Ohio Newborn Screening Study illustrates the potential for identification of DMD in newborns using CK 7 Neurol. as a biomarker (&#x3e;2000 U/L) with DNA confirmation on the same dried blood spot (Mendell et al., Ann. Neurol. 71: 304-313, 2012). This methodology is now being extended to other states in the USA (PPMD May 16, 2016: Next Steps with Newborn Screening) and in other countries, particularly the UK (UK National Screening Committee) and China (Perkin Elmer&#x2122; launches screening in China).</p><p id="p-0138" num="0137">miR-29 has also shown promise as a treatment modality for cardiac, pulmonary, and liver fibrosis. Myocardial infarction in mice and humans is associated with miR-29 down-regulation. Rooij et al. (Proc. Natl. Acad. Sci, USA 105:13027-13032, 2008) demonstrated that exposing fibroblasts to a miR-29b mimic decreased collagen transcripts providing a path for clinical translation for cardiac fibrosis. Subsequent studies showed that in a bleomycin-induced pulmonary fibrosis mouse model, attenuation of fibrosis could be achieved using the Sleeping Beauty (SB) transposon system-based delivery of miR-29b.14. Currently, a miR-29b mimic is in a clinical Phase 1 Safety-Tolerability local intradermal trial in healthy volunteers (miRagen Therapeutics&#x2122; MRG-201). Compared to miR-29 oligonucleotide delivery that would require repeated administration related to the half-life of the oligonucleotides, AAV gene therapy could potentially provide a path for single-delivery gene transfer.</p><heading id="h-0026" level="1">Example 10</heading><heading id="h-0027" level="1">Treatment with Muscle Specific Expression of miR-29 and Micro-Dystrophin Reduced Fibrosis and ECM Expression</heading><p id="p-0139" num="0138">AAV vectors comprising the miR29c sequence and a muscle specific promoter MCK were also generated and tested as a combination therapy with AAV vectors expressing micro-dystrophin. To generate the rAAV vector, referred to herein as rAAV.MCK.miR29c, the 22 nucleotide miR29c sequence (target strand SEQ ID NO: 3 and guide strand SEQ ID NO: 4) was cloned into a miR-30 scaffold driven by a MCK promoter (SEQ ID NO: 11). The expression cassette (SEQ ID NO: 12) was cloned into a single stranded AAV plasmid and packaged using AAVrh74, a serotype known to express well in muscle. The miR-29c cDNA was synthesized using a custom primer containing the miR-29c target (sense) strand, miR-30 stem loop and miR-29c guide (antisense) strand in the miR-30 backbone. Three bases of the miR-29c sequence were modified. This sequence was then cloned into a single stranded AAV ITR containing plasmid driven by the MCK promoter and polyA sequence.</p><p id="p-0140" num="0139">The pAAV.MCK.miR29C plasmid contains the mir29c cDNA in a miR-30 stem loop backbone flanked by AAV2 inverted terminal repeat sequences (ITR). It is this sequence that was encapsidated into AAVrh74 virions. In addition, a few nucleotides with in the miR-29c target sequence were changed to mimic Watson-crick pairing at this site as in shRNA-miR(luc). According to ShRNA-luc design, the hairpin should be perfectly complementary throughout its length. Plus, the more changes to the passenger strand, the more likely the elimination of any endogenous mechanism that regulates miR-29 processing that could recognize the miRNA via the stem. The 19<sup>th </sup>base of the guide strand was modified to a cytosine to mimic the nucleotide that precedes the cleavage site in natural mi-29c sequence and the corresponding base on the other strand was changed to preserve pairing.</p><p id="p-0141" num="0140">Early treatment of AAV.MCK.miR-29c/micro-dystrophin combination therapy was more effective at reducing fibrosis and ECM expression. 4-5-week-old mdx/utrn<sup>+\&#x2212;</sup> mice received an intramuscular injection of rAAVrh.74.MCK.MiR-29c and rAAVrh74.MCK.micro-dystrophin at 5&#xd7;10<sup>11 </sup>vgs to the left gastrocnemius muscle as described in Example 5. The muscles were harvested twelve weeks post injection. Picrosirius red staining of muscle harvested from uninjected and mice injected with combination therapy of rAAV.MCK.miR-29c/rAAV.MCK.micro-dystrophin showed co-treated muscle had a 50.9% reduction in collagen compared to untreated GAS muscle (See <figref idref="DRAWINGS">FIGS. <b>13</b><i>a </i>and <b>13</b><i>b</i></figref>). qRT-PCR confirmed an increase in miR-29c transcript levels in the treated cohort (<figref idref="DRAWINGS">FIG. <b>13</b><i>c</i></figref>). Semi-quantitative qRT-PCR showed a significant reduction in Collagen A1 and Collagen 3A (<figref idref="DRAWINGS">FIG. <b>13</b><i>d, e</i></figref>), Fibronectin (<figref idref="DRAWINGS">FIG. <b>13</b><i>f</i></figref>) and Tgf&#x3b2;1 (<figref idref="DRAWINGS">FIG. <b>13</b><i>g</i></figref>) levels in the AAV.MCK.miR-29c/AAV.micro-dystrophin treated muscle compared to the contralateral limb therapies. (*p&#x3c;0.05,****p&#x3c;0.0001). Late treatment of AAV.MCK.miR-29c/micro-dystrophin combination therapy is effective at reducing fibrosis and ECM expression. Three month old mdx/utrn<sup>+\&#x2212;</sup> mice received an intramuscular injection of rAAVrh.74.MCK.MiR-29c and rAAVrh.74.MCK.micro-dystrophin at 5&#xd7;10<sup>11 </sup>vgs to the left gastrocnemius muscle as described in Example 5. The muscles were harvested twelve weeks post injection. Picrosirius red staining of untreated, AAV.MCK.miR-29c and AAV.MCK.miR-29c/AAV.micro-dystrophin treated muscle showed co-treated muscle had a 30.3% reduction in collagen compared to untreated GAS muscle (See <figref idref="DRAWINGS">FIGS. <b>14</b><i>a </i>and <b>14</b><i>b</i></figref>) qRT-PCR confirmed an increase in miR-29c transcript levels in the treated cohorts (<figref idref="DRAWINGS">FIG. <b>14</b><i>c</i></figref>). Semi-quantitative qRT-PCR shows a significant reduction in Collagen 1A and Collagen 3A (<figref idref="DRAWINGS">FIG. <b>14</b><i>d, e</i></figref>), Fibronectin (<figref idref="DRAWINGS">FIG. <b>14</b><i>f</i></figref>) and Tgf&#x3b2;1 (<figref idref="DRAWINGS">FIG. <b>14</b>G</figref>) levels in the AAV.miR-29c/AAV.micro-dystrophin treated muscle compared to the contralateral limb. One-way ANOVA. All data represent mean&#xb1;SEM. (**p&#x3c;0.01, ****p&#x3c;0.0001).</p><heading id="h-0028" level="1">Example 11</heading><heading id="h-0029" level="1">Early Combination Therapy Restores Force and Protects from Contraction-Induced Damage Better than Late Treatment</heading><p id="p-0142" num="0141">In vivo force measurement was carried out on the GAS of the mice treated early with the muscle-specific expression of miR-29 and micro-dystrophin. as described in Examples 8 and 9. In 4-week-old mdx/utrn<sup>+/&#x2212;</sup> mice, co-treatment using rAAV.MCK.miR-29c/and rAAV expressing micro-dystrophin showed significant improvement in absolute force when compared to untreated mdx/utrn<sup>+/&#x2212;</sup> mice and there was no difference from wild type (<figref idref="DRAWINGS">FIG. <b>15</b><i>a</i></figref>). Specific force was also normalized to wild type levels following combination therapy (<figref idref="DRAWINGS">FIG. <b>15</b><i>b</i></figref>).</p><p id="p-0143" num="0142">Muscles were then assessed for loss of force following repetitive eccentric contractions as described in Example 9. Mice co-treated with rAAV.MCK.miR-29c/rAAV.MCK.micro-dystrophin and rAAV.MCK.micro-dystrophin alone showed a protection from loss of force compared with untreated mdx/utrn<sup>+\&#x2212;</sup> muscles (<figref idref="DRAWINGS">FIG. <b>15</b><i>c</i></figref>).</p><p id="p-0144" num="0143">In 12-week-old mdx/utrn<sup>+/&#x2212;</sup> mice, co-treatment using rAAV.MCK.miR-29c/and rAAV expressing micro-dystrophin restored force and protected against contraction-induced damage. Measurement of absolute (<figref idref="DRAWINGS">FIG. <b>16</b><i>a</i></figref>) and normalized specific force (<figref idref="DRAWINGS">FIG. <b>16</b><i>b</i></figref>) following tetanic contraction rAAV.MCK.miR-29c and rAAV expressing micro-dystrophin injected GAS muscles were significantly increased compared to untreated mdx/utrn<sup>+/&#x2212;</sup> muscle. Subsequently, muscles were assessed for loss of force following repetitive eccentric contractions as described in Example 9. Mice co-treated with MCK.miR-29c/micro-dystrophin showed a protection from loss of force compared with untreated mdx/utrn<sup>+\&#x2212;</sup> muscles (<figref idref="DRAWINGS">FIG. <b>16</b><i>c</i></figref>). These data show that reducing fibrosis and gene replacement lead to increase in both absolute and specific force and significantly protects muscle from contraction-induced injury.</p><heading id="h-0030" level="1">Example 12</heading><heading id="h-0031" level="1">Early Combination Treatment Increases Muscle Hypertrophy and Hyperplasia</heading><p id="p-0145" num="0144">Co-delivery of rAAV.MCK.miR-29 with rAAV expressing micro-dystrophin did not increase overall weight of the injected gastroc compared to either one injected alone at three months post-injection (<figref idref="DRAWINGS">FIG. <b>17</b><i>a</i></figref>). Myofiber diameters were also measured. miR-29c/micro-dystrophin combination treatment demonstrated an increase in average fiber size. Comparing mdx/utrn<sup>+/&#x2212;</sup> controls with miR-29c/micro-dystrophin treated mdx/utrn<sup>+/&#x2212;</sup>, the average diameter increased from 28.96 to 36.03 &#x3bc;m (<figref idref="DRAWINGS">FIG. <b>17</b><i>b</i></figref>). The co-delivery produced a shift towards wild-type fiber size distribution (<figref idref="DRAWINGS">FIG. <b>17</b><i>c</i></figref>). The number of muscle fibers per mm<sup>2 </sup>in the miR-29c/micro-dystrophin combination treatment was significantly less than untreated mice and wild-type (<figref idref="DRAWINGS">FIG. <b>17</b><i>d</i></figref>; ***p&#x3c;0.01, ****p&#x3c;0.0001).</p><heading id="h-0032" level="1">REFERENCES</heading><p id="p-0146" num="0000"><ul id="ul0001" list-style="none">    <li id="ul0001-0001" num="0145">1. Hoffman, E. P., Brown, R. H., Jr. &#x26; Kunkel, L. M. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. <i>Cell </i>51, 919-928 (1987).</li>    <li id="ul0001-0002" num="0146">2. Straub, V. &#x26; Campbell, K. P. Muscular dystrophies and the dystrophin-glycoprotein complex. <i>Curr Opin Neurol </i>10, 168-175 (1997).</li>    <li id="ul0001-0003" num="0147">3. Sacco, A., et al. Short telomeres and stem cell exhaustion model Duchenne muscular dystrophy in mdx/mTR mice. <i>Cell </i>143, 1059-1071 (2010).</li>    <li id="ul0001-0004" num="0148">4. Wallace, G. Q. &#x26; McNally, E. M. Mechanisms of muscle degeneration, regeneration, and repair in the muscular dystrophies. <i>Annu Rev Physiol </i>71, 37-57 (2009).</li>    <li id="ul0001-0005" num="0149">5. Zhou, L. &#x26; Lu, H. Targeting fibrosis in Duchenne muscular dystrophy. <i>J Neuropathol Exp Neurol </i>69, 771-776 (2010).</li>    <li id="ul0001-0006" num="0150">6. Desguerre, I., et al. Endomysial fibrosis in Duchenne muscular dystrophy: a marker of poor outcome associated with macrophage alternative activation. <i>J Neuropathol Exp Neurol </i>68, 762-773 (2009).</li>    <li id="ul0001-0007" num="0151">7. Kim, J., et al. microRNA-directed cleavage of ATHB15 mRNA regulates vascular development in <i>Arabidopsis </i>inflorescence stems. <i>Plant J </i>42, 84-94 (2005).</li>    <li id="ul0001-0008" num="0152">8. Ambros, V. MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing. <i>Cell </i>113, 673-676 (2003).</li>    <li id="ul0001-0009" num="0153">9. Eisenberg, I., et al. Distinctive patterns of microRNA expression in primary muscular disorders. <i>Proc Natl Acad Sci USA </i>104, 17016-17021 (2007).</li>    <li id="ul0001-0010" num="0154">10. Jiang, X., Tsitsiou, E., Herrick, S. E. &#x26; Lindsay, M. A. MicroRNAs and the regulation of fibrosis. <i>FEBS J </i>277, 2015-2021 (2010).</li>    <li id="ul0001-0011" num="0155">11. van Rooij, E., et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. <i>Proc Natl Acad Sci USA </i>105, 13027-13032 (2008).</li>    <li id="ul0001-0012" num="0156">12. Cacchiarelli, D., et al. MicroRNAs involved in molecular circuitries relevant for the Duchenne muscular dystrophy pathogenesis are controlled by the dystrophin/nNOS pathway. <i>Cell Metab </i>12, 341-351 (2010).</li>    <li id="ul0001-0013" num="0157">13. DiPrimio, N., McPhee, S. W. &#x26; Samulski, R. J. Adeno-associated virus for the treatment of muscle diseases: toward clinical trials. <i>Curr Opin Mol Ther </i>12, 553-560 (2010).</li>    <li id="ul0001-0014" num="0158">14. Mendell, J. R., et al. Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D. <i>Ann Neurol </i>68, 629-638 (2010).</li>    <li id="ul0001-0015" num="0159">15. Mendell, J. R., et al. Limb-girdle muscular dystrophy type 2D gene therapy restores alpha-sarcoglycan and associated proteins. <i>Ann Neurol </i>66, 290-297 (2009).</li>    <li id="ul0001-0016" num="0160">16. Mendell, J. R., et al. A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy. <i>Molecular therapy: the journal of the American Society of Gene Therapy </i>23, 192-201 (2015).</li>    <li id="ul0001-0017" num="0161">17. Carnwath, J. W. &#x26; Shotton, D. M. Muscular dystrophy in the mdx mouse: histopathology of the soleus and extensor digitorum longus muscles. <i>J Neurol Sci </i>80, 39-54 (1987).</li>    <li id="ul0001-0018" num="0162">18. Coulton, G. R., Morgan, J. E., Partridge, T. A. &#x26; Sloper, J. C. The mdx mouse skeletal muscle myopathy: I. A histological, morphometric and biochemical investigation. <i>Neuropathol Appl Neurobiol </i>14, 53-70 (1988).</li>    <li id="ul0001-0019" num="0163">19. Cullen, M. J. &#x26; Jaros, E. Ultrastructure of the skeletal muscle in the X chromosome-linked dystrophic (mdx) mouse. Comparison with Duchenne muscular dystrophy. <i>Acta Neuropathol </i>77, 69-81 (1988).</li>    <li id="ul0001-0020" num="0164">20. Dupont-Versteegden, E. E. &#x26; McCarter, R. J. Differential expression of muscular dystrophy in diaphragm versus hindlimb muscles of mdx mice. <i>Muscle Nerve </i>15, 1105-1110 (1992).</li>    <li id="ul0001-0021" num="0165">21. Stedman, H. H., et al. The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy. <i>Nature </i>352, 536-539 (1991).</li>    <li id="ul0001-0022" num="0166">22. Deconinck, A. E., et al. Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy. <i>Cell </i>90, 717-727 (1997).</li>    <li id="ul0001-0023" num="0167">23. Grady, R. M., et al. Skeletal and cardiac myopathies in mice lacking utrophin and dystrophin: a model for Duchenne muscular dystrophy. <i>Cell </i>90, 729-738 (1997).</li>    <li id="ul0001-0024" num="0168">24. Love, D. R., et al. An autosomal transcript in skeletal muscle with homology to dystrophin. <i>Nature </i>339, 55-58 (1989).</li>    <li id="ul0001-0025" num="0169">25. Tinsley, J. M., et al. Primary structure of dystrophin-related protein. <i>Nature </i>360, 591-593 (1992).</li>    <li id="ul0001-0026" num="0170">26. Tinsley, J., et al. Expression of full-length utrophin prevents muscular dystrophy in mdx mice. <i>Nat Med </i>4, 1441-1444 (1998).</li>    <li id="ul0001-0027" num="0171">27. Squire, S., et al. Prevention of pathology in mdx mice by expression of utrophin: analysis using an inducible transgenic expression system. <i>Hum Mol Genet </i>11, 3333-3344 (2002).</li>    <li id="ul0001-0028" num="0172">28. Rafael, J. A., Tinsley, J. M., Potter, A. C., Deconinck, A. E. &#x26; Davies, K. E. Skeletal muscle-specific expression of a utrophin transgene rescues utrophin-dystrophin deficient mice. <i>Nat Genet </i>19, 79-82 (1998).</li>    <li id="ul0001-0029" num="0173">29. Zhou, L., et al. Haploinsufficiency of utrophin gene worsens skeletal muscle inflammation and fibrosis in mdx mice. <i>J Neurol Sci </i>264, 106-111 (2008).</li>    <li id="ul0001-0030" num="0174">30. Gutpell, K. M., Hrinivich, W. T. &#x26; Hoffman, L. M. Skeletal Muscle Fibrosis in the mdx/utrn+/&#x2212; Mouse Validates Its Suitability as a Murine Model of Duchenne Muscular Dystrophy. <i>PloS one </i>10, e0117306 (2015).</li>    <li id="ul0001-0031" num="0175">31. Rodino-Klapac, L. R., et al. Micro-dystrophin and follistatin co-delivery restores muscle function in aged DMD model. <i>Human molecular genetics </i>22, 4929-4937 (2013).</li>    <li id="ul0001-0032" num="0176">32. Cushing, L., et al. MIR-29 is a Major Regulator of Genes Associated with Pulmonary Fibrosis. <i>Am J Respir Cell Mol Biol </i>(2010).</li>    <li id="ul0001-0033" num="0177">33. Roderburg, C., et al. Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. <i>Hepatology </i>53, 209-218 (2011).</li>    <li id="ul0001-0034" num="0178">34. Nevo, Y., et al. The Ras antagonist, farnesylthiosalicylic acid (FTS), decreases fibrosis and improves muscle strength in dy/dy mouse model of muscular dystrophy. <i>PloS one </i>6, e18049 (2011).</li>    <li id="ul0001-0035" num="0179">35. Rodino-Klapac, L. R., et al. A translational approach for limb vascular delivery of the micro-dystrophin gene without high volume or high pressure for treatment of Duchenne muscular dystrophy. <i>J Transl Med </i>5, 45 (2007).</li>    <li id="ul0001-0036" num="0180">36. Mulieri, L. A., Hasenfuss, G., Ittleman, F., Blanchard, E. M. &#x26; Alpert, N. R. Protection of human left ventricular myocardium from cutting injury with 2,3-butanedione monoxime. <i>Circ Res </i>65, 1441-1449 (1989).</li>    <li id="ul0001-0037" num="0181">37. Rodino-Klapac, L. R., et al. Persistent expression of FLAG-tagged micro dystrophin in nonhuman primates following intramuscular and vascular delivery. <i>Molecular therapy: the journal of the American Society of Gene Therapy </i>18, 109-117 (2010).</li>    <li id="ul0001-0038" num="0182">38. Grose, W. E., et al. Homologous recombination mediates functional recovery of dysferlin deficiency following AAV5 gene transfer. <i>PloS one </i>7, e39233 (2012).</li>    <li id="ul0001-0039" num="0183">39. Liu, M., et al. Adeno-associated virus-mediated microdystrophin expression protects young mdx muscle from contraction-induced injury. <i>Mol Ther </i>11, 245-256 (2005).</li></ul></p><?detailed-description description="Detailed Description" end="tail"?></description><us-sequence-list-doc id="SEQLST-1"><sequence-list file="US20230001015A1-20230105-S00001.XML" carriers="internal-electronic" seq-file-type="ST.25"/></us-sequence-list-doc><claims id="claims"><claim id="CLM-00001" num="00001"><claim-text><b>1</b>. (canceled)</claim-text></claim><claim id="CLM-00002" num="00002"><claim-text><b>2</b>. The recombinant AAV vector comprising<claim-text>a) the nucleotide sequences of SEQ ID NO: 3 and SEQ ID NO: 4,</claim-text><claim-text>b) the nucleotide sequence of SEQ ID NO: 2,</claim-text><claim-text>c) the nucleotide sequence of SEQ ID NO: 1 or</claim-text><claim-text>d) the nucleotide sequence of SEQ ID NO: 12.</claim-text></claim-text></claim><claim id="CLM-00003" num="00003"><claim-text><b>3</b>. The recombinant AAV vector of <claim-ref idref="CLM-00002">claim 2</claim-ref> wherein the vector is a the serotype AAV1, AAV2, AAV4, AAV5, AAV6, AAV7, AAVrh74, AAV8, AAV9, AAV10, AAV11, AAV12 or AAV13.</claim-text></claim><claim id="CLM-00004" num="00004"><claim-text><b>4</b>. The recombinant AAV vector <claim-ref idref="CLM-00002">claim 2</claim-ref> wherein the polynucleotide sequence is operably linked to a muscle-specific control element.</claim-text></claim><claim id="CLM-00005" num="00005"><claim-text><b>5</b>. The recombinant AAV vector of <claim-ref idref="CLM-00004">claim 4</claim-ref> wherein the muscle-specific control element is cytomegalovirus (CMV) promoter, human skeletal actin gene element, cardiac actin gene element, myocyte-specific enhancer binding factor mef, muscle creatine kinase (MCK), truncated MCK (tMCK), myosin heavy chain (MHC), MHCK7, C5-12, murine creatine kinase enhancer element, skeletal fast-twitch troponin c gene element, slow-twitch cardiac troponin c gene element, the slow-twitch troponin i gene element, hypoxia-inducible nuclear factors, steroid-inducible element or glucocorticoid response element (gre).</claim-text></claim><claim id="CLM-00006" num="00006"><claim-text><b>6</b>. The recombinant AAV vector of <claim-ref idref="CLM-00004">claim 4</claim-ref> wherein the muscle-specific control element comprises the nucleotide sequence of SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 13.</claim-text></claim><claim id="CLM-00007" num="00007"><claim-text><b>7</b>. A composition comprising the recombinant AAV vector of <claim-ref idref="CLM-00002">claim 2</claim-ref>.</claim-text></claim><claim id="CLM-00008" num="00008"><claim-text><b>8</b>. A method of treating muscular dystrophy comprising administering a therapeutically effective amount of the recombinant AAV vector of <claim-ref idref="CLM-00002">claim 2</claim-ref>.</claim-text></claim><claim id="CLM-00009" num="00009"><claim-text><b>9</b>. A method of reducing or preventing fibrosis in a subject suffering from muscular dystrophy comprising administering a therapeutically effective amount of the recombinant AAV vector of <claim-ref idref="CLM-00002">claim 2</claim-ref>.</claim-text></claim><claim id="CLM-00010" num="00010"><claim-text><b>10</b>. A method of preventing fibrosis in a patient suffering from muscular dystrophy comprising administering a therapeutically effective amount of the recombinant AAV vector of <claim-ref idref="CLM-00002">claim 2</claim-ref>.</claim-text></claim><claim id="CLM-00011" num="00011"><claim-text><b>11</b>. A method of increasing muscular force or muscle mass in a subject suffering from muscular dystrophy comprising administering a therapeutically effective amount of the recombinant AAV vector of <claim-ref idref="CLM-00002">claim 2</claim-ref>.</claim-text></claim><claim id="CLM-00012" num="00012"><claim-text><b>12</b>. The method of <claim-ref idref="CLM-00008">claim 8</claim-ref> wherein the muscular dystrophy is Duchenne muscular dystrophy or Limb Girdle muscular dystrophy.</claim-text></claim><claim id="CLM-00013" num="00013"><claim-text><b>13</b>. The method of <claim-ref idref="CLM-00008">claim 8</claim-ref> wherein the recombinant AAV vector or the composition is administered by intramuscular injection.</claim-text></claim><claim id="CLM-00014" num="00014"><claim-text><b>14</b>. The method of <claim-ref idref="CLM-00008">claim 8</claim-ref> wherein the recombinant AAV vector or the composition is administered systemically.</claim-text></claim><claim id="CLM-00015" num="00015"><claim-text><b>15</b>. The method of <claim-ref idref="CLM-00014">claim 14</claim-ref>, where the recombinant AAV vector or the composition is parenterally administered by injection, infusion or implantation.</claim-text></claim><claim id="CLM-00016" num="00016"><claim-text><b>16</b>. The method of <claim-ref idref="CLM-00008">claim 8</claim-ref>, wherein the recombinant AAV vector of composition is administered before fibrosis is observed in the subject or before muscle force is reduced in the subject or before muscle mass is reduced in the subject.</claim-text></claim><claim id="CLM-17-31" num="17-31"><claim-text><b>17</b>-<b>31</b>. (canceled)</claim-text></claim><claim id="CLM-00032" num="00032"><claim-text><b>32</b>. A method of producing a mature miR-29 polynucleotide sequence comprising infecting a host cell with a recombinant AAV vector of <claim-ref idref="CLM-00002">claim 2</claim-ref> and expressing a mature miR-29 polynucleotide in the host cell.</claim-text></claim></claims></us-patent-application>